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Abstract 
The mechanism of transcriptional regulation which allows oral mucosal-specific 
expression of the human keratin 13 (K13) gene remains unknown. The pattern of 
expression of keratin genes in the oral mucosa shows sequential synthesis of specific 
basal and suprabasal keratins. K15 and K13 are respectively basal and suprabasal 
markers of buccal epithelial tissue. K15 and K13 expression are known to alter in 
oral squamous cell carcinoma. When differentiation occurs basal cells migrate to the 
suprabasal layer and K15 synthesis stops and the synthesis of suprabasal markers like 
K13 begins. The aims of the study are to determine whether the K13 promoter can 
confer 1) oral mucosal cell-specific differentiation in in-vitro culture, 2) understand 
the mechanism by which different positive or negative regulators impose basal cell-
specific promoter expression and how this differs from suprabasal promoter 
expression and 3) whether K15 and K13 expression can be correlated with in-vitro 
cell differentiation stage. To provide insight into the basal and suprabasal expression 
of K15 and K13, their 5′-upstream sequence regions were linked to EGFP. The 
results show that the expression of K15 and K13 can be correlated with in-vitro cell 
differentiation stages in malignant epithelial cell lines. The full length K13 promoter 
construct drove negligible GFP expression in the human foreskin fibroblast cell line 
and had a greater expression in the oral SCC25 cell line than the epidermal-derived 
RTS3b cell line. Therefore, the K13 promoter sequence appears to contain 
suppressor elements conferring oral cell-specificity. The expression patterns of 
truncated K13 promoter fragments after transient transfection into permissive, non 
permissive and non-epithelial cell lines, suggest binding of a negative regulatory 
element to the full length K13-3089bp promoter. K13 expression is induced by 
pharmacological alteration of chromatin structure in non-permissive skin-derived 
RTS3b cells. The MEK 1/ 2 pathway seems not necessary for the expression of K13, 
but PI3K/Akt pathway is important for expression of K13 in oral mucosa. In 
conclusion, the results suggest that keratin gene promoter expression can be 
correlated with in-vitro cell differentiation stages and these restricted differences in 
keratin expression might be co-ordinated by the synergistic action of transcription 
factors. 
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α= alpha 
AKT= a serine/threonine kinase also known as protein kinase B (PKB) 
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0C= centigrade  
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1.1 The Structure and Function of the Oral Mucosa 
Different types of epithelial tissue can be classified according to their morphology 
and differentiation-specific protein expression patterns. Various epithelial types 
include simple epithelia such as those found in trachea, non-keratinized epithelia 
such as the oesophagus and buccal mucosa, and the keratinized epithelia found in the 
skin and palate and gingival tissue of the oral cavity (Figure 1.1). The oral mucosa, 
unlike the skin contains both keratinized and non-keratinized epithelium (Presland 
and Dale, 2000). The oral mucosa can be divided into three anatomical regions based 
on their pattern of keratinisation: masticatory, lining and specialized mucosa as listed 
below (Smart, 2004). 
• The masticatory mucosa covers about 50% of the oral mucosal surface and is 
found in regions of high compression and friction, such as the gingiva and 
hard palate (Seoane et al, 2002). The masticatory mucosa is characterised by 
a keratinised or parakeratinised epithelium and a thick lamina propria. The 
masticatory mucosa of the gingiva and hard palate are bound directly to the 
underlying bone (Smart, 2004).  
• The lining mucosa, which is mobile and distensible, which has a non-
keratinised epithelia and a loose lamina propria and covers the cheeks, lips, 
floor of the mouth, ventral surface of the tongue and the soft palate. The  
lining mucosa occupies  about 30% of the oral mucosal surface (Smart, 
2004).  
• The specialized regions of the oral cavity are the vermillion border of the lips 
and the dorsum of the tongue. The vermillion border of the lips is special 
because it represents a change from non-keratinized internal oral mucosa to 
the highly keratinized external skin (Figure 1.2). The dorsum of the tongue 
contains different types of papillae and taste bud receptors which enable 
distinction of four different types of taste: salty, sour, and sweet and bitter 
(Berkovitz and Moxham, 2002). 
Mucosal functions include protection against both mechanical and compressive 
shearing forces, forming a barrier to microorganisms, toxins and various antigens and 
also providing an immunological defence, both humoral and cell mediated 
(Berkovitz and Moxham, 2002). 
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Figure 1.1: Differentiation programmes of the keratinizing epithelium of the 
epidermis and the oral mucosal (A), non-keratinizing buccal oral mucosa (B) and 
gingival epithelium, which is composed of keratinized and non- keratinized epithelia 
(C). The keratin pairs expressed by each layer are indicated. In panel C the following 
abbreviations are used: AE =alveolar epithelium, OGE=oral gingival epithelium, 
GM=gingival margin, SE=sulcular epithelium and  JE=junctional epithelium (adapted 
from Presland and Dale, 2000). 
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Figure 1.2: The anatomical location of the three types (masticatory, lining, and 
specialized mucosa) of epithelial covering of the  oral cavity (adapted from Squier 
and Kremer, 2001).  
 
 
 
 
                            
Figure 1.3: A cross section of the oral mucosa. The oral mucosa is comprised of 
stratified epithelium, a basement membrane, lamina propria and sub-mucosa 
containing blood vessels and nerves which are directly attached to bone or muscle 
depending on the site of the oral mucosa (adapted from Smart, 2004).  
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1.2 Maintenance of the Oral Mucosa 
When the oral epithelium is faced with injuries that compromise its barrier function, 
it rapidly undergoes an epithelial repair programme, which includes the movement of 
cells to cover defects and a rapid production of cells that differentiate to repopulate 
the injured epithelium. The source of these differentiated cells within the injured 
tissues are stem cells which reside in the basal layer and have the ability to 
repopulate the injured epithelia and aid in oral epithelial homeostasis (Beachy et al, 
2004). When stem cells divide, they can give rise to two identical daughter cells that 
retains the characteristics of its parent – this process is termed symmetric division 
(Mackenzie, 2005). Stem cells can also divide to produce one daughter cell that 
retains the characteristic of the parent and another daughter cell that known as a 
transient amplifying cell that embarks on  a specific-differentiation program; this 
process is termed asymmetric division or fate (Alonso and Fuchs, 2003). These 
different types of stem cell fate patterns in epithelia are useful for the expansion of 
the stem cell population in the case of symmetric division and for maintaining the 
process of homeostasis, in the case of asymmetric stem cell division (Mackenzie, 
2005) as shown in Figure 1.4.  
 
 
 
 
 
 
 
Figure 1.4: The division pattern of epithelial stem cells: a) shows a stem cell 
dividing to produce two daughter cells which are identical to itself and this type of 
division is termed symmetric division. Whereas in b) a stem cell divides to produce 
one cell, which is identical to the parental stem cell and another, which 
differentiates. This type of stem cell division is termed asymmetric division. c) 
shows a non-stem cell daughter cell giving rise to transit amplifying cells to expand 
the differentiating cell population (adapted from Mackenzie, 2005) 
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1.2.1 Environmental Factors which Damage the Oral Mucosa 
The oral epithelium is damaged by  chronic infections such as those caused by the 
fungal organism Candida albicans, eating foods which cause abrasion, habits such as 
drug use, tobacco smoking, alcohol consumption and chewing Betel Quid (Shieh et 
al, 2003). A study by Lee et al, (2003), investigated the effect of the use of betel 
quid, tobacco smoking and alcohol consumption on the risk of developing oral 
precancerous lesions, such as oral leukoplakias (OL) and oral submucous fibrosis 
(OSF). The study showed people who chew betel quid significantly increase their 
risk of developing OL and OSF. Cigarette smoking was also reported to potentiate 
the effect of betel quid on causing OL (Lee et al, 2003). Arecoline, the alkaloid in 
areca nut of betel quid has been shown to have cytotoxic effects and increase the 
synthesis of double stranded polynucleic acid of human buccal fibroblasts, which 
eventually causes OL (Lee et al, 2003). 
 
1.3 Structure and Function of the Skin 
The skin covers the entire body and is a large organ, extending to approximately 2m2 
in area and it is around 2.5 mm thick on average (Tobin, 2006). Some of the skin 
associated appendages include the hair, hair follicles, sebaceous and sweat glands 
(Figure 1.7). The skin has many functions, including forming a protective barrier, 
enabling sensory perception, and thermoregulation (Heath et al, 2000).  The skin 
epithelium not only forms a barrier against the environment, but also aids in 
preventing the entry of toxic substances, bacteria, viruses and preventing dehydration 
by controlling the loss and gain of body fluids (Gibbs and Ponec, 2000). The skin is 
divided into two types: hairy skin and the glabrous non-hairy skin found on the palm 
of the hands and sole of the feet (Presland and Jurevic, 2002).  The skin comprises 
three main layers: the epidermis, dermis and hypodermis as shown in Figure 1.5 
(Heath et al, 2000). The epidermal and dermal skin layers are embryologically 
derived from ectoderm and mesoderm respectively (Heath et al, 2000). The 
epidermal layer consists of five layers: 1; Stratum corneum, 2; Stratum lucidum, 3; 
Stratum granulosum, 4; Stratum spinosum and 5; Stratum basale, (Section 1.7), and 
with the exception of stratum lucidum, these layers are also present in the oral 
mucosa. The stratum lucidum layer is histologically visible in palm and sole skin. 
Although the stratified epithelium is largely composed of keratinocytes, there are 
also other cell populations, namely melanocytes, Langerhans  cells (which have 
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immunological function) and Merkel cells (Presland and Jurevic, 2002). Melanocytes 
give pigment to the keratinocytes; this process involves melanosomes that 
transporting melanin granules and fuse with keratinocytes to release the melanin 
granules (Gu and Coulombe, 2007). The melanin pigment is then transported to the 
supernuclear region of the keratinocytes, where they are able to impart protection of 
the nuclear genome against UV irradiation (Gu and Coulombe, 2007). 
 
 
 
 
 
1.3.1 Skin Barrier Formation  
The primary role of the epidermis is to provide protection for the organism against 
the external environment; the epidermis does this by constructing  an elaborate and 
highly organised outer surface area, called the stratum corneum (Byrne et al, 2003). 
The essential component of the epidermal barrier is the keratinocyte cornified 
envelope (CE) (Marshall et al, 2001). The CE is a specialized structure which is 
formed in the inside of the plasma membrane of terminally differentiating cells 
(Steinert and Marekov, 1999). The CE is an insoluble 15nm thick structure, which is 
composed of two parts: the protein envelope and the lipid  envelope (Nemes and 
Steinert, 1999). The protein envelope is coated by a 5nm thick lipid envelope, which 
Figure 1.5: Haematoxylin and eosin (H&E) staining of thick skin of palmar and 
plantar epidermis, dermis and hypodermal layers (adapted from website number 8 
in the reference section). 
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is covalently attached to the exterior part of the  protein envelope (Nemes and 
Steinert, 1999). Many components make up the macromolecular assembly of the 
highly insoluble CE;  these include: small proline- rich proteins (SPRs and also 
known as cornifin),  loricrin, filaggrin, type II keratin proteins, trichohyalin as well 
as various cell junctional proteins which include envoplakin (Figure 1.6), periplakin 
and desmoplakin (Steinert and Marekov 1999). These insoluble proteins are 
interlinked together by disulfide bonds and isopeptide bonds formed by the action of 
transglutaminases (Steinert and Marekov, 1999). Transglutaminases (TGases), are 
Ca2+ dependent enzymes which are involved in the transfer of an acyl group between 
the γ–carboxamide group of protein-bound glutamine and the ε-amino group of 
lysine residues (Nemes et al, 1999). There are seven types of human TGases, of 
which only four (TGases 1, 2, 3 and X) are expressed in stratified epithelia of the 
epidermis (Nemes et al, 1999). TGase 1 and 3 enzymes are important for the cross-
linking of trichohyalin, small proline-rich proteins and loricrin substrates (Nemes et 
al, 1999). Involucrin and the desmosomal related proteins like envoplakin and 
desmoplakin together function as early scaffolding components of the CE (Steinert et 
al, 1998). SPRs serve as cross-bridging proteins and directly modulate the 
biochemical properties of CE (Nemes and Steinert, 1999). Filaggrin is released by 
proteolysis from profilaggrin, a major differentiation product of orthokeratinizing 
epithelia (Nemes and Steinert, 1999). Filaggrin functions by binding to keratins and 
forming a tight array which is typically seen in corneocytes (Nemes and Steinert, 
1999). Loricrin is by far the most abundant protein in CE  and accounts for over 70% 
of protein mass of CE and both TGase 1 and 3 use loricrin for CE assembly in-vivo 
(Nemes and Steinert, 1999). Moreover, the amount of structural proteins which 
constitute CE and the presence or absence of the lipid envelope differs between 
various stratified squamous epithelium, according to the different protective function 
required (Steinert et al, 1998). For example, in orthokeratinizing epithelia, such as 
that of epidermis, there is an additional water barrier function, which is imparted by a 
5nm thick lipid envelope and this is not present in internal oral epithelia (Steinert and 
Marekov, 1999). In addition, there is increased loricrin protein mass in CE of the 
epidermis in comparison to the palate and buccal mucosa (Nemes and Steinert, 
1999). Also the amount of SPR proteins in different epithelia differs in relation to 
resistance of the epithelia to physical trauma or in response to chemical insults. For 
example the SPR proteins in CE of the trunk epidermis is about 5% of total protein 
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content, while human buccal epithelia contains about 50% SPR3 protein  (Steinert et 
al, 1998). 
 
 
 
 
 
 
 
 
1.4 Comparison of the Oral Mucosa and Skin 
Different epithelial tissues show variation in their differentiation pattern and this 
contributes to some of the structural and functional differences in the oral mucosa 
and skin (Gibbs and Ponec, 2000). Generally, the oral mucosa contains more cell 
layers and hence is a thicker epithelium than to epidermal equivalent (Gibbs and 
Ponec, 2000). Although there is absence of hair follicles in oral mucosa, it does 
contain minor salivary glands and occasional sebaceous glands, known as Fordyce 
spots or granules, which are found in the upper lip and cheeks and appear as yellow 
spots protuding from the pink coloured mucosa (Winning and Townsend, 2000).  
Other phenotypic differences between oral mucosa and skin include the colour and 
melanin content; and the oral mucosa is more pink/reddish in colour because of the 
increased concentration of blood vessels in the connective tissue (Winning and 
Townsend, 2000). The melanin content in skin varies between individuals and is 
Figure 1.6: Diagrammatic representation of stratum corneum layer of adult 
epidermis. The stratum corneum is composed of keratinocytes which have undergone 
the process of terminal differentiation, this process results in the production of the 
cornified envelope. The cornified envelope is surrounded by a lipid capsule, shown in 
diagram as ceramide, free fatty acids and cholesterol. The cornified envelope is 
composed of  many structural proteins such as involucrin, envoplakin, periplakin, 
filaggrin, loricrin, SPRRs and Lep  (adapted from Byrne et al, 2003) 
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correlated with the level of skin pigmentation (Winning and Townsend, 2000). Table 
1.1 and 1.2 highlight some the structural developmental differences and similarities 
in both differentiation markers and cell to cell adhesion molecules of the oral mucosa 
and the skin (Figure 1.7). 
 
 
Figure 1.7: Schematic representation of skin and its associated appendages (adapted 
from website number 3 in the Reference ).  
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Table 1.1: Summary of similarities and difference between the oral mucosa and skin 
differentiation markers. 
Similarities of oral and Skin 
differentiation markers and their 
function  
Differences of oral mucosa from 
Skin  
Both the oral mucosa and skin express 
intermediate filament associated proteins 
and cornified envelope proteins such as  
involucrin, loricrin, cornifin-α/small 
profile–rich proteins.  
Cornifins consist of two isoforms, β 
and α which act as precursor proteins 
for the cornified envelope protein. 
Both β and α isoforms are expressed in 
oral mucosa but only cornifin-α is 
found in normal skin (Fujimoto et al, 
1997). 
Transglutaminase is expressed by both 
epidermis and keratinized oral mucosa. 
The non-keratinized oral mucosa 
expresses the filaggrin (although very 
weak patchy staining), involucrin, 
cornifin-α transglutaminase.  
K5, K14, K1 and K10 proteins are 
respectively found in basal and 
suprabasal layers of keratinized oral 
mucosa and the epidermis.  
Only the mRNA for K1 and K10 are 
expressed in the non-keratinized 
buccal mucosa. K19 is expressed in 
basal layer and K4/K13 pair is 
expressed in the suprabasal basal layer 
of non-keratinized oral mucosa. 
Cytokines such as interleukins, tumor 
necrosis factors, colony stimulating 
factors, chemokines, growth factors, 
interferon and associated receptors are 
produced by both the oral mucosa and 
epidermis under various conditions such 
as inflammation. 
K76 is expressed in keratinized oral 
mucosa, while K2 is expressed in skin. 
Chymotryptic protein is expressed in the 
stratum corneum of both epidermis and 
keratinized oral mucosa  
The membrane coating granules in the 
nonkeratinizing epithelial do not 
contain acylceramides and also contain 
only very small amounts of ceramides. 
The membrane coating granules  have 
no lamellate contents (Lesch et al, 
1989). 
 The palate oral mucosa is 10 times 
more permeable and floor of the 
mouth is 20 times more permeable 
than the skin. 
(adapted from Winning and Townsend, 2000) 
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Table1.2: Summary of the differences between expression of cell to cell and cell 
matrix adhesion molecules in Oral mucosa and Skin. 
Similarities of Oral mucosa and Skin 
cell-cell and cell matrix adhesion 
molecules  
Differences of Oral mucosa from 
Skin  
Both skin and oral mucosa epithelia 
express integrins in the their basal layer.  
In suprabasal layer of floor of the 
mouth and lateral border of the tongue, 
integrins α2, α3 and β1 are expressed, 
but not in skin does not. 
The transmembrane binding glycoprotein 
CD44 which is involved in cell to cell 
adhesion is expressed in all layers of 
epithelial lining both oral mucosa and 
skin.  
Desmoglien-1 expression is less in the 
oral mucosa in comparison to the skin. 
 The intracellular desmosomal proteins 
desmoplakins are involved in mediating 
the interaction of keratin filaments to the 
cytoplasmic domain of desmoglein and 
desmocollin. Both the skin and the oral 
mucosa express transmembrane and 
desmosome associated proteins such as 
desmoglein-3 and desmocollin.   
 
 In spinous layers of both epidermis and 
buccal epithelium connexin-43 
expression occurs. 
In the spinous layer of the buccal 
epithelium Connexin-26 expression 
occurs.  
 The constituent of hemidesmosomes 
proteins such as BP230, ladinin, BP180, 
laminin-5, collagen IV and VII and other 
lamina densa proteins are expressed by 
both the oral mucosa and skin. 
Cell surface carbohydrates (ABO and 
Lewis blood group antigens) show 
differential expression related to tissue 
differentiation status e.g. keratinized 
and non-keratinized epithelium, 
epithelial wounds, or malignant 
epithelium. 
(adapted from Winning and Townsend, 2000) 
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1.5 Developmental and Experimental Models used in Oral mucosa and Skin  
The functional demands and tissue features of the skin and oral mucosa are reflected 
by the structure and biology of the tissue and the cellular products which make them 
up (Winning and Townsend, 2000). Interactions between the epithelium and 
mesenchyme are essential for epithelial repair, homeostasis and morphogenesis 
(Costea et al, 2003). Although much is now known about the role of epithelial-
mesenchymal interactions, much controversy still exists regarding which layer 
causes the phenotypic differences observed in oral mucosa and skin (Costea et al, 
2003). Some groups argue that the properties of the keratinocyte making up the 
overlying oral mucosa and skin epithelium are innate or intrinsic to that epithelium, 
while others argue that the  mesenchymal tissue influences growth and differentiation 
of overlying epithelium through providing a suitable biomatrix environment or by 
synthesis of diffusible factors (Costea et al, 2003).  However, a large body of 
literature has attempted to address whether the variability in structure and functions 
of skin and oral mucosa are inherent or whether extrinsic stromal factors can regulate 
it (Compton et al, 1998). Early experiments have shown that by using a co-culture of 
the epidermis and buccal mucosa epithelia grown on top of uterine connective tissue 
have a normal histo-differentiation pattern (Squier and Kammeyer, 1983). This 
includes the formation of thick keratinized surface of the epidermis and skin 
appendages such as hair and the buccal epithelium which appeared slightly thinner 
than normal (Squier and Kammeyer, 1983). These results suggest that the oral 
mucosa and epidermis have some intrinsic capacity to develop normally and show 
significance of connective tissue for normal histo-differentiation patterns, given the 
fact that buccal mucosa was slightly thinner than normal (Squier and Kammeyer, 
1983). Other studies have used human cultured epithelial autografts (CEA) of sole 
skin transplanted to non-sole derived connective tissue from various other body sites 
of pediatric patients treated for acute burns (Compton et al, 1998). Sole skin 
transplanted to non-sole derived connective tissue was then compared to biopsies of 
sole derived for amputated specimens and non-sole derived skin of age matched 
controls. The results have shown that the site specific K9 expression in sole skin is 
innate to keratinocytes which make up this epithelium and can be maintained in the 
absence of site specific dermal tissue (Compton et al, 1998). Studies by Okazaki et 
al, (2003) looking at the influences of underlying mesenchymal tissues, using 
organotypic co-cultures of normal buccal mucosal epithelium and abdominal skin 
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have shown that skin differentiation is intrinsically controlled, however epithelial 
keratin specific differentiation and phenotype can be extrinsically modified by 
underlying mesenchymal fibroblast (Okazaki et al, 2003).  
 
Taken together, most of these studies suggest that although the connective tissue and 
mesenchymal fibroblasts are important, the intrinsic control innate to the 
keratinocytes of the skin and oral mucosa may play a more significant role in 
determining epithelial phenotype.  
 
1.6 Keratinocytes   
The stratified squamous epithelial surface lining the oral mucosa, oesophagus, 
cervix, cornea and the epidermis are predominantly made up of keratinocytes (Leask 
et al, 1991). In order for the epithelia to provide an effective cohesive barrier, 
keratinocytes are linked by several types of cellular junctions (Presland and Jurevic, 
2002). The adhesion structures and cellular junctions include desmosomes and 
hemidesmosomes, adherens junctions, gap junctions and tight junctions. Together 
these adhesion and cellular junctions have a role in mechanical, biochemical and 
signalling interaction between cells (Presland and Jurevic, 2002; Burns, 2004). 
 
1.6.1 Desmosomes  
Desmosomes consist of products of three gene families: the desmosomal cadherins, 
the armadillo family of nuclear and junctional proteins, and the plakins (Burns et al, 
2004). The desmosomal cadherins family of transmembrane proteins are made up of 
desmogleins (Dsg1-3) and desmocollins (Dsc1-3), which show epidermal 
differentiation specific expression. Dsg1 and Dsc1 are expressed in the superficial 
layer of the epidermis, whereas Dsg3 and  Dsc3 are expressed in the basal layer of 
the epidermis (Burns et al, 2004). The intracellular part of desmogleins and 
desmocollins are attached to keratin filaments via desmoplakins and plakoglobin as 
shown in Figure 1.8. The armadillo protein plakophilin 1 has a essential role in the 
adhesiveness of the site specific plakin cell envelope proteins, such as envoplakin 
and periplakin in differentiated keratinocyte (Burns et al, 2004). 
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1.6.2 Hemidesmosomes  
Hemidesmosome are adhesion structures that attach keratinocytes to the basement 
membrane, as shown in Figures 1.9 (Presland and Jurevic, 2002). Hemidesmosomes 
are a multiprotein complex which consist of six proteins, the  basal keratinocytes 
specific subunit of α6 and β4 integrin (Hatakeyama et al, 2004), the Bullous 
Pemphigoid antigen 180 (BP180 or BPAG2) and 230 (BP230 or BPAG1), CD151 
and plectin (Raymond et al, 2005). In addition there is also laminin 5, which 
mediates the attachment to basement membrane by traversing the lamina lucida and 
interacting with other extracellular matrix components (Hatakeyama et al, 2004). The 
β4 subunit of integrin is large and thus acts as a scaffolding for the binding of other 
hemidesmosomal components (Raymond et al, 2005). BP230 is an intracellular 
electron-dense plaque that acts as an auto-antigen in Bullous Pemphigoid 
(Hatakeyama et al, 2004). The cytolinker plectin protein located in the cytoplasm 
Figure 1.8: Macromolecular constitution of desmosomes, which link adjacent 
keratinocytes together. Keratinocytes are connected through the transmembrane 
cadherin glycoproteins known as desmogleins and desmocollins. Attachment of 
desmogleins and desmocollins to keratin filaments occurs via desmosomal plaque 
proteins known as desmoplakins, plakoglobin and plakophilin (adapted from  Burns 
et al, 2004)  
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mediates the binding of α6β4 integrin to the intermediate filament system. Both 
BP180, a collagen protein that extends from the intracellular to the extracellular 
space (Hatakeyama et al, 2004) and the CD151 hemidesmosomal components are 
transmembrane  proteins (Raymond et al, 2005). 
 
 
 
 
 
 
 
 
1.6.3 Tight Junctions  
Tight junctions (TJs) form a diffusion barrier (Figure 1.10C) which coordinates the 
influx of hydrophilic molecules through a paracellular pathway (the movement of ion 
through the intercellular space between epithelial cells) (Yuki et al, 2007). TJs 
regulate cell permeability in both simple and stratified epithelia and have an essential 
role in skin barrier integrity and in maintaining cell polarity (Burns et al, 2004). The 
TJ which link keratinocytes to one another are composed of transmembrane and 
intercellular molecules that include occludin, junction adhesion molecule and 
claudins (Burns et al, 2004). A single occludin gene exists, unlike claudins which 
forms a multi-gene family with 24 or more possible members (Yuki et al, 2007). 
Figure 1.9: Diagram showing hemidesmosomes components, which mediate 
attachment of basal keratinocytes to the extracellular matrix by connecting the 
keratin intermediate filaments with transmembrane proteins. The transmembrane 
proteins then interact with extracellular matrix. The α6 and β4 integrin subunit 
interacts with extracellular matrix. The α6β4 integrin subunit also interact with 
laminin-5 in the lamina lucida  and the anchoring fibrils attach and interlink the 
lamina densa and anchoring plaque  (adapted from Dabelsteen, 1998). 
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Claudin is thought to regulate epidermal permeability by directing the formation of 
TJs (Burns et al, 2004). Occludin was originally considered to be a structural protein 
that contributes to the formation and sealing of TJs, but was later found not to be 
essential to the formation of TJ strands, which indicates that it has a regulatory 
function as opposed to structural function (Yuki et al, 2007). An increase in 
extracellular Ca2+ in epidermal keratinocyte cultures was shown to induce the 
formation of desmosomes, adherens junctions, causing cells to stratify, and also to 
cause an increase in zonulae occludentes 1 (ZO-1), occludin and claudin-1 
expression (Yuki et al, 2007).  
 
1.6.4 Gap Junctions   
 Cell to cell communication is controlled through gap junction proteins and this is 
vital for the development and maintenance of the tissues (Burns et al, 2004). Gap 
junction proteins are known as connexins and form surface structures which permit 
the diffusion of low molecular mass substances directly between the cytoplasm of 
adjacent cells (Shore et al, 2001). Gap junctions regulate the electrical and metabolic  
activities of cells (Shore et al, 2001) and each gap junction is made up of two 
hemichannels or connexons, which are themselves each composed of six connexin 
molecules. The assembly of connexins takes place within the Golgi network and 
these connexins are then transported to the plasma membrane (Burns et al, 2004). 
Once the connexins are at the plasma membrane, the connexons from adjacent 
keratinocytes interact to form a complete intercellular channel (Essenfelder et al, 
2005). More then 20 different mammalians connexins have been described and show 
tissue specific distributions and different regulatory properties (Essenfelder et al, 
2005). Once a gap junction is formed either from homotypic or heterotypic 
connexins it can be regulated by protein kinase C, Src kinase, the local pH, 
calmodulin and calcium concentration (Burns et al, 2004). Connexin 30 (Cx30) is a 
family member that is expressed in the brain and in rat and human epidermis 
(Essenfelder et al, 2005). A point mutation and several deletion mutations in the 
human Cx30 gene have been shown to cause non-syndromatic autosomal profound 
hearing loss and also cause Hidrotic Ectodermal Dysplasia, which affects the nails, 
hair and skin. The association of Cx30 with loss of hearing and skin disease indicates 
the essential role of Cx30 in auditory signal transduction and epidermal 
differentiation (Essenfelder et al, 2005). 
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1.7 Keratinocyte Differentiation 
Differentiation is a process whereby cells undergo a change to become specialized 
cells within a particular tissue (Alberts et al, 1994). Keratinocyte differentiation can 
be recognized by the expression of differentiation markers characteristic for each 
stage of differentiation  (Plachot and Lelievre, 2004). The oral mucosal epithelia and 
the skin consist of defined layers, each of which contains keratinocytes expressing 
specific keratin gene pairs, for example K1/K10 are expressed in the epidermis. Most 
keratins are in pairs of type I and II, except for a few keratin genes such as K15 and 
K19 which do not have a keratin partner, due to the lack of a proper tail domain, but 
rather compensate for decreased or absent keratin genes (Owens and Lane, 2003; 
Radoja et al, 2004). For example in Epidermolysis Bullosa Simplex, K15 
compensates for the absence of K14 in the basal layer of the skin and pairs with K5 
Figure 1.10: The picture shows the three types of cellular junctions, which enable 
cells to connect with one another to form a tissue.  A given cell type may have more 
than one type of junction. (a) Adhesion junctions which acts as a staple like structure 
to hold the cells together in the tissue. (b) Tight junctions, these junctions as the name 
implies join the cells very tightly. (c) Gap junction aids in the flow of molecules such 
as calcium between cells (adapted from website number 7 in the Reference section).  
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(Radoja et al, 2004). The scheme below shows the various stages a keratinocyte 
undergoes in the process of keratinization (Figure 1.2A) before being shed from the 
surface (Whyte et al, 2002). 
  
? Stratum corneum                              
? Stratum lucidum  
? Stratum granulosum  
? Stratum  spinosum  
? Stratum basal         
 
Differentiation involves the detachment of basal keratinocytes and migration away 
from their basement membrane (Alt et al, 2004). Migration into the suprabasal layer 
is associated with selective loss of the α6β4 integrin complex (Alt et al, 2004). 
During the migration of keratinocytes into the spinous and granular layers, changes 
in keratinocyte cell structure occur, in which the keratinocytes become enlarged, 
flattened, lose organelles and nuclei; the cytoplasm becomes condensed and the 
cytoskeletal proteins become cross-linked to the cornified envelope (Waseem et al, 
1999). This is followed by stacking of multiple keratinocytes in the stratum corneum. 
In the final stage of differentiation, the keratinocytes transform into a rigid cornified 
cell and the flattened dead keratinocytes, are known as squames (Figure 1.11), that 
are eventually shed from the epithelial surface (Eckert et al, 2002). What triggers the 
differentiation process is now becoming better understood. Loss of integrins, which 
are receptors for extracellular matrix proteins such as collagens, laminins and 
fibronectins was initially hypothesised to cause the detachment of keratinocytes from 
the basal layer (Janes and Watt, 2006). This mechanism involves the loss of α6β-
integrin, which leads to loss of keratinocyte adhesiveness and hence detachment. 
However, it is now known that the start and stop signals for induction of keratinocyte 
differentiation mechanism is through integrin receptors and their ligand (Janes and 
Watt, 2006). When primary human keratinocytes were placed in cell suspension, 
they initiated the terminal differentiation process through integrin signalling. The cue 
for integrin to initiate differentiation was established by the use of anti-β1 integrin 
antibodies against the cell suspension (Janes and Watt, 2006). The mechanism 
through which integrin receptors and their ligand regulate differentiation initiation 
are through two types of signals (Janes and Watt, 2006). The ‘do not differentiate’ 
the mature keratinocytes accumulate and are then 
shed at this stage 
keratinocytes mature  and differentiate at this stage 
keratinocytes divide at this stage 
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signal is induced  by ligand occupied receptors, while the ‘do differentiate’ signal is 
induced by unoccupied integrin receptors (Janes and Watt, 2006).  
 
 
 
 
 
 
 
1.7.1 Molecules Involved in Transition from Basal to Suprabasal Differentiated 
Cells of the Epidermis  
There are many molecules such as cell cycle regulators and transcription factors, 
which regulate the process of terminal differentiation in the epidermis. Cdc42 protein 
is a small GTPase belonging to the Rho family and is constitutively expressed 
protein which is involved in the regulation of cell cycle (Wu et al, 2006). Cdc42 is 
essential for differentiation of skin progenitor cells into hair follicle lineage (Wu et 
al, 2006). The differentiation of skin stem cell into hair follicles requires the 
inhibition of β–catenin degradation, which is controlled by a complex of axin and 
protein kinase GSK3β (Wu et al, 2006). This control involves the phosphorylation of 
β–catenin in the cytosol by GSK3β, which marks β–catenin for proteasomal 
degradation (Wu et al, 2006). Cdc42 stabilizes β–catenin and prevents its 
degradation, by binding to the cytosolic complex of Par6, Par3 and PKCζ, which in 
turn inhibits GSK3β activity. (Wu et al, 2006). Inhibition of GSK3β activity leads to 
reduced phosphorylation of axin and degradation of β–catenin (Wu et al, 2006). This 
free β–catenin enters the nucleus together with LEF and TCF transcription factors 
 
Figure 1.11: The normal differentiation processes in the human interfollicular 
epidermis. The α2β1, α3β1 and α6β4 integrin subunits are expressed in the basal 
layer, which is attached to the basement membrane. The basal layer also contains 
stem cells, that give rise to transit amplify cells and cells which have lost the ability to 
divide and therefore become committed to terminal differentiation (adapted from 
Janes and Watt, 2006). 
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and thus induces hair follicle specific gene expression. The absence of Cdc42 results 
in increased GSK3β activity and increased axin phosphorylation and subsequent 
degradation of β–catenin, such that there is a reduced level of β–catenin in the 
nucleus and thus β–catenin is unable to induce hair follicle gene-specific expression 
(Wu et al, 2006). Therefore the loss of β–catenin during hair follicle development 
leads to progenitor follicular cells changing their fate from hair follicle to epidermal 
differentiation  (Wu et al, 2006). This finding indicates that Cdc42 is essential for 
terminal differentiation of hair follicle progenitor cells by regulating β–catenin 
turnover (Wu et al, 2006). p63 is a member of the p53 family of DNA-binding 
factors and has essential role in epidermal differentiation (Kashiwagi et al, 2007). 
The ectopic expression of p63 in simple epithelia has caused the induction of 
epidermal differentiation related keratin expression and thus it was suggested that 
p63 might be important for determining the squamous cell fate (Kashiwagi et al, 
2007). It also been reported that the retinoblastoma (Rb) family of proteins, which 
includes pRb, p130 and p107, are specifically expressed during epidermal 
keratinocyte differentiation in both in-vivo and in-vitro (Paramio et al, 2000). When 
different combinations of the retinoblastoma proteins are ectopically expressed, this 
triggers different stages of the differentiation program, which highlights the 
importance of retinoblastoma proteins in regulating differentiation process (Paramio 
et al, 2000). The E2F transcription factor family are also involved in regulating 
different stages of the differentiation process in the epidermis (Paramio et al, 2000). 
This was demonstrated by transfecting HaCaT keratinocytes cells with E2F1 or EF24 
plasmid constructs (Paramio et al, 2000). E2F1 transfected cells were unable to 
differentiate, which correlates with E2F1 been uniformly present throughout the 
epidermal keratinocyte layers (Paramio et al, 2000). Whereas E2F4 transfected cells 
show increase differentiation, which correlates with E2F4 been expressed at the 
onset of human epidermal keratinocyte differentiation (Paramio et al, 2000). It was 
suggested that both Rb and E2F transcription factor families interact to modulate the 
process of epidermal differentiation (Paramio et al, 2000). c-Myc is a member of the 
Myc transcription factor family, which plays an essential role in cell proliferation, 
apoptosis and cell differentiation (Gandarillas, 2000). In cultured keratinocytes, c-
Myc promotes differentiation, while in other cell types, activity of c-Myc promotes 
proliferation and apoptosis (Gandarillas, 2000).  In cultured keratinocytes, c-Myc is 
able to promote differentiation, by driving the keratinocytes out of the stem cell 
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compartment and into transit amplification (Gandarillas, 2000). Furthermore, cycle 
cell inhibitors such as the cyclin dependent kinase inhibitors including p16, p21 and 
p27 as well as the pocket protein p130, are all up-regulated during keratinocyte 
differentiation, leading to suppression of proliferation (Gandarillas, 2000).  Positive 
cycle cell regulators, such as the cyclin A, cdk2, and cdc2 are all down-regulated 
during keratinocyte differentiation (Gandarillas, 2000). Analysis of epidermal 
specific promoters has revealed a common set of transcription factors such as AP-1 
and Sp1, which regulate the expression of epidermal keratin differentiation markers 
(Smith et al, 2004). It was also suggested that tissue-specific and ubiquitously 
expressed transcription factors synergistically interact to regulate numerous genes 
expressed in different layers of the epidermis (Smith et al, 2004). The importance of 
specific transcription factors such as POU domain, NFkB and C/EBP in the normal 
epidermal differentiation process was demonstrated when these transcription factors 
where either ectopically expressed or mutated (Smith et al, 2004). This resulted in 
non-functional transcription factors, which in turn led to abnormal differentiation 
process in the epidermis (Smith et al, 2004). 
 
1.7.2 Factors influencing Keratinocyte Differentiation 
There are many factors which influence keratinocyte differentiation and these 
include epidermal growth factor (EGF), keratinocyte growth factor (KGF), 
transforming growth factor (TGF), retinoic acid, thyroid hormone and calcium 
(McBride et al, 1999). In adult epidermis, EGF receptor (EGFR) is mainly expressed 
in the basal layer and to a lesser extent in the suprabasal layer (Tomic-Canic et al, 
1998). The binding of the ligand to EGFR causes keratinocyte activation, 
proliferation, degradation of extracellular matrix and subsequent keratinocyte 
migration to different layers (Tomic-Canic et al, 1998). In the human epidermis there 
is a calcium gradient being lowest in the basal layer and the highest in the granular 
layer, and this gradient is essential for in-vivo differentiation (Bikle, 2004). 
Keratinocytes grown at low calcium concentration (below 0.07mM) undergo cell 
proliferation, in which there is a slow development of intercellular contact and slow 
formation of the cornified envelope. Increasing the calcium concentration (above 
0.1Mm) causes a number of changes including switching from the expression of 
proliferation markers to the expression of epidermal K1/K10 differentiation markers 
and elevated expression of transglutaminase and involucrin (Yang et al, 2003). The 
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basal keratinocytes contain vitamin D receptors, which allow keratinocytes to 
produce their own supply of the active metabolite of vitamin D, 1,25 (OH)2 D3, 
which causes keratinocyte differentiation (Bikle, 2004). Study looking at the effect of 
fibroblast secreted KGF on the morphogenesis of reconstituted human oral 
epithelium has shown that although KGF promoted epithelial growth, it did not 
significantly increase epithelial differentiation (Costea et al, 2003). 
 
Transforming growth factor-beta (TGF-β) is multifunctional cytokine which plays an 
important role in cutaneous wound repair and also has regulatory role in both 
epithelial proliferation and differentiation (Karatsaidis et al, 2003). Of the three TGF-
β isoforms, TGF-β1 inhibits epithelial cell growth by up regulating cyclin-dependent 
kinase inhibitors such as p15 and p21 and also by transcriptionally repressing the 
expression of c-myc gene, which normally promotes cell growth (Karatsaidis et al, 
2003). In addition, TGF-β1 causes keratinocyte apoptosis and regulates keratinocyte 
differentiation by increasing keratin expression (Karatsaidis et al, 2003). Retinoic 
acid (RA) is the active form of vitamin A found in epithelia (Kautsky et al, 1995).  
Using an air–liquid interface culture system which was adapted for growth and 
differentiation of oral  keratinocytes, the effect of RA on morphological 
differentiation and expression markers of keratinized oral epithelia was investigated 
(Kautsky et al, 1995). The results have shown that a specific range of RA 
concentration (10-9 to 10-8 mol/L) was required for epidermal differentiation, whereas 
lower (10-10 mol/L) RA concentration was shown to cause oral keratinocyte 
differentiation (Kautsky et al, 1995). The results have shown that RA works via two 
mechanisms to induce differentiation; 1) via direct RA dependent concentration and 
2) sub-epithelial fibroblasts mediate the affects of RA on differentiation markers 
(Kautsky et al, 1995). RA induces differentiation via concentration dependent 
mechanism, whereby low RA concentration causes decreased expression of K13 and 
K19, whereas proflaggrin and K1 expression was increased (Kautsky et al, 1995). 2) 
The effect of RA on differentiation markers is partially mediated by sub-epithelial 
fibroblasts and this regulation is more indirect, given that the fibroblast influences 
the apparent RA exposure of the keratinocytes independently of the actual RA 
concentration in the culture medium (Kautsky et al, 1995). Furthermore, recent work 
by  Hatakeyama et al, (2004) on the affect of RA on cell-cell and cell-matrix 
connections of gingival epithelial cells in a multilayered culture system, has shown 
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that RA disintegrated desmosomes by depriving the cells of desmoglein I. In 
addition, RA also dissociated desmocollin I, K13, K4, reduced the expression of 
hemidesmosome components BGAGI, and K14 expression in basal keratinocytes 
(Hatakeyama et al, 2004). Using gel mobility assay with purified receptors and 
transient transfection assays with vectors expressing various mutant and K5, K14 and 
K17 promoter-CAT constructs, the affect of Thyroid hormone (T3R) on markers of 
epidermal differentiation was investigated (Tomic-Canic et al, 1996). The results 
have shown that epidermal differentiation markers were constitutively activated by 
unoccupied T3R receptors, while suppression of epidermal differentiation marker 
expression occurred in presence of T3R occupied with ligand. T3R regulates 
epidermal keratin gene expression by directly binding to its response element present 
in keratin gene promoters (Tomic-Canic et al, 1996). 
 
1.8 Intermediate Filament Proteins (IFPs)  
Eukaryotic cells contain a cytoskeleton composed of three types of structural protein 
that continuously reorganize the cell as it changes shape, proliferates and responds to 
its environment (Purves et al, 1998). These structural proteins are actin, which forms 
microfilaments, tubulin which forms microtubules and the intermediate filament 
proteins (IFPs) (Paramio and Jorcano, 2002). Actin and tubulin are important for cell 
shape, mobility and cell division, whereas IFPs have a role in cell and tissue strength. 
There are six types of IF proteins, which are categorized according to their sequence 
and pattern of expression (Hesse et al, 2001). One type of protein is nuclear, while 
the other five are cytoplasmic and differentially expressed in tissues at various stages 
of embryonic and adult development (Fuchs, 1994). Type I and II IFPs are known as 
keratins and comprise 49 proteins expressed in epithelium, hair and nail. Type III IF 
proteins include vimentin (normally expressed in mesenchymal cells), desmin 
(expressed in muscle cells), glial fibrillary acidic protein (expressed in glial cells) 
and peripherin (expressed in the peripheral nervous system). Type IV IF proteins 
include the neurofilament specific proteins (NF-L, NF-M, and NF-H) and Internexin 
which are found in neurones. Type V are the nuclear lamins A, B, B2 and C which 
are found in the nuclear lamina (Paramio and Jorcano, 2002). The rod domain of 
most cytoplasmic IF proteins is approximately 310 amino acids long, while the rod 
domain of nuclear lamins is slightly larger with approximately 352 amino acids 
(Depianto and Coulombe, 2004). The main criteria used to assign a particular protein 
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to the IF family is its ability to polymerize either alone or with other IF proteins into 
a 10-12nm filament. IF proteins possess several conserved features that are essential 
for filament polymerization (Depianto and Coulombe, 2004). The structure of IF 
proteins show that they are composed of three domains: amino-terminal head 
domain, central rod domain and carboxyl-terminal tail domain. The head and tail 
domains differ from the rod domain in many respects, they are smaller in size, differ 
in primary structure and do not adopt a rigid structure like the rod domain (Figure 
1.12). The rod domains are well conserved throughout the IF proteins and are 
essential for keratin filament stability. The ends and middle of the rod domain are the 
sites of most keratin mutations that are responsible for disease (Richard et al, 1995). 
However, mutation involving a single amino acid substitution in a highly conserved 
residue of the amino end of helix 1A of the K14 α-helical rod domain leads to a 
subtype of epidermal bullosa simplex known as Dowling-Meara (Fuchs, 1994). EBS 
Dowling-Meara, is characterised by severe intra-epidermal blistering and clumping 
of keratin filaments in the basal cell cytoplasm (Fuchs, 1994). The rod domain is 
predominantly α-helical in nature, which is interrupted by non-helical linker regions 
at conserved locations. Moreover, the N and C-terminals, which respectively 
correspond to the head and tail portions of the rod domain, posses conserved 
signature motifs that are vital to the formation of biologically functional filaments 
(Depianto and Coulombe, 2004). The above sub-families of IF proteins together form 
the intermediate filaments, but a particular emphasis on type I and type II keratins 
will be the focus of this study. 
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Figure 1.12: Structure of IF proteins. Type I and type II keratins consist of a central 
α-helical rod domain flanked by non-helical N and C terminal segments. The rod 
consists of 4 consecutive α-helical segments (1A, 1B, 2A and 2B), which are 
interrupted by helix breaking linker (L) regions. A coil-coil heterodimer, consisting 
of type I and type II polypeptide, aligned in parallel, is shown above. The most 
severe keratin mutation occurs as single amino acid substitution in the helix 
initiation peptide (HIP) and helix terminal peptide (HTP) (adapted from Presland 
and Dale, 2000). 
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1.9 Intermediate Filament Structure 
 
Keratins are the building blocks of IFs and they go through a series of stages to form 
a functional 10-12nm IFs, these stages are as follows: 
 
? Monomer: keratins are initially synthesized as single proteins. 
  
? Dimers: keratins then form a pair of type I and type II. 
  
? Anti-parallel tetramer: keratins then form into a twisted rope-like structure. 
 
? Protofilament: the tetramers then link in head to tail fashion to form linear 
chains. 
 
? Protofibril: two protofilament intertwine to form a protofibrils, and then 
groups of four protofibrils intertwine.  
 
? Intermediate filament 10-12nm, produced from intertwined protofibrils as 
shown in Figure1.13 (Chu and Weiss 2002).  
 
 
  
 
Figure 1.13: The formation of keratin polypeptide into intermediate filaments,
(adapted from website number 13 in the reference section).  
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1.10 Keratins 
Keratins are insoluble structural proteins that are a major constituent of the epithelial 
cells and their products such as hair, nails, horns and hooves (Reference: website 6). 
Keratin expression in epithelial tissue generally occurs as pairs of type I and II 
heteropolymer (Waseem et al, 1998). Type I keratins of soft epithelia (K9-K23) and 
hair-specific keratins (Ha1-Ha8), are more acidic and smaller than type II keratins, 
having  molecular weight range of 40–56.5kDa. Type II keratins of soft epithelial 
tissues (K1-K8) and hair (Hb1-Hb6) are basic to neutral and are larger in size: 53–
67kDa (Waseem et al, 1998). To date there are a total of 33 type I and 34 type II 
keratin genes known. In type I, 5 are pseudogenes, 17 are epithelial keratin genes and 
11 are hair-specific keratins genes. In type II, there are 8 pseudogenes, 20 epithelial 
keratin genes and 6 hair-specific keratins genes. (Schweizer et al, 2006). Type I 
human keratin genes are located on chromosome 17, with the exception of keratin 18 
which is located on chromosome 12, while type II keratin genes are located on 
chromosome 12 (Hesse et al, 2004). The number of exons and introns in type I and II 
keratin genes are normally 8 and 7 respectively, while the type II K8 (Figure 1.14) 
has intron 5 missing (Krauss and Franke, 1990). Therefore, it seems that keratin gene 
structure is conserved and this conservation is important for filament formation. 
Certain keratin pairs are expressed at certain stage of embryonic development such 
that expression of type I and type II keratins are tissue specific, maturation dependent 
and developmentally regulated (Lu et al, 2006). Keratins can be identified by the 
following properties: 
• they are water insoluble 
• molecular weight range between (40-70kDa) 
• ability to reconstitute into 10-12nm filaments 
• they show epithelial tissue specificity  
• association with desmosomal protein (Sun et al, 1983). 
 The original and most widely used classification of keratins is that proposed by  
Moll et al, (1982), in which keratins were classified according to molecular weight  
as well as into acidic and basic proteins based on their isoelectric properties. 
However, keratin nomenclature has been recently reviewed by Schweizer et al, 
(2006), as shown in the Tables 1.3 and Table 1.4. 
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Table 1.3: New Type I Keratin Nomenclature  
KRT40K40--
KRT39K39--
KRT38K38KRTHA8Ha8
KRT37K37KRTHA7Ha7
KRT36K36KRTHA6Ha6
KRT35K35KRTHA5Ha5
KRT34K34KRTHA4Ha4
KRT33BK33bKRTHA3BHa3-II
KRT33AK33aKRTHA3AHa3-I
KRT32K32KRTHA2Ha2
KRT31K31KRTHA1Ha1
Type I hair-specific keratins
KRT28K28KRT25DK25irs4, HIRSa2
KRT27K27KRT25CK25irs3, K10C, 
HIRSa1
KRT26K26KRT25BK25irs2, K10D
KRT25K25KRT25AK25irs1, K10C, 
HIRSa1
KRT24K24KRT24K24
KRT23K23KRT23K23
--no designationK21 Rat 
KRT20K20KRT20K20
KRT19K19KRT19K19
KRT18K18KRT18K18
KRT17K17KRT17K17
KRT16K16KRT16K16
KRT15K15KRT15K15
KRT14K14KRT14K14
KRT13K13KRT13K13
KRT12K12KRT12K12
KRT10K10KRT10K10
KRT9K9KRT9K9
Type I human epithelial keratins
Current gene 
designation
Current protein 
designation 
Old gene designationOld protein 
designation 
(adapted from Schweizer et al, 2006). 
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Table 1.4: New Type II Keratin Nomenclature  
KRT86K86KRTHB6Hb6, K2.11
KRT85K85KRTHB5Hb5, K2.12
KRT84K84KRTHB4Hb4
KRT83K83KRTHB3Hb3, K2.10
KRT82K82KRTHB2Hb2
KRT81K81KRTHB1Hb1, K2.9
Type II hair-specific keratins
KRT80K80no designationKb20
KRT79K79no designationK6I
KRT78K78no designationK5b
KRT77K77no designationK1b
KRT76K76KRT2BK2p
KRT75K75no designationK6hf
KRT74K74no designationK6irs4
KRT73K73no designationK6irs3
KRT72K72no designationK6irs2
KRT71K71no designationK6irs1
KRT8K8KRT8K8
KRT7K7KRT7K7
KRT6CK6cno designationK6e/h
KRT6BK6bKRT6BK6b
KRT6AK6aKRT6AK6a
KRT5K5KRT5K5
KRT4K4KRT4K4
KRT3K3KRT3K3
KRT2K2KRT2AK2e
KRT1K1KRT1K1
Type II human epithelial keratins
Current gene 
designation
Current protein 
designation 
Old gene 
designation
Old protein 
designation 
(adapted from Schweizer et al, 2006). 
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K1
K2
K3
K4
K5
K6
K7
K8
Type II
K9
K10
K11
K12
K13
K14
K15
K16
K17
K18
K19
K20
I III IV V VI VII II VIII
Keratin family exon and intron conservation
I III IV V VI VII II VIII
I III IV V VI VII II VIII
Type I
I III IV V VI VII II VIII
 
 
 
 
 
 
 
Figure 1.14: Exon and intron conservation among the keratin gene family, light 
yellow boxes with roman numerals represent the number of exons and small tiny 
arrows facing down indicate the number of introns. The black circle shows type II K8 
is missing intron five. The bold long arrow facing right indicates the conserved 
number of exons and introns among keratin type I and type II (adapted from Krauss 
and Franke, 1990).  
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1.11 Keratin Function 
The main function of keratins in epithelial tissue is to provide the cell with 
mechanical support and maintain cell integrity, by imparting strength to the cell and 
prevent it from collapsing. The function of keratins was first discovered in the early 
1990’s when mutations affecting some basal keratins K5/K14 were shown to 
correlate with a type of skin blistering disorder, Epidermolysis Bullosa Simplex 
(Meleady and Clynes, 2001). Another mechanical function of keratin includes 
protecting the cell from apoptosis (Zhou et al, 2006). Recently observed non-
mechanical functions of keratin gene (Figure 1.15) include protecting the cell from 
injury, tissue specific expression, involvement in cell signalling, maintaining the 
position and function of sub-cellular organelle (Zhou et al, 2006). 
 
                   
. 
 
 
Figure 1.15: Function of keratins and other intermediate filament proteins. The 
arrows protruding from the centre box point to the six major cellular functions of 
keratins and other intermediate filament proteins, which are 1; mechanical support 2; 
cyto-architecture 3; regulation and execution of apoptosis 4; regulation of protein 
synthesis 5; organelle distribution and 6; response to stress. The smaller arrows are a 
summary of experimental studies supporting the specific function within the broad 
category of cellular functions (adapted from Gu and Coulombe, 2007). 
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Table 1.5:  The function of epithelial keratins 
Keratins are involved in tissue-specific expression in differentiation dependent functions (the 
head and tail domains which shows heterogeneity in its sequence among different keratins, 
contributing to tissue-specific expression and function of keratins genes. 
Keratins are involved in aiding the targeting of protein to polarized epithelia (apical destined 
membrane markers are either rearranged or absent in villus of intestine keratin null mice 
models).
Keratins are involved in the regulating the availability of cellular proteins (such as keratin 
associated proteins by either providing anchoring or by maybe effecting the enzymatic activity 
of keratin associated proteins).
Keratins act as stress proteins (for example in protecting liver cells from toxins).
Keratins are involved in cell signalling
 
(adapted from Coulombe and Omary, 2002) 
 
1.12 Mechanisms of Transcriptional Regulation of Keratin Gene Expression  
A transcription factor is defined as any molecule participating alone or as apart of a 
complex, in binding to a gene response element with the ultimate outcome of either 
up or down regulation of that gene (Nebert, 2002). Eukaryotic genes show 
differentiation specific expression patterns, which are regulated by cis-acting 
elements (Huff et al, 1993). The two types of positive cis-acting DNA elements are 
described as enhancers and promoters. Promoters by definition are gene region that 
initiates gene transcription, and they are normally only functional when placed 
immediately upstream from the region to be transcribed (Jiang et al, 1990). An 
enhancer can act at a distance, regardless of position or orientation (Jiang et al, 
1990). Such cis-acting elements often serve as the binding sites for transcription 
factors and the cis-elements which regulate keratin gene expression are said to reside 
in the 5′-upstream region or the 3′-downstream of the gene and sometimes in the 
introns (Huff et al, 1993).  To account for the tissue specific expression of keratin 
genes, two mechanisms have been suggested: 1) a positive regulatory mechanism 
with an epithelial specific activator or 2) a negative regulatory mechanism which 
involves a reducer of signal strength in non-epithelial cells or cells which do not 
express the endogenous keratin gene (Jiang et al, 1990). 
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1.13 Transcriptional Regulation of Keratin Gene Expression  
Several studies have identified an increasing number of transcription factors 
implicated in the regulation of  keratin gene expression (Leask et al, 1990; Chen et 
al, 1997; Wang et al, 2002). The control of cell specific gene transcription plays a 
central role in the formation and maintenance of various tissues, including the oral 
mucosa (Wu et al, 1993). Structural variation in the oral mucosa is governed by 
keratinocyte-specific gene expression (Leask et al, 1990), but to date no specific set 
of transcription factors is known to govern tissue-specific expression of keratin 
genes, despite the fact that the 5′-upstream sequences of many keratin genes have 
been cloned and found to function in a tissue specific manner in cultured 
keratinocytes (Wang et al, 2002).  
 
1.13.1 Transcriptional Regulation of K12 Gene  
Important cis-regulatory elements of the mouse K12 gene serve as cornea epithelial 
cell specific factors, these factors include AP-1, C/EBP and  KLF6 and has been 
found to bind in between -0.4Kb to -0.6Kb of the K12 promoter region (Wang et al, 
2002). The defining DNA sequence of the K12 promoter regions has been found by 
deletion analysis of promoter in plasmid constructs either transfected into cultured 
cells or studied in-vivo by the use of transgenic mice (Wang et al, 2002).  
 
1.13.2 Transcriptional Regulation of K14, K3, K15 and K6 Genes  
The AP-2 transcription factor has been implicated in epidermal K14 gene regulation. 
The 5′-upstream sequences of several other keratin gene promoters, including the K3, 
K15 and K6a are also known to harbour AP-2 binding motifs. However, with K5 and 
K14 genes, AP-2 alone does not seem to be sufficient for epithelial specific 
expression (Chen et al, 1997). The 5′-upstream region of bovine K6a gene confers 
tissue-specific expression and hyper-proliferation related induction in transgenic 
mice (Ramirez et al, 1995). 
 
1.13.3 Transcriptional Regulation of K19 Gene  
The K19 promoter has been shown to be active in a subset of gastrointestinal cancer 
cells derived from the oesophagus and pancreas (Opitz and Rustgi, 2000). This 
activity was mapped to a short region containing an overlapping binding site for gut- 
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enriched-Kruppel-like-factor (GKLF/KLF4) and Sp1 in these cells, which leads to 
aberrant K19 gene expression (Opitz and Rustgi, 2000).  
 
1.13.4 Transcriptional Regulation of K4 Gene  
K4 shows tissue specific expression in cornea, oral mucosa and oesophagus, the 
tissue specific transcriptional regulation of K4 expression in the cornea is mediated 
by the binding of Sp1 to two independent Sp1 cis-acting elements. However, the 
transcriptional control of K4 expression in the oesophagus is regulated by GKLF 
oesophageal-specific transcription factor (Opitz and Rustgi, 2000) 
 
1.13.5 Transcriptional Regulation of K17 Gene  
K17 is not normally expressed in the skin, but it is expressed under numerous 
pathological conditions which affect the skin such as cutaneous allergic reactions and 
psoriasis (Milisavljevic et al, 1996). The mechanism involved in the transcriptional 
regulation of K17 is not understood, but in an attempt to unravel the molecular 
mechanism which regulates the expression of K17 gene expression, a 0.45Kb 
promoter region of K17 gene was used (Milisavljevic et al, 1996). The results have 
shown that there is an interferon responsive element, nuclear factor 1 (NF1), AP-2 
and Sp1binding sites in K17 promoter. Site-directed mutagenesis and electrophoretic 
mobility shift assays were used to demonstrate the importance of these transcription 
factors binding sites to the K17 promoter and their functional involvement in both 
the interferon-gamma induced and constitutive K17 expression (Milisavljevic et al, 
1996). 
 
1.13.6 Transcriptional Regulation of K3 Gene  
K3 is expressed in the basal layer of the corneal epithelium and in the suprabasal 
layer of the peripheral cornea (Wu et al, 1993). Using 3.6Kb of K3 upstream 
promoter sequence linked to chloramphenicol acetyl transferase (CAT) reporter 
gene, the K3 promoter construct showed corneal and esophageal cell specific 
expression, but was not expressed in fibroblasts (Wu et al, 1993). This keratinocyte 
specific expression of K3 was localized to 0.3Kb in the upstream sequence and this 
sequence was also shown to contain a cluster of NFkB transcription factors binding 
sites, which is thought to confer the K3 keratinocyte differentiation specific 
expression (Wu et al, 1993). 
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1.13.7 Using Proximal Promoters  
Some studies are subject to methodological criticism of their use of a small promoter 
fragment for investigating vital regulatory sequences. Larger fragments maybe 
essential for a better picture of overall suppressor and enhancer elements important 
for the expression of keratin genes. In addition, experiments with larger fragments 
have produced results with closer to the in-vivo levels of keratin gene expression. 
This is exemplified by K1, the first suprabasal keratin to be investigated as a 
transgene, in which a 10.8Kb fragment containing the human K1 (HK1) coding 
region, 1.2Kb of upstream sequence and 4.4Kb of downstream sequence, is used to 
generate transgenic mice (Blomhoff, 1994). The results have shown that 1) 10.8Kb 
HK1 fragment might be missing sequence information required for correctly 
regulating tissue and developmental specific expression in transgenic mice. 2) The 
Ca2+ concentration in the medium caused induction of both mouse keratin 1 (MK1) 
and HK1 fragment, while other agents such as retinoic acid suppressed MK1 but not 
HK1 (Rosenthal et al, 1991). This data suggest that neither the 10.8Kb  (Blomhoff, 
1994),  nor 12Kb HK1 fragment contain the important cis-acting elements which 
may function to regulate the suppressive action of RA on HK1 (Rosenthal et al, 
1991). In an attempt to support the hypotheses that 1) HK1 can show tissue and 
developmental specific expression in transgenic mice and 2) a further upstream 
regulatory element might be required to enable the observation of the suppressive 
effect of RA on HK1 (Blomhoff, 1994). Transgenic mice were generated from a 
larger HK1 fragment containing the coding region, 13Kb of upstream sequence and 
3.4Kb of downstream sequence (Blomhoff, 1994). As a result of generating this 
larger HK1 fragment, the staining pattern of HK1 was absent in epidermal basal 
layer and the same expression as the endogenous HK1 protein was found (Blomhoff, 
1994). Retinoic acid suppressed expression of larger HK1 fragment in transgenic 
mice (Blomhoff, 1994). Taken together, these results emphasize the importance of 
using larger upstream and downstream sequences of the gene in order to show 
correct regulation with regards to tissue and developmental specific expression of 
keratin genes. Although in this thesis, a larger K13 and K15 promoter (3Kb) 
sequence is used in comparison to other studies (Wang et al, 2002), nevertheless the 
maximum promoter size was estimated to be around 8Kb for K13 and 4.6Kb for K15  
(Appendix: Figure 7.6). Thus, this thesis could have benefited from using the 
complete upstream sequence as opposed to the 3Kb used. As highlighted above with 
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HK1, larger fragments are more likely to show correct regulation and thus are closer 
to resembling the in-vivo differentiation-specific expression of keratin genes.  
 
Table 1.6: Summary of studies showing type I and II keratin epithelial specific 
expression and the transcription factors involved. 
(Ohkura et al, 
2005)
Luciferase
reporter gene 
assay has shown 
that the -1759 to 
-1629 of the K14 
promoter a 
caused 
substantial 
increase of K14 
promoter in 
several OSCC 
cell lines. There 
are several  SP-1 
and SP-3 
complex binds to 
that region of the 
promoter.
K14 expression 
in up-regulated 
in oral squamous 
cell carcinoma 
and dysplastic 
tissue.
K14 is basal 
marker in all 
stratified 
epithelia
K14
(Casatorres et al, 
1994)
Most of the 
transcriptional 
activity is located 
to an enhancer -
762-1009 which 
was shown to 
bind AP-1 
Analysis of 
5.2Kb5`upstream 
region of the K5 
gene was able to 
confer corneal 
specific 
expression
The basal layer 
of all stratified 
epithelia
K5
Reference Transcription 
factor  
Notes Normally areas 
of expression 
Name of Keratin 
 
Table 1.6 shows summary of keratins that show epithelial specific expression and the 
transcription factors which are implicated in conferring this specific expression.  
 
1.14 Post-translational Modification of Keratin Proteins  
Keratin proteins can intrinsically regulate their own function by undergoing 
bundling, which enables them to acquire greater elasticity to withstand 
experimentally induced deformation and thus show enhanced mechanical resilience 
(Coulombe and Omary, 2002). Keratin protein function can also be regulated 
extrinsically by their interaction or association with other non-keratin proteins, which 
results in keratin phosphorylation, glycosylation, transglutamination, ubiquitination  
(Figure 1.16) and proteolytic cleavage (Coulombe and Omary, 2002). Amongst all 
the post-translational modifications which regulate keratin protein expression, 
phosphorylation is the most studied (Zhou et al, 2006). Keratin phosphorylation 
involves the addition or removal of a phosphate group which commonly occurs in 
heterogenic sequences present in the head and tail domain of keratins (Zhou et al, 
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2006). Phosphorylation and de-phosphorylation of keratin and other intermediate 
filament proteins are required for transient assembly and disassembly during mitosis, 
leading to remodelling of the epithelium (Owens and Lane, 2003). 
Hyperphosphorylation of keratin causes the assembled keratin filaments to 
irreversibly depolymerize, while specific phosphorylation causes reversible 
remodelling of keratin filaments (Owens and Lane, 2003). For example as result of 
ser52 site phosphorylation in K18, the importance of this site in filament 
reorganisation was recognised; also another phosphorylation site ser33 in K18 was 
identified as been essential for the binding of 14-3-3 protein (Ku et al, 1998). The 
function of keratin associated proteins such as 14-3-3 is to regulate the enzymatic 
activity of the protein to which it is bound to (Ku et al, 1998). For example,  when 
14-3-3 protein reversibly associates with K18/K8 in cultured cells, this leads to 14-3-
3 induced keratin subcellular distribution (Ku et al, 1998). Another posttranslational 
modification of keratins is  glycosylation (Omary et al, 1998).  Glycosylation is the 
addition of polysaccharides to target proteins, this addition of polysaccharides serves 
various function for the protein,  including the correct folding of proteins such that 
they are not degraded rapidly (Omary et al, 1998). Glycosylation of K18, K8, and 
K13  occurs via O-GlcNac (Omary et al, 1998). Three serine glycosylated sites were 
identified in the head domain of K18 protein and, although the function of this 
posttranslational modification is unknown, it is thought that all keratins are  
glycosylated (Omary et al, 1998). Transglutamination occurs in both stratified 
epidermal and simple epithelial keratins (Omary et al, 1998). Transglutamination of 
keratin proteins occurs during normal physiological and diseases state (Coulombe 
and Omary, 2002). Transglutamination modification of keratin protein occurs in the 
cornified envelope (CE) and links, a few type II keratins (K6, K5, K2 and K1) 
proteins to other structural CE proteins like loricrin, involucrin and envoplakin, by 
the highly conserved lysine in the head domain (Coulombe and Omary, 2002). Use 
of fractionated mouse epidermis for analysis of keratin expression, has led to the  
identification of a 67kDa protein (K1) and another smaller protein product of 
65.5kDa (K1a) which arose by proteolytic cleavage  in the granular layer of the 
epidermis (Bowden et al, 1987). In addition, further proteolytic modulation of the 
58kDa (K10), has led to the production of another smaller product of 55.5kDa 
(K10a) in extracts derived from stratum corneum of fractioned mouse epidermis 
(Bowden et al, 1987). This proteolytic modification is thought to take place in the 
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lower and upper stratum corneum of the epidermal environment (Bowden et al, 
1984). The proteolytic modification of K1 and K10 is thought to permit the tight 
packing of filaments in the stratum corneum and thus contribute to the specific 
protective function of the epidermis  (Bowden et al, 1984). 
 
1.14.1 Phosphorylation Modification of Other IFPs 
Other intermediate filament proteins (IFPs) such as vimentin, have been reported to 
be regulated by p21-activated kinase (PAK), a downstream target of Cdc42 or Rac 
(Goto et al, 2002). As result of PAK enzyme binding to vimentin, the following 
serine sites, ser25, ser38, ser50, ser65 and ser72 in the amino terminal head domain 
of vimentin are phosphorylated by PAK (Goto et al, 2002). It was suggested that 
vimentin phosphorylation by PAK in COS-7 cells might regulate the reorganisation 
of vimentin filament (Goto et al, 2002). 
 
 
 
                                                                                                  
 
 
 
 
 
 
Figure 1.16: Various post-translational mechanisms which regulate the expression of 
keratin and keratin associated proteins (adapted from Coulombe and Omary, 2002).
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1.15 Keratin Expression in Normal Epithelia   
The expression of a specific pair of keratins (Table 1.7) begins in the basal layer of 
the stratified squamous epithelium, which typically expresses K5, K14 and to a lesser 
extent, K15 (Radoja et al, 2004). However, in the basal layer of the oesophageal 
epithelium K14 is substituted by K15 (Brembeck et al, 2001). The expression of the 
K5/K14 pair is down-regulated when keratinocytes detach from the basement 
membrane. This is followed by the expression of a suprabasal keratin pair, which 
differs between epithelial tissues; for example, in keratinizing epithelia of the 
epidermis, gingiva and hard palate, the K1/K10 are expressed (Waseem et al, 1998). 
However, in non-keratinizing buccal and oesophagus epithelium K4/K13 are 
expressed. In the more differentiated central cornea K3/K12 are expressed in both the 
basal and suprabasal layers, but in the stem cell rich peripheral cornea (the limbus),  
K12/K3 are expressed only in the suprabasal layer (Jiang et al, 1991) The adult 
tongue expresses K1, K2, K4, K5, K6a, K10, K13, K14, and K16 and infrequently 
expresses K17. In the basal layer of both the fungiform and filiform papillae K5 and 
K14 are expressed (Vaidya et al, 2000). K6a and K16 are usually expressed in the 
outer root sheath of hair follicles, the gingiva and hard palate, oesophagus, and 
female genital tract (Waseem et al, 1999). K6a and K16 are also expressed in the nail 
bed and the epidermis covering the palms and the soles (Rothnagel et al, 1999). 
Other keratins that are normally expressed in palm and sole skin include K1, K5, K9, 
K10, K14 and K17 (Rugg et al, 2002). The suprabasal layer of the hard palate and 
gingiva express K76 which distinguishes it from the epidermal K2 (Presland and 
Dale, 2000). K11, which was identified in the original keratin cataloguing by Moll et 
al, (1982), was later identified as a modified form of K10 and thus K11 does not 
exist in the human genome (Bowden, 2005). K7 and K17 are expressed in simple 
epithelial, for example the kidney (Jiang et al, 1991). K8 and K18 are normally 
expressed in the simple epithelia of the liver, small and large intestine and the 
pancreas which particularly expresses high levels of K8 and K18 (Brembeck et al, 
2001). K8 and K19 are normally expressed in glandular and in foetal buccal and 
tongue epithelium until 27 weeks of gestation (Fillies et al, 2006). Sites of K19 
expression include the oesophagus, stomach, pancreas, small intestine, colon in 
human adults, outer root sheath of the hair follicle and foetal liver, which expresses 
particularly high levels of K19, but this is not normally expressed in adult liver cells 
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or epidermis (Brembeck and Rustgi, 2000; Chu and Weiss, 2002). K20 is normally 
expressed in gastrointestinal epithelia and urothelia (Owens and Lane, 2003).  
 
Table 1.7: Keratin expression in simple and stratified epithelia 
Hyperproliferative squamous epitheliaK16, K17K6a, K6b
Non-keratinizing stratified squamous 
epithelia of internal organs.
K13K4
Corneal epitheliumK12K3
Gingiva, hard palateK76
Epidermis (high layers)K2
Epidermis of the palms and solesK9
Epidermis (entire suprabasal compartment)K10K1Suprabasal 
cells
Squamous epithelia.K15
Basal cells of the squamous and glandular 
epithelia, myoepithelia, and mesothelium.
K14K5Stratified 
squamous 
epithelial
Gastrointestinal epithelia, Merkel cells of 
the skin and taste buds of the oral mucosa
K20
Ductal epithelia (bile and pancreatic, renal 
collecting duct) and gastrointestinal 
epithelia.
K19K7
Most secretory and parenchymatous cellsK18K8Simple 
epithelial 
Type IType II
DistributionKeratins Epithelial type
(adapted from Chu and Weiss, 2002). 
 
1.15.1 Hair-Specific Keratins  
The hair keratins were originally designated as hard keratins and the epithelial 
keratins as soft keratins (Langbein et al, 2001). The hard keratins are involved in the 
formation of keratinized structures such as nails, claws and hair (Langbein et al, 
2001). Like the soft keratins, the hard keratins are also divided into an acidic (Ha) 
type I (44-48kDa), whose genes are located in chromosome 17, and a basic (Hb) type 
II (55-60kDa) keratins, whose genes are located in chromosome 12 (Langbein et al, 
2001). Using two-dimesional gel electrophoresis and Coomassie blue, stained 
proteins of each hair keratin subfamily were numbered 1 to 4 (Langbein et al, 2001). 
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These type I hair keratins were designated as hHa1 to hHa4, while the type II were 
designated hHb1 to hHb4. In addition, a subsequent characterisation of type I and II 
hair keratins has led to the discovery of 7 type I and 4 type II keratins proteins 
(Langbein et al, 2001). Based on sequence characteristics, the type I hair keratins 
have been divided into 3 distinct groups (Cribier et al, 2001). Group A, which 
includes hHa1, hHa3-I, hHa3-II and hHa4, is expressed in the hair cortex; group B 
members, which include hHa7 and hHa8, are expressed in the vellus hair and in the 
cortex of terminal hair. Group C members, which include  hHa6, hHa5 and hHa2, are 
expressed in the cuticle and matrix or the cortex (Cribier et al, 2001). However, 
recent studies have shown that the type I and II hair keratins comprise exactly 11 and 
6 members of hair keratins and are designated as K31 to K40 for type I and K81 to 
K86 for type II as shown in Tables 1.3 and 1.4 (Schweizer et al, 2006). 
 
1.16 Keratin Expression in Pathology  
Epithelia are the origin of most human cancers, and are located at sites where cell 
division is high and epithelial cells are environmentally stressed, these factors make 
the proliferating cells more prone to oncogenic transformation (Owens and Lane, 
2003). Importantly, the epithelia also interface with the environment. The causes of 
epithelial cancer can be both genetic and environmental, such as smoking (Reibel, 
2003). Studies on various populations have reported that smokers have higher risks 
of getting oral cancer than non-smokers (Reibel, 2003). Although the exact 
mechanism through which smoking causes oral cancer remains unknown, it is 
thought that the carcinogens in tobacco smoke can cause changes in DNA (Reibel, 
2003). Markers used for determining future cancer development in oral pre-
malignant lesions are divided into three categories, 1) genomic markers including 
chromosome aberrations (which cause loss or gain of allele), 2) proliferation markers 
and 3) differentiation markers (Reibel, 2003). Keratins are differentiation markers of 
oral mucosa and can also be utilized for characterization of malignant tumours, since 
expression of a particular keratin in tumour cells is dependent on the degree of 
differentiation (Kim et al, 1996). Furthermore, in oral squamous cell carcinoma 
(OSCC), there is marked reduction of K13 and K4 expression, with the appearance 
of K1 and K10 as well as K2 (Boisnic et al, 1995). OSCC accounts for 90% or more 
of all oral malignant neoplasms, but with respect to all cancers, oral cancer accounts 
for appropriately 4% (Soames et al, 2005). OSCC is the sixth most frequent cancer in 
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the world with approximately 30,000 new cases diagnosed annually (Nagler 2002). 
The incidence of oral cancer varies enormously around the world and it is most 
prevalent in India and south East Asia (Soames et al, 2005). The overall 5 year 
survival rate for patients with oral squamous cell carcinoma is among the lowest for 
major cancers, despite progress in therapeutic and diagnostic oncology in the past 
two decades (Nagler, 2002). Prognosis remains poor owing to continued diagnosis of 
the disease only at an advanced stage (Nagler, 2002) and a major area of 
improvement should be aimed at promoting awareness of OSCC by educating the 
general public about signs, symptoms and aetiological factors which increase the risk 
of oral cancer. This would assist early detection of oral cancer when treatment is 
most effective (Gervasio et al, 2001). The finding of biological tumour markers 
might increase the early diagnosis and treatment rates of OSCC (Nagler, 2002). 
Epithelial tumours retain specific features of keratin expression patterns of their cell 
type of origin, and in cases where clinical data or conventional histopathology 
remain unclear, keratin proteins can be used to aid in identifying and classifying the 
tumour (Moll et al, 2008). Keratins are thought to be a good biological tumour 
marker because they are stable and effective immunogens for generating monoclonal 
antibodies (Owens and Lane, 2003). Staining for keratins in epithelial tumours, 
indicated patterns of keratin expression associated with:  
? Expression of new subsets of keratins not expressed by normal tissue.  
? Lack of expression of  the original keratins (Kim et al, 1996). 
OSCC originates from different sites and is normally characterised by stratified 
epithelial-specific keratins, which might be co-expressed with simple epithelial-
specific keratins (Moll et al, 2008). Of all the known keratin genes to date, only a 
few have been used as a diagnostic markers (Moll et al, 2008). An example of 
expression of new subsets of keratins not expressed by normal tissue, has recently 
been reported in SCC of the oral cavity whereby the expression of simple epithelial-
specific K8/K18 expression was used as an independent prognostic marker and has 
been shown to correlate with decreased overall and progression free survival (Fillies 
et al, 2006). 
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1.17 Keratins Implicated in Genetic Diseases    
A link between keratins and their inherited mutations which lead to skin fragility and 
oral mucosa disorders was discovered in the early 1990s; this proved to be a valuable 
discovery in the understanding of intermediate filament function (Lane and McLean, 
2004). K5 or K14 gene mutations in mouse and human epidermis have been shown 
to cause a skin blistering disorder known as epidermolysis  bullosa simplex (EBS) 
(DePianto and Coulombe, 2004). EBS is a genetic skin disease affecting 
approximately 1:2000 of the population (Csikos et al, 2004). Almost all cases of EBS 
are characterized by mechanical-stress-induced blistering of the skin and, in severe 
cases, the oesophagus and oral mucosa may also blister (Csikos et al, 2004). This is a 
results of keratin filament bundle degeneration in the basal keratinocytes which 
begins within a few days after birth (Csikos et al, 2004). Furthermore, common 
phenomenon occurring in keratin gene families is substitution for one member of the 
keratin family by another mutated or missing one (Radoja et al, 2004), which leads to 
a lack of phenotype in gene knock-out. An example of the above was observed in 
mutant K14 gene in EBS patients, which was counteracted by increasing the cellular 
content of K15 using thyroid hormone and IFN-  agents, in an attempt to compensate 
for the mutant K14 and thus ease the skin blistering in EBS patients (Radoja et al, 
2004). Mutations in palm and sole skin associated K1, K5, K6b, K10, K14, K16, 
K17 and K9 genes are thought to cause palmoplantar keratodermas (PPKs), which 
involves thickening and hyperkeratosis of palmoplantar skin (Rugg et al, 2002). 
Furthermore, mutation of epidermal suprabasal markers K1 and K10 results in a 
condition known as epidermolytic hyperkeratosis, a blistering of the suprabasal layer 
caused by cell lysis, degeneration and basal cell hyperplasia (Brembeck et al, 2001). 
Additionally, keratins have been implicated in functional roles beyond that of 
mechanical resistance. For example, the K8 and K18 filaments network found in the 
simple epithelia of the liver contributes to the resistance of hepatocytes to chemical 
and osmotic stress (DePianto and Coulombe, 2004). K8 or K18 gene knockout mice 
experiment has demonstrated a predisposition of mice to liver cirrhosis (DePianto 
and Coulombe, 2004).  
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1.17.1 Keratin Mutations and Overlapping Phenotypes in Skin and Oral 
Mucosa Epithelia  
Some of the mutations in keratin genes can cause overlapping phenotypes in 
different tissues which expresses the keratin gene. An example of this is a 3bp 
deletion in exon 1 of KRT6A, which leads to removal of asparagine from position 8 
in the conserved 1A helical domain. This results in a rare autosomal dominant 
condition known as Pachyonychia Congenita (PC) (Bowden et al, 1995). PC is more 
common in Slovenian  and Croatian families who are from specific locations having 
isolated populations where family members intermarry (Bowden et al, 1995). K6a 
and K16 are normally expressed in palm and sole epidermis, hair follicle, nail and 
oral epithelia of the tongue (Bowden et al, 1995). Thus mutations in KRT6A, results 
in thickened nails, palmoplantar keratoderma and leukokeratosis of the tongue 
(Bowden et al, 1995). In addition, mutation in the KRT13 and KRT4 genes has been 
shown to cause a benign autosomal dominant disorder known as White Sponge 
Nevus (WSN), which is characterized by thick, white spongy fold in the oral mucosa, 
and to a lesser extent in the mucosal membrane of the nose, oesophagus and the  
rectum (Opitz et al, 1998). Histological analysis of the white spongy plaque shows 
evidence of acanthosis, hyperproliferation and tonofilament aggregation and these 
pathological changes are also associated with many epidermal keratin disorders 
(Rugg et al, 1995). Furthermore, a three-base-pair deletion in the helix initiation 
peptide of K4 was discovered in some families affected by WSN (Rugg et al, 1995), 
while a substitution mutation has been found in one allele of K13 gene leading to 
substitution of conserved leucine for proline (Richard et al, 1995). This substitution 
mutation occurred in the conserved 1A region of the helical rod domain which is 
important for keratin filament stability and is the site which corresponds to most 
keratin mutations that causes disease (Richard et al, 1995).  
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Table 1.8: Keratin proteins and associated Keratinopathies of Epidermis and Oral 
mucosa 
White sponge nevusK4, K13
EB simplexK5, K14, K19 (basal)Buccal/soft palate
None reported K76
None reportedK1, K10
Pachyonychia congenitaK6a, K16,
EB simplexK5, K14 (basal)Gingiva/hard palate
Epidermolytic hyperkeratosis 2K1, K10
Pachyonychia congenitaK6a, K16, K19
Non-Epidermolytic form of PPKK16
Epidermolytic PPKK9Palm and Sole skin
Ichthyosis bullosa of Siemens K2
Epidermolytic hyperkeratosisK1, K10
EB simplex (K5,K14)K5, K14 (basal)Epidermis
Associated KeratinopathiesKeratin proteins 
expressed
Tissue
 
(adapted from Presland and Dale, 2000). 
 
1.18 Keratin 13 
 Human keratin 13 (K13) is a type I acidic keratin with a molecular weight of 54kDa. 
The K13 gene (KRT13) is 4601 nucleotides long and contains seven introns and eight 
exons (Waseem et al, 1998). Human KRT13 has been mapped to the long arm region 
of chromosome 17 (Romano et al, 1992). Although there are pseudogenes or 
functional isoforms of some keratins such as K14 (in the human genome there are 
three K14 pseudogenes), only one appears to be functional (Vassar et al, 1989) and 
there is no evidence of multiple KRT13 genes (Richard et al, 1995; Waseem et al, 
1998). K13 is heavily O-glycosylated in certain cultured keratinocytes but not in 
mucosal tissues of human or mouse origin. Although N-acetylglucosamine is the 
residue involved in K13 glycosylation, neither the site of this sugar attachment nor 
the function of this post-translational modification has been clarified (King and 
Hounsell, 1989). K13 is one of the most abundant filament proteins in buccal non-
stratified epithelia (Kim et al, 1996) and together with K4, its type II basic keratin 
partner, it forms the major keratin network of most internal stratified epithelia 
(Waseem et al, 1998). Furthermore, in most stratified squamous epithelia K13 is 
expressed in suprabasal layers, although in human urothelium K13 has been 
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identified in basal as well as in suprabasal layers (Kuruc et a, 1989). Using 
immunohistochemistry to stain for K13, expression was found in buccal, soft palate, 
gingiva and conjunctival mucosa (Brysk and Tyring, 1995). K13 is also strongly 
expressed in the ventral surface of the tongue (Sawaf et al, 1990). The epidermis 
does not normally express K13, but exceptions are the penile foreskin, the anus and 
regenerating epidermis (Waseem et al, 1998). 
 
1.18.1 Factors influencing K13 Expression 
 The reported factors which influence K13 expression are retinoic acid and calcium 
(Waseem et al, 1998). The expression of K13 has been shown to be elevated in 
presence of 1.2mM calcium in comparison to keratinocyte growth medium without 
calcium (Brysk and Tyring, 1995).  Retinoic acid (RA), the active form of vitamin A, 
has been reported to directly and indirectly modulate the growth and differentiation 
of various normal and malignant cells (Kim et al, 1996). The direct  effects of 
retinoic acid are thought to be mediated by changes in K13 expression, since the K13 
promoter has been reported to contain an retinoic acid responsive element (RARE) 
consensus sequence (GGTTCA(N)5TGTTCT). This sequence has homology to the 
natural RARE of the β2 retinoic acid receptor gene (Winter et al, 1994). Using 
differential cDNA cloning, 10 genes were identified as been regulated by retinoic 
acid in a head and neck squamous carcinoma cell line (MDA886Ln). Among the 10 
genes identified, K13 gene expression was most related to the degree of sensitivity of 
growth to RA, as K13 was not expressed in a series of RA-resistant cell lines tested 
and it was suggested that low K13 expression might be mechanistically related to 
resistance to RA-induced growth inhibition (Kim et al, 1996). Furthermore, RA 
regulates oral epithelial differentiation by effecting gene transcription via interaction 
with specific nuclear receptor proteins that function as retinoid activated 
transcription factors (Kautsky et al, 1995). 
 
1.18.2 K13 Expression in Development and Experimental Models 
K13 is expressed by foetal epidermis and cultured epidermal keratinocytes, but it is 
seen in adult skin only as occasional patches in the basal-cell layer. It was suggested 
that the association of K13 expression with mucosal surfaces and with submerged 
keratinocyte cultures may be linked to its expression in foetal skin (Brysk and 
Tyring, 1995).  However, human K13 is only transiently expressed in keratinocytes 
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of foetal epidermis, and is replaced by K10 later in adulthood (Kuruc et al, 1989). 
Furthermore, the normal pattern of K13 expression and other keratins is altered in the 
presence of chemically and virally induced tumours. For example, the expression of 
K1 and K10 in DMBA and TPA-induced epidermal tumours is suppressed, with an 
increase in K13, which is considered to be an early marker of carcinoma progression. 
Nevertheless, although K13 expression is induced by DMBA and TPA in epidermal 
tumours, K13 is not normally expressed in human epidermis (Waseem et al, 1998). 
 
1.18.3 Epigenetic Control of Gene Expression  
Epigenetic refers to features of chromatin and DNA modification that are stable over 
many rounds of cell division but do not involve changes in the underlying DNA 
sequence of the organism (Bird, 2007). Epigenetic control of gene expression (Figure 
1.17) occurs in two ways: modification of the state of histone proteins, or chemical 
alteration of the DNA (Qiu, 2006). The histone proteins determine whether the 
chromatin is tightly packed,  so transcription factors cannot have access to the DNA 
and gene transcription is silenced; or whether the chromatin is in a relaxed state and 
thus the gene can be transcribed (Qiu, 2006). Chemical DNA alteration occurs by 
methylation, that is the addition of methyl group by DNA methyltransferase to the 
cytosine base when it is followed by guanine in the DNA (Qiu, 2006). The addition 
of methyl groups to DNA attracts proteins that specifically bind methylated DNA, 
and this results in blocking access of transcription factors required for the induction 
of gene expression (Curradi et al, 2002). These proteins contain a methylated-DNA 
binding domain (MBD) and have been implicated in gene transcriptional repression 
(Curradi et al, 2002). In addition, when the MBD proteins were biochemically 
characterised they were found to exist in complexes with histone  deacetylase, which 
indicates that methylated CpGs (mCpGs) suppress transcription by establishing a 
repressive chromatin environment (Curradi et al, 2002). Thus Curradi et al, (2002) 
have proposed that CpG methylation and histone deacetylation act synergistically to 
silence gene expression. Both DNA methylation and histone modification are 
important for genome reprogramming during development, large-scale gene 
silencing and tissue specific expression (Beri et al, 2007).  
 
Tissue–specific expression of murine K13 in internal stratified squamous epithelia 
and its abnormal expression during two-stage mouse skin carcinogenesis is 
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associated with the methylation state of the remote 5'-flanking region of the gene 
(Winter et al, 1990). The murine K13 gene CpG methylation site termed M1 is 
located -2.3Kb upstream from the transcriptional start site, is involved in controlling 
the tissue specific K13 expression in stratified squamous epithelium. The methylated 
M1 site was observed in both basal and suprabasal cells of the epidermis (Winter et 
al, 1990) and thus correlated with the lack of K13 expression in the epidermis. On 
the other hand, the M1 site is unmethylated in the cells of internal stratified 
squamous epithelia of the tongue and oesophagus, which leads to K13 expression in 
these tissues (Winter et al, 1990). However, unlike its mouse counterpart, human 
K13 (Waseem et al, 1998) expression is not regulated by DNA methylation.   
 
Figure 1.17: The epigenetic control of gene expression by DNA methylation and 
histone acetylation. Both mechanisms synergistically act together to either cause 
gene expression or silence gene expression such that lack of protein expression in 
tissues which do not endogenously express the gene occurs (adapted from website 9 
in Reference).  
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1.19 Keratin 15 
Human keratin 15 (K15) is a 57kDa protein which belongs to the acidic or type I 
keratin family and assembles into keratin filament network paired with K5, its basic 
type II partner (Romano et al, 1992). The K15 gene comprises  8 exons spanning 
appropriately 5.1Kb (Whittock et al, 2000). K15 is located in the q12-q24 region of 
chromosome 17 (Romano et al, 1992). The proliferating basal keratinocytes of all 
stratified squamous epithelial are characterized by their attachment to the basement 
membrane and expression of K14/K5 and to a lesser extent K15 (Radoja et al, 2004). 
K15 is normally expressed in basal cells of many epithelial tissues, such as those of 
the oral mucosa and the epidermis. In the epidermis, K15 is present in higher 
amounts in basal cells of thin skin than in the rapidly turning over thick sole plantar 
skin (Porter et al, 2000). In cultured keratinocytes, K15 levels are suppressed until 
the stratification of cultures, whereas K14 is constitutively expressed (Porter et al, 
2000). In mouse and sheep K15 is expressed in the outer root sheath cells of hair 
follicle bulb and is restricted to the basal layer of the oesophagus. However, in 
human oesophagus, K15 is expressed throughout the epithelium (Whitbread and 
Powell, 1998). K15 is also weakly expressed in the ventral surface of the tongue 
(Sawaf et al, 1990). 
 
1.19.1 K15 and K13 Expression as Models of in-vitro Epithelial Differentiation. 
The K15 promoter was incorporated into this study for the following reasons: unlike 
K13 which is expressed in the suprabasal layer, K15 is expressed in the basal layer of 
both epidermis and oral mucosa (Porter et al, 2000). Furthermore, when basal cells 
differentiate, they migrate to the suprabasal compartment and during this process, the 
tissue stops synthesizing K5, K14 and K15 and induces other keratin pairs, 
characteristic of each tissue type (Casatorres et al, 1994). Thus to understand cell-
specific keratin expression, it is necessary to study the mechanism by which the K15 
gene promoter will enable positive or negative regulation in different environments 
(Casatorres et al, 1994) in comparison to suprabasal expressed K13 gene promoter. 
In addition, of the entire human type I keratin group, K13 shows the closest 
relationship to K15, since both K13 and K15 are characterized by relatively short tail 
domains of 46 and 43 amino acid residues respectively and are generally rich in 
hydroxyl-amino acids (Kuruc et al, 1989). While the location of stem cells can be 
related to the anatomic structure of some tissues (such as intestine, tongue papillae, 
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and hair follicles), stem cells are not easily identifiable morphologically in most 
areas of skin and oral mucosa. The presence of adhesion molecules such as the β1-
integrins and β-catenin were reported to be stem cell markers (Squier and Kremer, 
2001). Staining for K15 and K19 has been used to identify stem cells in hair follicle, 
skin and in oral mucosa and are reported to be putative “stem cell markers” in these 
regions (Tudor et al, 2004). The utilization of K15 as a stem cell marker in the oral 
mucosa may enable researchers to identify the properties of stem cells in-vitro more 
easily and may lead to elucidating the molecules that coordinate specific 
developmental programs important in determining the influences of the environment 
on stem cell regulation and differentiation (Alonso and Fuchs, 2003). 
 
1.19.2 Factors and Regulatory Elements Influencing K15 Expression  
Analysis of murine K15 regulation has shown that the 5'-upstream region of the 
promoter may possess inhibitory cis-acting elements. Promoter sequences have 
exposed numerous potential cis-regulatory elements such as AP-1 and Sp1 binding 
sites, which are also important for regulation of numerous keratin genes. The AP-1 
and Sp1 regulatory elements which bind the promoter region of the K15 gene are  
thought to inhibit K15 expression at some level and could be important for the basal 
specific expression of K15 gene (Liu et al, 2003). In addition, the manipulation of a 
cloned human K15 promoter with transcription factor and extracellular agents has 
shown that retinoic acid, glucocorticoid receptors and NF-kB suppressed K15 
expression, while C/EBP-β and AP-1 induced K15 gene expression (Radoja et al, 
2004). However, thyroid hormone and IFN-  are the only agents which potently 
increased the K15 promoter expression (Radoja et al, 2004). Other factors reported to 
downregulate K15 gene expression include TGF-β and tumour necrosis factor-α 
(TNF-α). K15 expression was suppressed by TGF-β and TNF-α, but to a lesser extent 
than epidermal growth factor (EGF) and keratinocyte growth factor (KGF) (Werner 
and Munz, 2000). Unlike K15, K14 has been shown to be upregulated by TGF-β. 
K15 mRNA was also reduced in expression after skin injury, whereas K14 
expression increased during wound healing process (Werner and Munz, 2000). Using 
immuno-staining, K15 was localized to basal layer of the epidermis next to the 
wound, but not in the hyperproliferative epidermis (Werner and Munz, 2000). K15 
exclusion from activated keratinocytes of the thickened wound epidermis was 
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explained by the increase of growth factor expression in injured skin leading to the 
absence of K15  expression (Werner and Munz, 2000).  
 
1.20 Hypothesis and Aims of the Study 
As outlined in this review, very little is known about K15 and K13 transcriptional 
regulation during differentiation-specific expression in the oral mucosa. In order to 
shed light on the molecular mechanism governing oral mucosa basal and suprabasal 
marker expression, this study will use K15 and K13 promoter-linked GFP reporter 
assays.   
 
1) The mechanisms which regulate tissue specific expression of K13 are unknown. 
Therefore, the first hypothesis is that the expression of K13 promoter is regulated by 
suppressor elements rather than enhancer elements. This will be investigated by 
using a human K13 promoter linked GFP reporter gene construct and 5'-end 
truncated K13 promoter constructs which will be transiently transfected into 
permissive and non-permissive cell lines. Also, the importance of PKC, MEK 1/2 
and PI3K/Akt pathways for the expression of K13 will be tested. This will be done 
by using transient transfection of a full length K13 promoter construct and Western 
blot to detect K13 protein expression in the presence or absence of PKC, MEK 1/2 
and PI3K/Akt pathway inhibitors or activators.  
 
2) The second hypothesis to be tested is that isolated human K13 and K15 promoter-
linked GFP reporter gene expression is correlated with heterogeneous 
morphologically-distinct subpopulations present in oral mucosal cell lines. This will 
be investigated by transfecting the K15 and K13 promoter constructs into epithelial 
cell lines and using FACS to measure GFP expression. Colony assay will also be 
used to count the number of colonies formed by cells counting K15 or K13 FACS 
sorted promoter constructs. Immunocytochemistry will also be used to detect K15 
and K13 protein expression in oral epithelial cell lines. 
 
3) The third hypothesis is that the use of a transcription factor database is likely to 
reveal that suprabasal keratin promoters are governed by a set of transcription factors 
which are different from those governing basal keratin promoters. This hypothesis 
will be addressed by the use of a transcription factor database to see if transcription 
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factors which confer tissue specific expression in the basal and suprabasal layer are 
the same or different.   
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Figure 1.18: Diagram illustrating the overall aim of the study: the use of a 
transcription factor database (A) to detect putative transcription factor binding sites in 
keratin gene promoters as described in chapter 3 and how this chapter interlinks with 
chapter 4 and 5 is shown. (B) Shows the tissue specific differentiation as marked by 
K13 expression in the oral mucosa but not in the epidermis, as described in chapter 4. 
(C) Shows the correlation of K15 and K13 expression with oral mucosa maturation as 
described in chapter 5 (pictures were taken from website 1, 4 and 5 in the Reference 
section). 
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Chapter 2 
 
 Materials and Methods  
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 2.1 Introduction to the use of Reporter Gene Assays and the Advantages of 
using a GFP Reporter Gene. 
Analysis of individual cells at the molecular and physiological levels requires 
establishment of in-vitro culture systems whereby individual cells can be separately 
identified and investigated. In order to follow a particular gene of interest in a culture 
system it would be useful to develop methods of foreign gene transfer which make it 
possible to change cellular physiology or functions  (Kishi et al, 2001). There are 
several ways to study signal transduction, promoter activity and gene expression, and 
one way is using an in-vivo reporter system. The reporter gene is placed downstream 
of a regulatory DNA sequence of interest (for example a promoter), and changes in 
reporter gene activity reflect changes in regulatory signals received by the promoter 
(Furtado and Henry, 2002). There are many reporter genes available today  to study 
gene expression and promoter activity in eukaryotic cells (Furtado and Henry, 2002). 
These reporter genes include: uidA encoding β-glucuronidase, LacZ encoding β-
galactosidase, cat encoding chloramphenicol acetyltransferase (CAT) and luc 
encoding luciferase reporters whose activities can be detected by measuring the 
product of an enzymatic reaction. However, green fluorescent protein (GFP) from 
jelly fish (Aequorea Victoria) is the only reporter which can be used for quantitative 
as well as qualitative assays. It is widely used as a reporter to study gene expression 
and protein localization in mammalian, bacterial and plant systems. The gfp gene 
encodes a green fluorescent protein (GFP), which emits green fluorescence (500-
510nm) when exposed to 488nm blue/green visible light. The use of GFP has the 
following advantages: addition of substrate or cofactor in in-vivo or in-vitro is not 
required, it is resistant to photo bleaching and it remains stable under a wide variety 
of conditions. In addition, the GFP fluorescence can be detected with minimal 
handling and, in particular, no preparation of lysate is required and a fluorescence 
microscope, a fluorometer, a fluorescence-activated cell sorting machine, or an 
imaging microplate reader can used to either quantify or visualize GFP expression 
(Furtado and Henry, 2002).  
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2.1.1 From Wild-Type GFP to Variant EGFP and Dual Coloured Fluorescent 
Proteins  
The wild-type GFP protein has the undesirable property of low fluorescent intensity, 
when excited by blue light, which is due to lag in the development of fluorescence 
after the GFP has been synthesized (Zhang et al, 1996). The low fluorescent intensity 
of the wild-type GFP leads to poor expression in different mammalian cells and 
insensitivity of GFP, such that the GFP is below the standard for reporter proteins 
(Zhang et al, 1996). In an attempt to overcome this problem and thus improve GFP 
expression and detection in transfected mammalian cells, a mutation in the 
chromophore (the primary structure of GFP protein) was created, to make a EGFP 
protein which is 35 times more brighter than wild-type GFP protein (Zhang et al, 
1996). The other alteration in the EGFP variant is codon optimization, whereby, in 
place of the jellyfish codon, favoured codons of highly expressed human proteins are 
used (Zhang et al, 1996). The GFP variants, which differ in their excitation and 
emission spectra, have been created by site-directed mutagenesis of the Serine, 
Tyrosine and the Glycine sequences which make up the amino acid that interact with 
the fluorophore (Ellenberg et al, 1999). As result of the original GFP gene mutation, 
the protein has been optimized for better expression and emission of fluorescent 
light. The variant fluorescent proteins include enhanced blue fluorescent protein 
(EBFP, which has an excitation and emission of 380/440nm), enhanced cyan 
fluorescent protein (ECFP, which has an excitation and emission of 433/453 and 
380/440nm respectively) and also enhanced yellow fluorescent protein (EYFP, 
which has an excitation and emission of 488/509nm).  
 
Figure 2.1 illustrates how the procedure of transient transfection experiments was 
carried out using pEGFP-N3 vector, whereby the CMV promoter of the vector was 
replaced with K13 or K15 promoter. These promoter constructs were then 
transfected into different pre plated epithelial and non-epithelia cells (6 well dishes) 
(Fisher, Leicestershire, UK). The cells were then harvested and the K13 and K15 
promoter linked GFP fluorescence was analysed using a FACS machine. 
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2.1.2 Control Plasmid Constructs used for Transfection  
Gene transfer experiments in cell lines often benefit from the use of very active 
constitutive promoters, which cause transgenes to be expressed strongly at all times. 
Such promoters are generally derived from viruses, which have evolved to express 
their genes in many cell types (Strachan and Read, 2004). pEGFP-N3 encodes for a 
wild type GFP which has been optimized for a brighter fluorescence and higher 
expression (EGFP) in mammalian cells. The pEGFP-N3B parental vector (BD 
Bioscience Clonetech Ltd, Oxford, UK) was used as positive control for all 
Figure 2.1: Schematic diagram showing a simple overview of how CMV promoter of 
pEGFP-N3B vector was replaced with K13 and K15 promoter (A). These promoter 
constructs were transfected into epithelia and non-epithelia cells pre-plated in a 6 well 
plate (B). The cells were then harvested and K13 and K15 promoter linked-GFP 
fluorescence (C) was quantified using FACS (D) machine (adapted from website 
number 10, 11 and 12 (pictures A-C) in the reference section and the pEGFP-N3 
vector was adapted from the BD Bioscience Clonetech Ltd, Oxford, UK,  website 21 
in the Reference section) 
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transfection experiments. To make the promoterless (negative control) vector, the 
CMV from the pEGFP-N3B parental vector was removed to make a promoterless 
pEGFP-N3B vector (PL). pDsRed1-N1 vector (BD Bioscience Clonetech Ltd, 
Oxford, UK) was used an internal control for transfection efficiency and to take into 
account the biological variation which occurs from day to day, the pDsRed1-N1 
vector (Figure 2.2) was co-transfected with each construct.  
 
CMV promoter linked 
to EGFP used as a 
positive control
(A)
(C)
CMV promoter replaced 
with K13 or K15  
promoter
Removed CMV promoter to 
create PL vector used as a 
negative control
(D)
(B)
CMV promoter linked 
to DsRed used as a 
internal control
 
 
 
 
 
 
 
 
2.2 Cloning strategy for K15 and K13 Promoter Constructs 
3.018kb of the 5'-flanking region of the human K15 and K13 genes was amplified 
using a standard PCR protocol. The PCR product obtained was initially cloned into 
the pCR2.1-TOPO vector. The amplified DNA fragments were sub-cloned into 
BstZ17I and EcoRI for the K15 and K13 promoters; they were cloned into BstZ17I 
Figure 2.2: Constructs used in the study: (A): the CMV promoter linked to DsRed in
pDsred1-N1 vector was used as an internal control for the transfection efficiency. (B): 
the CMV promoter linked to EGFP in pEGFP-N3 vector was used as positive control 
for the transfection efficiency. (C): the EGFP fluorescent protein was removed to 
create the promoterless (PL) vector, which was used as a negative control for the 
transfection experiments. (D): the CMV promoter was replaced with K13 or K15 
promoter linked to EGFP in pEGFP-N3 vector (pDsred1-N1 and pEGFP-N3 vectors 
were  adapted from the BD Bioscience Clonetech Ltd, Oxford, UK,  website 21 and 
22 of the reference section) 
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and KpnI. Once the K13 and K15 promoters were completely digested with the 
appropriate enzyme for each promoter, a ligation reaction was set up to clone the 
K13 and K15 promoters into pEGFP-N3B vector to generate the K15 and K13 
promoter driven GFP reporter constructs. Then utilizing site-directed mutagenesis, a 
5'-end deletion series of K13 promoter constructs were generated. 
 
2.2.1 Construction of K15 and K13 Promoter Reporter Gene Plasmids 
The 3.018Kb K15 and K13 5′-upstream regions of the gene were obtained from the 
Ensemble genome browser database where all gene sequence are stored. Forward 
and reverse primer sequences (Appendix: table 7.1) were manually designed to 
amplify a 3.018Kb fragment for both the K13 and K15 promoter sequences using 
human genomic DNA.   
 
2.3 Polymerase Chain Reaction (PCR) 
The PCR reactions were carried out using standard protocols. Briefly, all PCR 
reactions were carried out using a thermal cycler block (Hybaid, Ashford, Middlesex, 
UK). The optimal annealing temperature was determined for each set of primers 
across a gradient of 50 to 65oC. The cycling conditions were as follows: an initial 
denaturing at 95oC for 2 minutes, followed by 35 cycles at 95oC for 30 seconds of 
denaturing. This was then followed by an annealing time of 30 secs at 56oC and 5 
mins of final per cycle extension time at 72oC. The samples were then left to cool at 
4oC over night. The standard PCR reaction was set up as in table 2.1. Many 
thermostable polymerases including Taq polymerase have a terminal 
deoxynucleotidyl transferase activity which selectively modifies PCR generated 
restriction fragments by adding single nucleotides (usually adenine), which is added 
onto the 3′-end of the amplified DNA fragment (Strachan and Read, 2004). This 
resulting overhang can make PCR product cloning difficult and in an attempt to 
overcome this difficulty, several approaches have been used (Strachan and Read, 
2004). The first is the use of vectors such as TOPO TA vectors with overhanging T 
residues in the multiple cloning site. The second approach is to use enzymes such as 
Pfu which remove the overhanging single nucleotide (Strachan and Read, 2004).  
Thirdly, when designing the primers for the K15 and K13 PCR product a few extra 
extension nucleotides can be added onto the designed primer containing a suitable 
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restriction site at the 3′-end to generate an overhang ends and thus facilitating 
subsequent sub cloning into the pEGFP-N3 vector (Strachan and Read, 2004). 
 
Table 2.1: Standard 50μl reaction for polymerase chain reaction (PCR) 
50μl50μlTotal
31.75μlxWater
0.25μl 1.25 units4 u/μl Bio Taq polymerase                           
5μl 100nM50μg/ml reverse  primer               
5μl 100nM50μg/ml forward primer                                       
5μl 1x10x reaction buffer                                 
1μl 200nM of each dNTP100mM dNTP mix                                             
1μl 1mM50mM MgCl2
1μl1-2ng/μl50-100ng template DNA                              
Volume usedFinal concentration 
used
Stock concentration 
 
 
2.4 pEGFP-N3B Vector 
The pEGFP-N3 vector expresses enhanced green fluorescent protein (EGFP) under 
the control of a human cytomegalovirus (CMV) immediate early promoter with pUC 
and SV40 origins of replication for prokaryotic and eukaryotic cells respectively. It 
expresses a kanamycin resistance gene, which enables selection of transformed 
bacteria, and a neomycin resistance gene, which allows stably transfected eukaryotic 
cells to be selected using G418. This information is presented on the vector map of 
pEGFP-N3 (Figure 2.2 A-B).  
 
2.4.1 Abolishing AseI restriction site in pEGFP-N3 vector to replace with 
BstZ17I site to create pEGFP-N3B vector  
In the pEGFP-N3B vector, the AseI restriction site was abolished and replaced with a 
unique BstZ17I (GTA/TAC) restriction site (Figure 2.2 A-B to 2.2 C- F). In addition, 
when designing the primer sequence in the 5′-end region of the forward primer used 
to amplify the K13 and K15 promoter sequence, BstZ17I site was incorporated into 
the DNA sequence. BstZ17I cuts at a GTA/TAC blunt sequence. There are two ways 
the DNA sequence can be cut, depending on the location of the cleavage sites 
produced by the restriction nucleases, and therefore the resulting restriction fragment 
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might have an overhang or a blunt end (Strachan and Read, 2004). Blunt end 
involves cleavage points which occur on the axis of symmetry, while overhanging 
ends involve cleavages that do not fall on the symmetry axis, such that the resulting 
restriction fragments either posses a 5′-end or 3′-end overhangs (Strachan and Read, 
2004). Some of the disadvantages associated with blunt end restriction sites are  that 
ligation efficiency with a blunt end is less than with a 3'-end overhang (Sanchez et al, 
1996). In addition, the other disadvantages associated with blunt end ligation are that 
when using a DNA ligase to join two molecules into one, the amount of ligation 
product is significantly lower with blunt ends, and thus a higher concentration of 
plasmid DNA and DNA ligase enzyme is required (References: website 15). In 
addition, when sub-cloning, blunt end ligation has the disadvantage of potentially 
inserting the DNA insert in the opposite orientation to that desired. The advantage of 
blunt end ligation is that the strand ends are always compatible with each other 
(References: website 15).  
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(D) 5'-AT-'3
3'-TAAT-'5
5'-TAAT-'3
3'-TA-'5
Correct AseI restriction sequence
(E)
A primer sequence was designed which contains BstZ17I in the middle and with 
altered AseI restriction sequence
Altered AseI restriction sequence to render AseI site non- functional
5'-GTATAC-'3
3'-CATATG-'5
5'-TAAT-'3
3'- TA-'5
5'-TA-'3
3'-AT-'5
(F)
AseI BstZ17I AseI
5'-GTATAC-'3
3'-CATATG-'5
5'-TAAA-'3
3'- TT-'5
5'-TT-'3
3'-AA-'5
(C)
4.7kb pEGFP-N3 vector was linearised by cutting with AseI restriction enzyme
AseI AseI
 
 
 
 
 
 
 
 
Figure 2.3 C-F: Abolishing AseI restriction site in pEGFP-N3 Vector:   
C: shows the circular pEGFP-N3 vector linearised by digesting the 4.7kb pEGFP-N3 
vector with AseI enzyme. E: shows the linearised 4.7kb pEGFP-N3 vector. D: shows 
the linearised 4.7kb pEGFP-N3 vector with AseI restriction enzyme and its correct 
nucleotide sequence. E: a primer (straight lines) was then designed which contains the 
BstZ17I site in the middle and AseI sites on other side of the linearised pEGFP-N3B 
vector, the highlighted 5'      3'  T and A (green) and A and T on 3'      5'  (red) 
either side of the vector sequence indicate the nucleotides to be changed. F: shows a 
designed primer sequence used to ligate to the pEGFP-N3 vector with non-functional 
AseI sites, this was done by replacing A with T and replacing T with A on either side 
of the pEGFP-N3 vector, such that AseI site is non-functional and BstZ17I restriction 
site is used instead. 
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2.4.2 Making the K13 and K15 Promoter Constructs using pEGFP-N3B 
expression vector   
The K13 and K15 promoter fragments were amplified from human genomic DNA 
using PCR. The BstZ17I/KpnI or BstZ17I/EcoRI restriction promoter fragment for 
K13 and K15 was then cloned into TOPO TA cloning vector (Invitrogen Ltd, 
Paisley, UK, Figure 2.4 and Table 2.1). Then using several molecular biology 
techniques such as transformation, colony selection, mini and maxi-preparation a 
large scale of K13 and K15 DNA promoter fragments were made. The BstZ17I/KpnI 
or BstZ17I/EcoRI restriction promoter fragment for K13 and K15 was then cloned 
into a pEGFP-N3B expression vector (Figure 2.5 and Table 2.1). This was done by 
removing the CMV promoter (0.583kb) and replacing it with the K13 and K15 
promoter fragment (3.018kb insert). The cloning of the K13 and K15 promoter 
fragment (3.018kb insert) into a pEGFP-N3B expression vector (Figure 2.5), started 
with the linearization of the pEGFP-N3B expression vector by using BstZ17I/KpnI 
or BstZ17I/EcoRI restriction enzymes (Figure 2.5 and Table 2.1). The same was also 
done for the K13 and K15 promoter fragments, whereby each PCR product was 
initially digested overnight with BstZ17I/KpnI or BstZ17I/EcoRI restriction enzymes 
for K13 and K15 promoter respectively. Then both vector and insert DNA were run 
Figure 2.3 A-B: Vector Map of pEGFP-N3 and abolishing AseI restriction site:  A: 
shows the features of pEGFP-N3 vector which includes the CMV promoter, the 
multiple cloning sites (MCS) and the antibiotic selection marker gene. B: shows AseI 
restriction site in pEGFP-N3 vector replaced with BstZ17I restriction to generate a 
pEGFP-N3B vector, instead of the original pEGFP-N3 vector. 
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on 1% agarose gels, and then purified using the Qiagen purification kit (Qiagen Ltd, 
Crawley, UK). The pEGFP-N3B vector and K13 or K15 promoter insert were both 
digested, then ligated to the pEGFP-N3B vector. 
 
Table 2.2:  Vectors used in the Study 
ClontechVector designed for 
high level 
expression of 
recombinant 
proteins in 
mammalian cell 
(expression rate 10-
20%)Kanamycin4.7KbpEGFP-N3B
InvitrogenUsed to facilitate 
subsequent cloning 
of both of K13 and 
K15 promoter into 
pEGFP-N3B.Ampicillin/ Kanamycin3.9kbTopo TA
Source  of 
VectorCommentResistanceSize
Name of 
Vector
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K13 or K15 Promoter
BstZ17I
Topo TA
3.9kb
Human Genomic DNA
A A
BstZ17I KpnI or 
EcoRI
Colony Selection 
Mini DNA preparation 
Maxi DNA preparation 
Isolation of BstZ17I/KpnI or BstZ17I/EcoRI fragment 
Transform using Sure 
cells and then Plate out 
using L-AMP agar plate
Amplify using K13 or 
K15 specific Primers
K13 and K15 Promoter Plasmid Construction
3.18kb
3.18kb
Total of 6.9kb 
construct is 
made  after K13 
or K15 insert is 
incorporated 
into Topo TA 
vector
KpnI or 
EcoRI
(A)
(B)
(C)
(D)
(E)
 
 
 
 
Figure 2.4:  Diagram illustrating how both human K13 and K15 promoters were 
constructed. A: illustrates the initial amplification of K13 and K15 promoters from 
human genomic DNA using a specific set of primers. The letter A in the diagram B: 
represents the amplified fragment and the size of BstZ17I/KpnI or BstZ17I/EcoRI 
fragment for K13 and K15 promoter. C: shows BstZ17I/KpnI or BstZ17I/EcoRI 
fragment for K13 and K15 promoter (3.018kb insert) ligated to the Topo Ta vector
(3.9kb vector), the size of the whole plasmid becomes 6.9kb, as the size of the vector 
is 3.9kb and that of K13 and K15 insert is 3.018kb. D: shows the procedure for 
making large scale K13 and K15 DNA fragments using colony selection, mini and 
maxi-preparation of K13 and K15 promoter. E: shows the isolated K13 and K15 
fragments. 
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Figure 2.5:  Diagram illustrating how both human K13 and K15 promoters were 
constructed. F: illustrates the full length isolated BstZ17I/KpnI or BstZ17I/EcoRI 
fragment for K13 and K15 promoter (insert). G: shows K13 and K15 promoters 
(3.018kb insert) H: shows how the pEGP-N3 vector was modified, by removing the 
CMV promoter (0.583kb) and ligating the K13 or the K15 promoter. I: shows the 
pEGFP-N3 vector been cleaved with BstZ17I/KpnI or BstZ17I/EcoRI fragment for 
K13 and K15 promoters, in an attempt to linearise the vector. J: shows the K13 and 
K15 insert ligated to the pEGFP-N3B vector. K: shows the final modified pEGFP-
N3B vector (4.117kb) containing the K13 and K13 insert (3.018kb).  
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2.5 Agarose Gel  
The PCR products were fractionated on 0.8-2% (W/V) agarose gel (electrophoresis 
Grade, sepharose) using 1X TBE buffer containing 1µg/ml ethidium bromide. 
Double digested the DNA with BstZ17I/KpnI or BstZ17I/EcoRI using DNA ladder 
(Fermentas, Inc, Glen Burnie, USA) as molecular marker. This was left to run for 30 
minutes at 100 volts. Pictures for K13 and K15, as well as the vector bands prior to 
ligation were taken using a gel document programme in the Autochemi system (UVP 
Bioimaging Ltd, Kent, UK).  
 
2.5.1 Isolation of DNA from Agarose gels and DNA Purification  
The DNA bands in the gel were visualized using a long UV light 
autochemilumenence UVP Bioimaiging system. Bands were excised from the gel 
using a scalpel, placed into an Eppendorf tube, and weighed. The Minelute gel 
extraction kit protocol (Qiagen Ltd, Crawley, UK) was followed and DNA was 
stored at -20oC until required. 
 
2.5.2 Ligation of Insert to Vector  
After the DNA was isolated from agarose gel and purified, the vector (Topo TA or 
pEGFP-N3B) was ligated to insert (K13 or K15 promoters) using the quick ligation 
kit (Invitrogen) and a ratio of 2:1 insert to vector was used. The ligation reaction was 
set up as in Table 2.2 and 2.3. 
 
Table 2.3: Ligation of K13 or K15 promoter (Insert) into TOPO TA vector 
15μlTotal                                                    
4μlSterile dH2O                                        
1 unitT4 DNA ligase (1 unit/µl)                                  
3μl2X quick ligation buffer                       
4μlSalt Solution
2µl (2ng)                            PCR product (Insert)                           
1µl (1ng)                               TOPO® vector                                    
K13/K15      Ligation components                        
 
Reaction was vortexed and incubated for 5 minutes at room temperature and stored 
 at 20oC until required. 
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Table 2.4: Ligation of K13 or K15 promoter (Insert) into pEGFP-N3B vector  
12μlTotal                                                    
4μlSterile dH2O
1 unitT4 DNA ligase (1 unit/µl) 
4 μl2X quick ligation buffer                       
2µl (2ng)                            PCR product  (Insert)                           
1µl (1ng)                               pEGFP-N3B vector                              
K13/K15            Ligation components                 
 
Reaction was vortexed and incubated for 5 minutes at room temperature and stored at 
20oC until required. 
 
2.5.3     Bacterial Strains used for Transformation in this Study 
• One shot E.coli competent cells (Invitrogen Ltd , Paisley, UK).  
• XLI0-Gold ultra competent cells (Stratagene Inc, La Jolla, USA) 
• XLI0-Blue ultra competent cells (Stratagene Inc, La Jolla, USA)  
• NovaBlue competent cells (Novagen Ltd, Beeston, UK) 
 
2.5.4   Plasmid Transformation using Competent Bacterial Cells 
50μl of a competent bacterial cell suspension were thawed on ice and 0.1μg of 
ligation mix or 1ng of plasmid was added, mixed and left on ice for 30 mins. The 
bacterial cells were then heat shocked at 420C for 30 seconds and transferred onto ice 
for 2mins. 250μl of SOC medium (nutrient rich medium used for recovery of 
competent cells) was pipetted into bijou tubes, into which the transformation reaction 
was pipetted and left on the shaker at 370C for 1 hour at a speed of 250 rpm. 100μl 
was spread onto plates containing agar and 50mg/ml of ampicillin and these were 
incubated overnight at 370C. Single colonies were picked with a sterile loop to 
inoculate in L-broth media.  
 
2.5.5 Restriction Digestion  
Miniprep DNA (2ng) was digested with 1μl of restriction enzyme (BstZ17I) in the 
presence of the appropriate reaction buffer supplied with endonuclease (1μl of 10X 
buffer) in a total volume of 10μl reaction mixture. The mixture was incubated for 1 
hour at 370C or overnight depending on the endonuclease and then 4μl of DNA 
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loading dye was pipetted into the digested DNA prior to electrophoresis on a 1% w/v 
agarose gel.  
 
2.6 Purification of Plasmid DNA from 3-10ml of Bacterial Culture  
 
For the initial analysis to confirm whether the insert had successfully been cloned 
into the vector, only a small amount of DNA was required and this was generated 
using a mini plasmid purification Qiagen kit and Beckman centrifuge tubes (40ml). 
1ml of an overnight bacterial culture was pipetted into a 1.5ml Eppendorf tube and 
then centrifuged at 15,000 rpm at 4oC for 15 minutes. The supernatant was then 
discarded and the DNA was extracted from pellet using the Qiagen kit protocol for 
mini preparation of DNA (Qiagen Ltd, Crawley, UK), except for an alteration in the 
last step in which instead of using elution buffer provided with the kit, DNA was 
eluted off the column with 10mM Tris at pH 8.5. 
 
2.6.1 Purification of Plasmid DNA from 100-500ml of Bacterial Culture 
(Maxiprep) using Qiagen Kit  
A maxi plasmid purification kit (Qiagen Ltd, Crawley, UK) and a larger (250 ml) 
centrifuge tube (Beckman Instruments, UK) were used to prepare large amounts of 
DNA. A 500ml overnight bacterial culture was poured into two 250ml Beckman 
tubes and centrifuged at 6, 000 rpm at 4oC for 15 minutes. The supernatant was then 
discarded and DNA was extracted from pellet using the Qiagen kit protocol. 
 
2.6.2 DNA Precipitation 
One tenth of 3M Sodium acetate at pH5.2 was added to the DNA solution in a 1.5ml 
eppendorf tube. This was then vortexed and 3X the volume of 100% ethanol was 
added. The solution was left at -70oC for 20 minutes and then microcentrifuged for 
15 minutes at 15,000 rpm. The supernatant was discarded and the pellet formed was 
washed with 500μl of 70% v/v alcohol. The solution was re-centrifuged for 2 
minutes in a microcentrifuge and the supernatant was discarded. Using a DNA 
concentrator vacuum, the DNA was spun at a speed of 13,000 rpm for 2 minutes and 
the supernatant discarded, leaving the pellet to dry. The DNA was resuspended in an 
appropriate volume of 10mM Tris HCl pH 8.5. 
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2.7 Spectrophotometer 
The concentration and purity of DNA were determined by measuring absorbance at 
260nm wavelength using a spectrophotometer. The concentration of DNA was 
calculated using the formula: Concn=Abs260 x dilution factor x 50 [A solution 
containing 50μg/ml of double stranded DNA has an absorbance of 1 at 260nm 
wavelength, assuming that the mass of a nucleotide pair in DNA is 0.66kDa]. 1:100 
dilution of the DNA was made in a quartz cuvette and placed in the 
spectrophotometer. Another cuvette containing 100μl of 10mM Tris HCL pH8.0 
alone was used as the blank 
 
2.8 Cell Culture Media  and Types of Cell  
Cancer Research UK (CRUK) central stores supplied Ham’s F12 and E4 media (1:1 
v/v) as 400ml aliquots which were then supplemented with RM+ reagent mix 
(Appendix: Table 7.8) and 10% foetal calf serum (Invitrogen Ltd, Paisley, UK), was 
added to the media. The RM+ supplemented media was used to maintain certain 
types of keratinocyte derived cell lines (Table 2.5). DMEM media was also 
supplemented with 10% foetal calf serum and 1% penicillin and 1% streptomycin 
(Invitrogen Ltd, Paisley, UK). 
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Table 2.5: The names of cell lines used in this study and their derivation 
Clinical 
diagnostic and 
oral sciences 
departmental 
archive
(Prime et al, 
1990)
ventral tonguehuman oral 
squamous cell 
carcinomas
H357
Clinical 
diagnostic and 
oral sciences 
departmental 
archive
(Waseem et al, 
1998)
Human vulval
carcinoma cell 
line 
A431 cell line 
was derived from 
an 85-year-old 
female with 
epidermal 
carcinoma
A431
Clinical 
diagnostic and 
oral sciences 
departmental 
archive
-
Foetal 
epidermal skin
Normal human 
epidermal 
keratinocytes 
NHEK
Clinical 
diagnostic and 
oral sciences 
departmental 
archive
(Boukamp et al, 
1988)
Adult SkinEpidermal 
keratinocytes
HaCaT
Obtained from 
cancer research 
UK
-
Human foreskin 
fibroblast
Human foreskin 
fibroblast
HFF
Clinical 
diagnostic and 
oral sciences 
departmental 
archive
(Macville, et al. 
1999)
Cervix Adenocarcinoma
of the  cervix 
HeLa     
Obtained from 
cancer research 
UK
(Purdie, et al. 
1993)
Skin of the ear Human 
Papillomavirus
negative skin 
derived
keratinocyte cell
RTS3b   
obtained from 
cancer research 
UK
(Rheinwald and 
Beckett 1980)
ventral tongueSquamous cell 
carcinoma of the 
tongue of 70 year 
old male         
SCC25     
Where it was 
obtained from 
Reference Site Information of 
origin
Name of cell 
line 
 
 
2.8.1 Cell Seeding and Counting using a Haemocytometer  
The media in the flasks containing adherent cells were aspirated using a glass pipette. 
Cells were washed with 10ml of PBS by swirling the flask from side to side. The 
PBS was aspirated, the cells were trypsinized with 5ml pre-thawed trypsin 
(Invitrogen Ltd, Paisley, UK), and spun using a microcentrifuge for 5 mins at 1, 800 
rpm. The supernatant was aspirated and cells were resuspended with appropriate 
fresh medium, which was then vortexed. To count the number of cells in the 
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medium, 10µl of resuspended cells were pipetted onto the haemocytometer under the 
cover slip (Chance, Propper, Warley, UK). The number of cells in four grids 
consisting of 16 square boxes was counted and the average number of cells/ml was 
determined, using the following formula. 
 
Average number of cells in four grids of 16 squares x 104= number of cells in 1 ml 
 
2.9 DNA Transient transfection into adherent cell lines using Fugene 6 
Fugene-6 (Roche, Diagnostic, Mannheim, Germany) is a lipid based reagent, which 
works by forming a complex with DNA, which is then taken up by the cell via 
endocytosis. Cell lines (Table 2.5) were grown in separate flasks until 90% 
confluent, seeded into six well plates at a cell density of 80-200 x 103 cells per well 
with 2ml of appropriate growth medium, and left for 24 hours in a 5% CO2 incubator 
at 370C prior to transfection. The medium was aspirated 8 hours before transfection 
and replaced with 1ml of fresh medium. The transfection master mix was made up in 
sterile Eppendorf tubes with PBS, to which Fugene 6 was added and the tube was 
vortexed for few seconds followed by the addition of DNA and further vortexing for 
few seconds, and then left at room temperature for 15 minutes. The transfection 
master mix was then pipetted dropwise into each well with swirling; 1ml of 
appropriate fresh media was used to top up each well, followed by incubation at 370C 
in 5% CO2 for 48-72 hours. 
 
To match the same number of molecules to the promoterless pEGFP-N3B negative 
control plasmid, (Appendix; Table 7.3), different concentrations of the following 
constructs were used: K13 full length promoter, K13 promoter deletion fragments 
(R1 to R6) and pEGFP-N3B positive control vector were transiently transfected into 
each cell line (Table 2.5). 
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Table 2.6: Master Mix for Transfection 
25μl. Total
0.5μg   0.5μg pDsRed1-N1 plasmid.
made up to 2μg with pUC 18 plasmid Non-specific pUC 18 plasmid
xμgPlasmid DNA (K13 full length promoter, 
K13 promoter deletion  fragments, 
promoterless pEGFP-N3B or pEGFP-N3B 
positive control vectors.
7.5μl     Fugene 6
15μl    PBS
3:1: ratio of Fugene 6 to plasmid DNA. 
 
 
2.9.1 DNA Transient Transfection into Adherent Cell Lines using Lipofectamine  
The day before transfection, cells were seeded in media without antibiotic in a 6 well 
plate, so that they were 50-80% confluent on the day of transfection. The DNA was 
pre-complexed with the Plus reagent by diluting 1.2μg of either K13, K15 promoter 
constructs, pEGFP-N3B or promoterless pEGFP-N3B construct plus 0.4μg 
pDsRed1-N1 (internal control) DNA into 100μl of DMEM medium without serum. 
The Plus reagent was vortexed prior to use, then 16μl Plus reagent was added to the 
diluted DNA, vortexed and incubated at room temperature for 15 minutes. 
Lipofectamine (Invitrogen Ltd, Paisley, UK) reagent was then diluted (4μl into 100μl 
dilution medium without serum) in a second tube, and vortexed for a few seconds. 
The pre-complexed DNA was combined with diluted lipofectamine reagent, then 
vortexed and incubated at room temperature for 15 minutes. While the complexes 
were forming, the medium on the cells was replaced with 0.8ml of fresh medium 
without serum. The DNA-Plus lipofectamine reagent complexes were added drop 
wise into each well. Complexes were gently mixed into the medium by swirling the 
plates, and then the plates were incubated at 370C in 5% CO2 for 3 hours. After 3 
hours incubation the medium was replaced with 2ml of fresh media containing 10% 
foetal calf serum (FCS). 
 
2.10    Fluorescence Activated Cell-Sorting (FACS) Analysis  
Over the past 30 years, fluorescence activated cell sorting (FACS) machines have 
evolved to become powerful equipment for analyzing and isolating single cells at 
very high rates.  The properties of recombinant DNA can be expressed as fluorescent 
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tags in carrier cells. Modern FACS machines are capable of quantifying multicolour 
fluorescent signals and making sort decisions at the rates of up to 50,000 cells per 
second. As a result, cell sorting is an extremely efficient  tool for screening large 
DNA libraries and reporter cell populations  (Choe et al, 2005). FACS was used to 
measure the intensity and percentage of K15, K13 and CMV promoter driven GFP 
positive cells. 
 
2.10.1 Visualization of EGFP and DsRed Labelled Promoters  
The transfected cell lines expressing GFP and/or PDsRed1-N1 labelled promoters 
were visualized as live cells using a Nikon ECLIPSE TE2000-S biomedical 
microscope equipped with an epifluorescence attachment, a high speed filter wheel 
(Lambda 10-3) and photographed using an integrated digital camera. All images 
were obtained using Metamorph software, using a magnification of 10x or 20x. 
Reproduction and editing were completed using Adobe® Photoshop and Corel® 
Graphics Suite 11.  All cell lines were transfected in triplicate with GFP and/or 
PDsRed1-N1 labelled promoters. The number of cells in suspension selected for 
analysis by the BD LSR II (Becton Dickinson Ltd, Plymouth UK) analyzer was 
constant (20,000 cells/s). Forward scatter (FS) and side scatter (SC) were collected 
through separate filters. The EGFP and DsRed signals were collected in separate 
channels through 530/30nm and 575/26nm band pass filters respectively. The smaller 
numbers in the band pass filter represent the width of the filter while the larger 
numbers represent the fluorescence emission. A light scatter gate was drawn in the 
FITC-A (EGFP) versus PerCP-cy5-5-A (DsRed) plot to exclude cell debris and 
include the viable transfected cells. The fractions of the various cell types were 
quantified using quadrant statistics in BD FACS Diva software version 4.12 
(Beckton-Dickinson), while the formula below and student t-test were used to 
compare the significance of the data generated. 
 
2.10.2 Flow Cytometry Data Analysis 
To calculate the expression of K13 promoter, K15 promoter, promoterless constructs 
and CMV positive control in pEGFP-N3B vector transfection into different cell lines 
either transiently or stably, the following formulas were used: 
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The formula above was also used by (Soboleski et al, 2005), when green 
fluorescence was used as a quantitative reporter gene in individual eukaryotic cells. 
However, they used the mean to calculate the GFP fluorescence intensity, while in 
this thesis the median value was used to calculate the GFP fluorescence intensity, 
since the mean only measures normal distributed data but not skewed data. In 
addition, with GFP FACS data, a skewed data set is normally obtained and thus since 
median value is a measure of 500 events on either side of the data mean a more 
accurate measure was obtained using this parameter.  Thus the median value is a 
measure of both normal and skewed distributed data, while the mean only measures 
the peak of the histogram data obtained.   
 
2.10.3 Flow Cytometry 
Post transfection, the medium was aspirated from cells in six well plates and the cells 
washed with phosphate buffer saline (PBS). The cells were trypsinized and the 
suspensions was collected into prelabelled 5ml Falcon FACS tubes, centrifuged at  
1,000 rpm for 5 minutes, and the supernatant removed. Cells were washed with PBS 
and centrifuged at 1,000 rpm for 5 minutes, the supernatant was aspirated and the 
cells resuspended in an appropriate volume of PBS containing 2mM EDTA and 1% 
foetal calf serum. The resuspended cells were vortexed and transfered onto ice, ready 
for fluorescent activated cell sorting.  
 
2.11 Addition of Pharmacological Agents to K13 and K15 Promoter Constructs  
Transient transfection was carried out as in Section 2.9, except from 24 to 72 hours 
post transfection the cell medium was changed and replaced with 2ml of the 
appropriate fresh media containing the following pharmacological agents: 100nM 
1) % of positive cells expressing GFP (pEGFP-N3B) or DsRED MFI (median fluorescence intensity) 
for stable transfection experiments.
2) % of positive cells expressing GFP (pEGFP-N3B)* GFP MFI (median fluorescence intensity) for 
stable transfection experiments.
3) % of positive cells expressing GFP (pEGFP-N3B)* GFP MFI (median fluorescence intensity)
=GFP fluorescence intensity
% of positive cells expressing DsRED (pDsRed1-N1)*DsRED MFI (median fluorescence intensity)
= DsRED fluorescence intensity
GFP expression =GFP fluorescence intensity
DsRED fluorescence intensity
for transient transfection experiments.
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TPA, 4-α-PMA, 3μM Trichostatin A, 2mM Sodium Butyrate, 50μM of PD98059 or 
25μM LY294002 into each of the six well plates. This was then swirled and 
incubated at 37oC in 5% CO2 from 6 to 48 hours depending on the drug used. 
 
2.12 DNA Sequencing  
DNA sequencing (kindly done by Dr Ahmad Waseem) was performed to confirm the 
assembled constructs, since using PCR can introduce mutations into the amplified 
DNA (Jiang and Blumenberg, 1991). DNA templates were sequenced with the ABI 
PRISM® BigDye™ v2 (Applied Biosystems) which is based on the dideoxy chain 
termination Sanger method (Sanger et al, 1977). The DNA sequence obtained from 
the K13 promoter construct 5`end deletion series, generating 6 fragments (R1 to R6), 
was put together and blasted against the entire genome using a BLAST database 
from NCBI (National Centre for Biotechnology Information) from the following 
website http://www.ncbi.nlm.nih.gov/BLAST/.  The search located a homology 
sequence in chromosome 17 where all type I keratins genes are found in or the K13 
sequence (Chapter 4 Figure 4.8). The K15 3.018kb upstream (promoter) and 
downstream (exon 1 and intron 1) nucleotide sequence was also placed in the 
appendix (Figure 7.7). 
 
2.13  Transcription Factor Database  
Using the following web address (http://genome.ucsc.edu/cgi-bin/hgGateway), 
roughly 2000 to 3400bp of the keratin 5'-end upstream region (promoter) was 
selected. Then the keratin promoter sequence was selected and subsequently pasted 
onto the following website (http://www.cbrc.jp/htbin/nph-tfsearch) in an attempt to 
find novel binding sites in basal and suprabasal keratin genes. A threshold score of 
90% was selected in the database; this means that only transcription factors which 
have a binding site in keratin promoter sequences that have 90% or above homology 
sequence predicted by the database should be returned. This was to ensure that 
transcription factors with high homological sequence were returned. Information 
about transcription factors that bind the keratin promoter DNA sequence was 
grouped according to their site of expression in the human body.  The basal keratins 
are expressed universally in all stratified epithelia. Each graphical representation of a 
transcription factor which binds to a keratin promoter was presented as basal versus 
suprabasal keratin markers at different sites (Chapter 3: Table 3.2). 
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2.14 Isolating and Truncating the Human K13 Promoter Construct  
Once the K13 promoter was isolated from human genomic DNA using PCR, it was 
cloned into pCR-TOPO and then sub-cloned into pEGFP-N3B vector (Figure 2.5 A). 
Then a 5'-end deletion series of the full length parental pEGFP-N3BK13-3018bp 
(Figure 2.6 B and C) DNA to yield the following constructs: pEGFP-N3BK13-
2540bp, pEGFP-N3BK13-1953bp, pEGFP-N3BK13-1512bp, pEGFP-N3BK13-
1017bp, pEGFP-N3BK13-670bp and pEGFP-N3BK13-289bp. This was done using 
full length parental pEGFP-N3BK13-3018bp DNA as a template for PCR and 
forward primers located at -2540bp, -1953bp, -1512bp, -1017bp, -670bp and-289bp  
upstream of the K13 exon 1 (Figure 2.6 B). A BstZ17I restriction sequence  was  
incorporated into the designed primers at the following sites -289, -670bp, -1017bp, -
1512bp,  -1953bp and 2540bp using PCR against the full length parental pEGFP-
N3BK13-3018bp DNA insert as a template (Figure 2.6 H-N). To introduce these 
PCR based deletion mutations into the full length parental pEGFP-N3BK13-3018bp 
fragment in order to generate R1-R6 of (Figure 2.6 H-N) K13 promoter fragments a 
Quick change multi site directed mutagenesis kit (Stratagene) was used. Once the full 
length K13 promoter fragment (3.018kb) was 5′-end deleted to generate six K13 
promoter fragments which were ligated to the 4.117kb pEGFP-N3B vector (Figure 
2.6 H1-N1), these plasmid constructs were transformed with E.coli (Section 2.5.4).  
Once plasmids were transformed, the bacterial colony was selected in an appropriate 
antibiotic containing agar plate. Then the bacterial colonies formed for each of the 
six (R1-R6) K13 promoter fragment plasmids were miniprepared (Section 2.6). The 
resulting six (R1-R6) K13 promoter fragment plasmids DNA was analysed by 
restriction digest with BstZ17I and KpnI enzymes used to confirm the expected size 
and then the digested DNA plasmids was separated on 1% agarose gel at 100 volts 
for 2 hours. Once the six (R1-R6) K13 promoter fragment plasmids were confirmed, 
a maxipreparation (Section 2.6.1) of K13 truncated promoter constructs was made.  
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The amplified K13 or K15 
promoter via PCR 
Human genomic DNA
Amplified the K13 or K15 
promoter from human 
genomic DNA 
(A)
Intron 2
-3.18kb K13 or K15 Promoter region
+
1
ATG
Ex 1 Ex 2 Ex 3 Ex 4 Ex 5 Ex 6 Ex 7 Ex 8
Intron 4 Intron 5 Intron 6 Intron 7Intron 3Intron 1
(B)
(C)
 
 
 
 
 
 
 
 
Figure 2.6 A-C: Diagram illustrating the steps involved in the cloning K13 or K15 
promoter: The K13 and K15 promoter (B) were amplified from human genomic DNA 
(A) using PCR (C), then the PCR product was cloned into pCR TOPO vector, the 
K13 and K15 promoter fragments were sub-cloned into the pEGFP-N3 expression 
vector (picture A and C were adapted from website number 16 and 17 in the reference 
section and the two vectors from Invitrogen website (TOPO) Clontech (pEGFP-N3) 
website). 
  94
Cloned the K13 or K15 
promoter into pCR-
TOPO vector
Sub cloned K13 or K15 
promoter into pEGFP-
N3B vector
3.18kb K13 or K15 promoter region 
4.117kb 
pEGP-N3B 3018bb 
K13p 
3018bp K13 or K15 prom
oter  
(D)
(E)
(F) (G)
 
 
 
 
 
 
 
 
Figure 2.6 D-G: Diagram illustrating the steps involved in the cloning K13 or K15 
promoter: The K13 and K15 promoter PCR product were cloned into pCR TOPO 
vector (D). Then the K13 or K15 promoter fragment (E) was sub-cloned into the 
pEGFP-N3B expression vector (F). Once the K13 but not the K15 promoter fragment 
was successfully sub-cloned into pEGFP-N3B vector (G), to made K13 promoter 
deletion series PCR was used against the K13 full length (K13 3018bp) promoter 
fragment  insert (picture A and F were adapted from the Invitrogen and Clontech 
website). 
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-3.18kb K13 Promoter region
-3.18kb K13 Promoter region
-3.18kb K13 Promoter region
-3.18kb K13 Promoter region
-3.18kb K13 Promoter region
-3.18kb K13 Promoter region
-3.18kb K13 Promoter region
2540bp
1953p
1512bp
1017bp
670bp
3018bp
289bp
(H)
(I)
(J)
(K)
(L)
(M)
(N)
BstZ17I
BstZ17I
BstZ17I
BstZ17I
BstZ17I
BstZ17I
BstZ17I
KpnI
KpnI
KpnI
KpnI
KpnI
KpnI
KpnI  
 
 
 
 
 
Figure 2.6 H-N: PCR against the K13 full length (3018bp) promoter in 4.117Kb 
pEGFP-N3B vector: Using the K13 full length promoter (3018bp) in 4.117Kb 
pEGFP-N3B vector as a DNA template (H) for PCR, a 5′-end deletion series using 
specific designed primers (pink arrows), generated six fragments (purple numbers) of 
K13 promoter.  The six fragments generated from the full length K13 promoter are -
2540bp (I), -1953bp (J) -1512bp (K) -1017bp (L) -670bp (M) and -289bp (N). 
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2.14.1 Designing Primers for Site-directed mutagenesis of pEGFP-N3BK13Pro-
7.117kb. 
A BstZ171 restriction site (GTATAC) was introduced into the full length parental 
pEGFP-N3BK13-3018bp promoter sequence at positions K13-2540bp K13-1953bp, 
K13-1512bp, K13-1017bp, K13-670bp, and K13-289bp upstream from exon 1 
sequence. The above positions were selected because they correspond to specific 
sequences which required minimal change to the BstZ17I site (GTATAC) in the 
original 3.018kb K13 promoter (Figure 2.7 A) sequence (Figure 2.7 B). Then once 
the positions were established for BstZ17I sequence a 20 nucleotides sequence up 
Figure 2.6 H1-N1: Various length of the truncated K13 promoter in 4.117kb pEGFP-
N3B vector: Using the K13 full length promoter (H1) in 4.117kb pEGFP-N3B vector 
(blue half circle) as a DNA template (H) for PCR, a 5′-end deletion series using 
specific introduced BstZ17I site to generate six fragments (red half circle) of K13 
promoter.  The six fragments generated from the full length K13 promoter are -
2540bp (I), -1953bp (J) -1512bp (K) -1017bp (L) -670bp (M) and -289bp (N). 
 
  97
and downstream from the BstZ17I site were selected.  A complementary sequence 
(forward primer) was manually designed to this region. Then the reverse of this 
complementary sequence was deduced (reverse primer), and both forward and 
reverse primers were made (Appendix: Table 3). 
 
-3.18kb K13 Promoter region
+1 ATG
Ex 1 Ex 2 Ex 3 Ex 4 Ex 5 Ex 6 Ex 7 Ex 8
Intron 4 Intron 5 Intron 6 Intron 7Intron 3Intron 2Intron 1
(A)
(B) 5,end deletion series of K13 promoter
-3001 caattacaaactcaatgtccggcccctctccccttcccggaggaccagcgatggggtggg
-2941 ctgaaagtctttgtggtgaccagcctccctccgggagctcaccaagaatcacctcattag
-2881 aacagaagacgctcctttcactaggagattctaagggagtaaaagttctatgtcagaaac
-2821 tgggcttaaagactaaacattagaactaagatgctcctagcacccttattactcagggaa
-2761 ttacaagggttttaagaacattcagagatcatacatctgaattcacagcaaggttgctga
-2701 gatgtcatcagggtagagaaggccagaagccaggtctaaatcttgctttcttggtatcct
-2641 tggataagtgactttccctccctgaaccttggctgcctcatctataaaatggggctgact
-2581 taaaccctctcctgttgtgagacttggtgacagtgtgttaagcccagccttgcttgcagg
-2521 ggtactcataatgcagttttgctgctccttcccttgaaacgttcttgggaggagaccgca
-2461 gtcattgggtttctttttgttgttgttgttgtttttgccaaaaaacaaagcagaaagctt
-2401 aagacgaggtagcagtgcctcagccccagcgctctctccttcttccattaggaccagggt
-2341 ggaaataggaaaaaagatgggtccctggttggatctctgcctagcttcctcccagagggc
-2281 tctgggattcactgcgggttggaggaaggcagtcctgtgtcaaggcattacaagtccccg
-2221 ctaagcgggcagaggctgtgccctgaccccgcaaaggaaggaatgtcacgggccactccg
-2161 tgtttgtgttactggggctttggaggatctgcagcattgttactctaagaggcgttggcc
-2101 tgaacctgcttgtcagctctgggaggtttggggcattgttaccccaggcatggcaggttc
-2041 cattaatcaccttcttgtcagttttgatcctctaccgagagagcaagagctcctgctttg
-1981 ggctgaatcaccccttttcagagagagagagagagagagagagagctgagccatcagctt
-1921 gggcaggagggccgggcagggtcaggggttagcctgaatccctggcctcgcaaggctgtt
-1861 agaacactggcaacgtgccctggctctgtccctgctgatacccctgcgggaagcacaggc
-1801 ccgcttctctaccccagaaaacaaaggcccagaaagccctgactcagatttctcctttct
-1741 gatcttgctgaatcagtgaagggggttccaggagaacctcatgcctgtgccaccccaccc
-1681 agcccctggcctggtatcatccagacctttgtggctgctgtgggccagaaagctgctccc
-1621 aagatgccatccacagcaaccctggccccttggtgagtggggcctgggagtctgcattca
-1561 gggtcctccattgtcagccctggaatggaggaccttctatcctggcctcacagatgccat
-1501 ctgaggtccttttctcccagcctgaatggggaagctccctctggcagggttcttacatag
-1441 tccctgagtttctcagccacatctcaggatcctaagctgagaccctggccctgggtcctg
-1381 tgtcacatcctcttatgtggcctcttggctgggacagacctcatatgactggcgtactag
-1321 aaaggaccctgctcacattattacagggccgtcttcctggatgtgactgtgccctaaagc
-1261 agtcagcgtaatggagtgattcaacccgagggccagactgacccaggcatctcaacctca
-1201 acactattgatattttgggtctgataattctttgctgtggggacagtcctgcaccttata
-1141 ggatgtttagcagcatacctggtgtttagctatcagtagtgcccccaagttgtgacaacc
-1081 aaaatgttcctagacattgtcaaacgtcccctggagagcaaagcagcctctagctgagga
-1021 cctctgaacttgtctatggggacagaagttggaagagtggttacaccaggggtgtggagt
-961  caggtaattgactgggaaaaggtacaaggacctttatggaatgctgggaatgtcctgggt
-901  ggtgtttacacaggtcgtgcatacccatgcgtgacatcaagctggacacgtgatctatac
-841  attttactgtatgaaaaatgtacctaaaaaatgcaccttagcgtcagacagaaccagact
-781  tggatttcagtcctgattctgcccttaaggttcattttcctcatgtgtaaatgggggcaa
-721  tagtaggaccctcctcctgtggctgctgtgaaggttaaatgagatgatgagtgtaaagta
-661  acttcacccagttcctgcctatggtgagggctcggagaatattcgctatgataatggaca
-601  gggccacttcctctttccatgcctgagtttccacagctgtgtctgatggtccctaagatc
-541  ccttaaggtctctgtcactgtgactttttctgatggcctcggagctatttctttctcagt
-481  ctaaatactttcaaggcaggtgattctatcgaaccaagcaaagtttgtcatcagagttgc
-421  tggggcccctggagtagatgaagtgctaagaaggatccaggacatcccagtcagaagttt
-361  taggtatagaaaaaaggaaggtcgagggctacggtgaccttgcaaagcacagagccactc
-301  tgcacccaccaccctcgcatttgaagctcctggcaggcctccgcatctcaggtcccgttc
-241  taatactgggtggggctcagagcctgcacagtgaactccttaagtggaggtgaaacagaa
-181  ttcacttgtcaaaagggcagtctcaggcagaatgctgtcccctctgaatcattctttttg
-121  ttgaagattaaaaaaaaagccacccccaaaaggcacaacccaccctggagagatcagaga
-61   taactaagcttgtgggaaacagaagtgtagttggcaccaagtcagagggtggggaaggga
-1    ggagagaagataaccagcccctatggaggtgtataaaaggtgtccactctggggaagagc
+1    cacagtcctcggcccaggccaagcaagcttctatctgcacctgctctcaatcctgctctc
61    accatgagcctccgcctgcagagctcctctgccagctatggaggtggtttcgggggtggc
K13 up and downstream DNA sequence
1017bp
670bp
289bp
3018bp
2540bp
1953bp
1512bp
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: (A) Diagrammatic representation of K13 gene (with 3.018kb promoter, 8 
exons and 7 introns). (B) illustrates the K13 upstream and downstream sequence from 
exon 1 position, the different coloured sequences correspond to various different 
length of the full length K13  promoter (-3018bp, turquoise), and the six (R1-R6) 
fragments generated from full length K13, R1 (-2540bp, red), R2 (-1953bp, navy 
blue), R3 (-1512bp, green), R4 (-1017bp, pink),  R5 (-670bp  lime green) and R6 (-
289bp,). The purple underlined 6 nucleotides sequence correspond to the site where 
KpnI was designed. The original K13 promoter sequence (6 nucleotides, underlined 
in black) does not differ much from the BstZ17I site (GTATAC), so this sequence 
corresponds to the site where BstZ17I primer was designed, in attempt to retain or 
minimise change to the BstZ17I sequence. The red 3 nucleotides sequence 
corresponds to the ATG and the yellow highlighted sequence corresponds to the start 
of coding region. 
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2.14.2   Designing Primers for Sequencing of pEGFP-N3BK13Pro Deletion 
Series 
Using the sequence for pEGFP-N3B vector at the AseI enzyme site (which was 
changed to BstZ17I) within 60-80 nucleotides to the left of the AseI enzyme site, a 
21 nucleotide forward sequence was designed making sure the GC content was 40% 
or above. The designed primer was in the region between 4658 and 4678bp of 
pEGFP-N3B vector, the forward primer sequence (GCT GGC CTT TTG CTC ACA 
TGT T) was then synthesised (Appendix: Table 7. 4).  
 
2.14.3 Site-Directed Mutagenesis Kit  
Site-directed mutagenesis (SDM), is an in-vitro technique used for studying gene and 
protein structure-function relationship, this technique is also used for modifying 
vectors sequences to make cloning and expression more easier (Stratagene SDM kit 
booklet). Several approaches for SDM have been published, but these methods 
generally require the use of single stranded DNA template and normally permit a 
single point mutation at only one site per round; these methods are also technically 
difficult to carry out and labour intensive (Stratagene SDM kit booklet).  However, 
the use of Stratagene's quick change site-directed mutagenesis kit has the advantages: 
that there is no need for sub-cloning into M13-based bacteriophage vector (normally 
used for cloning a large insert), since any plasmid of up to 8kb can be used. This 
techniques is also very is simple to carry out using the kit, allows oligo-mediated 
introduction of specific mutations in any double stranded plasmid and permits 
mutation at three different sites simultaneously (Stratagene SDM kit booklet). The 
principle behind SDM, as outlined in Figure 2.8, briefly involves 3 step procedures. 
In step one, after having set up 6 PCR reactions (Table 2.7), the K13 R1 to R6 DNA 
is denatured, then the mutagenic primers are able to anneal and the primers are 
extended and nicks are ligated with the quickchange multi-enzyme blend. Then in 
step two of the procedure the resulting mutant (synthetic) and original parental DNA 
template (methylated by bacteria during transformation stage) used for PCR are 
separated by digestion of template with DpnI enzyme (methylation sensitive). In the 
final step of the three stage procedure, the mutated R1-R6 K13 promoter fragments 
are transformed (Section 2.5.4). 
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2.14.4   Quick-change Multi-site Directed Mutagenesis Kit (Stratagene) 
The mutant strand synthesis reaction for thermal cycling was prepared as in Table 
2.12  and depending on the plasmid size, the reaction components differed according 
to the Stratagene Quick-change multi-site directed mutagenesis kit, for a plasmid of 
exactly 5kb or more. Also according to the Stratagene kit protocol, depending on the 
number of mutagenesis primers used (1 to 3 primers =100ng) or (3 to 4 primers 
=50ng), the concentration of primers would differ; for this experiment, however, 
only single reverse primer sets were used. The cycling parameters used for both 
mutagenic and control reaction consisted of an initial cycle of denaturing at 950C for 
1 minute, then 20 cycles of denaturing at 950C for 1 minute, then annealing of 
mutagenic primers to DNA at 550C for 1 minute, then a final extension at 650C for 2 
mins per kilobase pair of plasmid length. Although normally an extension 
temperature of 700C is used, with the Stratagene kit an extension temperature of 
650C was used because this is the optimal temperature recommended by the 
manufactures for the quick change multi blend enzyme used.  Having followed the 
temperature cycling above, both mutagenic and control reaction PCR products were 
placed on ice for two minutes to cool the reaction to ≤370C. The Quick-change multi 
site directed mutagenesis Stratagene kit manufacture protocol was then used except 
for an alteration in the Dpn I enzyme digestion of the amplified PCR products step in 
which the mutated PCR products obtained were subjected to sequential double 
digestion with Dpn I enzyme instead of the one time only as recommended in the 
Figure 2.8: Overview of the Quick-change multi site directed mutagenesis method 
(Stratagene SDM kit booklet) 
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Stratagene protocol; this was done to ensure complete digestion of mutated PCR 
products. 
 
Table 2.7: Mutagenesis Reactions 
25μl                                                               Total    
1μl  (1 unit)Quick-Change Multi Enzyme blend                                    
1μl              100mM dNTP mix                                                 
1μl (100ng)Mutagenic Primers (1-3)                                                          
1μl (100ng)ds-DNA templates
0.75μl                                                              QuickSolution
18μl Double distilled H2O                                                              
2.5μl10x Quick-change Multi reaction buffer                                  
 
A control reaction was set up as in Table 2.8 and ran along with the site directed 
mutagenesis reaction.  
 
Table 2.8: Control Reactions  
25μl                                                               Total  
1μl  (1 unit)Quick-Change Multi Enzyme blend                                    
1μl      100mM dNTP mix                                                      
0.75μl     Quick Solution                                                  
1μl(100ng/μl)                Quick-change multi control primer mix                                 
0.75μl (50ng/μl)                        Quick-Change Multi control template                                   
18μl Double distilled H2O                                                              
2.5μl10x Quick-change Multi reaction buffer                                  
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Table 2.9: The primary antibody used in the study 
Primary antibody  Dilution used  Manufacturer  Catalogue number 
Mouse 
monoclonal (IC7) 
to cytokeratin 13  
1:10 for 
immunocytochemistry 
1:50 for Western 
Abcam Ab22685 
Mouse 
monoclonal (AE8) 
antibody  
1:1000 Abcam A166112 
Anti-actin  1:10,000 Sigma A2066 
Mouse IgG2a 
Kappa 
monoclonal 
Mg2a-53 isotype 
control 
1:10 Abcam Ab18414 
Cytokeratin 15 
antibody (LHK15) 
1:100 Abcam Ab2414 
Mouse 
monoclonal 
C8/144B clone 
1:100 Dako M7103 
 
Table 2.10: The secondary antibody used in the study  
Secondary antibody  Dilution used  Manufacturer  Catalogue number  
Alexa 
fluorochrome 488 
goat antimouse IgG 
1:100 Invitrogen A11029 
Horseradish 
Peroxidase-
Conjugated Goat 
Anti-Mouse IgG 
1:4000 chemical A11000 
Horseradish 
Peroxidase-
Conjugated Rabbit 
Anti-Mouse IgG 
1:1000 Santa Cruz C3006 
 
2.15 Immunocytochemistry  
Cells were seeded at 1x105 onto sterile cover slips (Chance, Propper, Warley, UK) in 
24 well plates containing 1ml of appropriate medium for the cell type used and cells 
were then incubated at 370C in 5% CO2 for 24 hours. Cells were fixed with 1ml of 
ice-cold methanol/acetone (1:1) for 20 mins at -200C. The fixative was aspirated and 
the cells washed with PBS three times. Using a 6 by 6 inch glass plate sealed with 
parafilm, 15μl of 10% goat serum (Invitrogen Ltd, Paisley, UK) was dropped onto 
the parafilm to block non-specific binding of the primary antibody. The cover slips 
were flipped (ensuring that the cells were facing down) onto the drop of goat serum 
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and left for 20 minutes. After blocking, the cells were flipped onto a 15μl drop of 
primary K13 mouse monoclonal (Abcam Plc, Cambridge, UK) antibody (1:10 
dilution of 500μg/ml stock concentration) made up in 10% goat serum and incubated 
for 1 hour at R/T. The cells were washed with 1ml of 0.2% tween in PBS for 3 
minutes; this was repeated twice. Then, the goat anti-mouse secondary antibody 
Alexa fluorochrome 488 (Invitrogen Ltd, Paisley, UK) conjugated (1:100) was 
prepared  in 10% goat serum and left on the cells for 1 hour at  R\T in the dark. The 
cells were washed with 1ml of 0.2% Tween in PBS for 3 minutes and this step was 
repeated twice. The cells were then finally flipped onto 15μl of DAPI (Chroma 
Technology Corp Inc, Rockingham, USA) diluted with PBS 1:1000  in the dark for 1 
min. The cells were washed with PBS containing 0.2% Tween once and then dipped 
into distilled water. The cover slip was flipped onto a slide with a drop of immuno-
mount (Thermo electron corporation Ltd, Cheshire, UK), and then gently pressed 
down to get rid of bubbles.  After a few minutes of air drying the edges of the cover 
slip were sealed with clear nail varnish.  
 
2.16 MTT Assay 
MTT is an assay (Mosmann 1983)  based on the ability of viable cells to release 
mitochondrial dehydrogenase enzyme to cleave the tetrazolium rings of the pale 
yellow MTT to produce dark blue formazan crystals. These formazan are 
impermeable to cell membranes, which results in their accumulation within living 
cells. Solubilisation of the formazan crystals in the cells occurs when an appropriate 
solvent such as DMSO is added, which liberates the crystals into solution. The 
number of surviving cells is directly proportional to the level of the formazan product 
created. To assess the effectiveness of any pharmacological agent’s ability to cause 
cell death, the amount of purple formazan produced by treated cells is normally 
compared to the amount of formazan produced by untreated control cells, usually 
through the production of a dose response curve. The quantification of colour is 
carried out using a simple colorimetric assay. One of the main advantages of the 
MTT assay is  speed and accuracy and for this reason it was used to analyse the 
effect of Trichostatin A, Sodium butyrate, 4-α –PMA and TPA, MEK 1/2 inhibitor 
(PD98059) and PI3K/Akt pathway (LY294002) inhibitors (EMD Chemicals Inc, 
Darmstadt, Germany) on cell proliferation. 
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2.16.1 MTT Assay procedure 
Depending on the cell line, cells were seeded between 5x103 and 12x103 per well of 
a 96 well plate and incubated overnight in a 5% CO2 at 370C. Each cell line (SCC25, 
RTS3b and HeLa) was treated for different time points and with a different dose 
range. The following pharmacological agents were used: TPA and 4-α-PMA (10nM, 
20nM, 30nM, 40nM, 50nM, 100nM, 150nM, 200nM) for 6 hours, Trichostatin 
(0.5μM, 1μM, 2μM, 3μM, 4μM, 5μM and 6μM) for 14 hours, Sodium butyrate 
(0.5mM 1mM, 1.5mM, 2mM, 4mM, 6mM, 8mM and 10mM) for 24 hours. In 
addition, the other pharmacological agents used to treat the cells included: 
LY294002 (5μM, 10μM, 20μM, 25μM, 50μM, 75μM and 100μM) for 48 hours and 
PD98059 (10μM, 20μM, 40μM, 50μM, 75μM, 100μM and 110μM) for 48 hours. 
Appropriate media alone for the cell line used and equal volume of DMSO were used 
as normal and vehicle controls. Then 200µl of Thiazolyl Blue Tetrazolium 
Bromide solution (0.5mg/ml made in 20ml of appropriate media for the cell type 
been used was wrapped and stored at 40C) was left at R/T for 10 minutes, then  
pipetted into each well of the 96 cell plate and incubated for 1 hour in a 5% CO2 
incubator at 370C. The media containing MTT were carefully removed using a fine 
tip attached to the aspirator. The purple formazan dye was dissolved by adding 200µl 
of DMSO in each well and left until purple colour was formed. This was read at 
570nm Optical Density using Fluostar OPTIMA BMG LABTECH plate reader. 
Epithelial monolayer cell line and primary cell viability was expressed as a 
percentage of the control cultures as: 
                  Viability = OD (570nm) of Treated / OD (570nm) of Untreated (Control)*100 
 
2.17 Western Blot  
2.17.1 Sample Collection 
1x106 of each cell type was plated into a 6cm Petri dish and incubated (5% CO2 at 
370C) until 70-90% confluence was reached. The cells were then treated with various 
drugs and their vehicle control (DMSO) for a given period of time, after which they 
were washed with an appropriate of volume of ice cold PBS twice. Then an 
appropriate volume (depending on cell density) of 2x Laemmli buffer was used to 
lyse cells, by pipeting Laemmli buffer onto the cells and leaving it for 2-3 minutes. 
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Cell scraper was used to remove the lysed cells, and the  lysates were pipetted into a 
prelabelled Eppendorf tube and immediately placed onto a heating block, preset at 
950C, for 5mins.  
 
2.17.2 SDS PAGE  
A pre-cast Nupage 4-12% Acrylamide Bis tris gel 1.5mm thick with either 10 or 15 
wells was used which was placed into an Xcell (Invitrogen Ltd, Paisley, UK) sure- 
lock gel tank. Appropriate volumes (such that roughly same band density would be 
obtainable for loading control β-actin) of sample lysates were loaded into the gel 
with 3µl of magic marker (MW range of 20-220kDa, Invitrogen Ltd, Paisley, UK). 
The tank was then filled with 1x NuPage (Invitrogen Ltd, Paisley, UK) buffer and 
sample in gel was run at 100volts until the samples had migrated a third of the length 
of the gel. The voltage was then increased to 140 volts. 
 
2.17.3 Protein Transfer Membrane using Semi-dry Method 
Once the gel was run to completion, the cassette was removed from the gel unit and 
taken apart. The gel was removed and placed in transfer buffer for 5 minutes. Four 
square filter paper sheets (Whatman International Ltd, Kent, UK) were cut to size 
(8x8cm) and left to soak in transfer buffer.  A square of nitrocellulose transfer 
membrane (8x8cm) was left to soak in transfer buffer for 5 minutes. The filter paper, 
membrane and gel were taken out of the transfer buffer and placed on top of each 
other in the following sequence: 2 sheets of Whatman filter paper, nitrocellulose 
transfer membrane, gel and 2 sheets of Whatman filter paper. This was then placed 
into the Invitrogen protein transfer tank unit and the cathode plate cover was placed 
on top and the proteins were transferred at 32 volts for 1 hour.  
 
2.17.4 Membrane Staining 
The nitrocellulose membrane was stained with Ponceau-S staining solution for 1 
minute while shaking gently. The Ponceau-S solution was poured into its container, 
and the excess dye was washed off with distilled running water, shaking and pouring 
off (repeated several times).  
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2.17.5 Blocking Membrane  
10ml of 5% w/v milk powder (Marvel Ltd, Bristol, UK) solution was made up in 
PBS containing 1% Tween 20 (PBSMT) and membrane was immediately incubated 
with PBSMT solution and left on the shaker at 40 rpm for 1 hour.  
 
2.17.6 Antibody Binding 
The membrane was incubated in solution containing 10ml of PBSMT solution with 
primary mouse monoclonal AE8 anti-K13 (Abcam Plc, Cambridge, UK) at 1:1000 
dilutions and left on the shaker at 10 rpm in a cold room overnight. The membrane 
was then washed with PBST three times for 5 minutes and then incubated with 
secondary goat anti-mouse IgG conjugated horseradish peroxidase (EMD Chemicals 
Inc, Darmstadt, Germany) at a dilution of 1:1000 in 10ml of PBSMT; the membrane 
was then left on the shaker at 40 rpm for 1 hour. The membrane was washed with 
PBST solution three times for 5 minutes. The loading control mouse anti-human β-
actin antibody was made in 10ml of PBSMT solution at a dilution of 1:10,000 and 
this was then incubated with the membrane on the shaker at 40 rpm for 1 hour. The 
membrane was washed with PBST solution three times for 5 minutes. The secondary 
rabbit anti-mouse IgG conjugated horseradish peroxidase was made in 10ml PBSMT 
at a dilution of 1:4,000 and this was incubated with the membrane and left on the 
shaker at 40 rpm for 1 hour. The membrane was washed with PBST solution three 
times for 5 minutes. 
 
2.17.7 ECL Detection  
Enhanced Chemiluminescence Plus reagents (GE Healthcare, Bucks, UK) were made 
by mixing 1ml of solution 1 and 50μl of solution 2 and pipetting the mixture onto the 
membrane, then covering the membrane and leaving it for 1min. The excess ECL 
substrate was drained onto a tissue by holding the side of the membrane with forceps, 
and then the membrane was wrapped in a cling film inside the cassette and quickly 
closed. In a dark room the film (GE Healthcare, Bucks, UK) was placed on top of the 
membrane and the cassette was closed for 30 seconds to 5 minutes. The film was 
developed using a Hyperfilm processor (GE Healthcare, Bucks, UK).  
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2.17.8 Densitometry  
The band density measurements were carried out using the densitometry programme 
of an Autochemi system (UVP Bioimaging) and each experiment was repeated three 
times using different lysate samples. The student t-test was used to assess significant 
differences between treated and untreated lysate samples for the expression of K13 
protein.  
 
2.18 Stable Transfection  
The H357, SCC25 oral mucosa or vulval carcinoma A431 cells lines were 
transfected with the K13 or K15 promoter linked GFP constructs alone. Post-
transfected cells were selected for 2 weeks using 0.5-1mg/ml G418 antibiotic, to 
create stable cell lines. Then the stably transfected K13 or K15 promoter linked GFP 
constructs cells were either 1) selected for over several more weeks in a T75 flask, 2) 
split and seeded onto a four 20mm coverslips placed in a 10cm Petri dish, or 3) 
FACS sorted according to four distinct populations (negative expressing, low 
expressing, medium expressing and high expressing GFP populations). 
 
2.18.1 K13 or K15 Promoter linked GFP Expression in Oral SCC25 Cells 
 
K13 or K15 promoter linked GFP constructs transfected into oral SCC25 were 
selected for several weeks in T75 flasks until selected cells formed many 
heterogeneous colonies corresponding to holoclone, meroclone and paraclones. The 
expression of the K13 or K15 promoter-linked GFP construct in holoclones or 
paraclones formed by oral SCC25 in T75 flasks was quantified by grading them from 
no expression to high GFP expression in 10 holoclone and in 10 paraclone colonies. 
 
2.18.2 Analysis of K13 and K15 Promoter linked GFP Construct expression by 
FACS  
Oral SCC25 cells stably transfected with K13 or K15 promoter linked GFP 
constructs were trypsinized and seeded at a clonal cell density of 2000/ml onto four 
20mm cover slips pre-placed in a 10cm Petri dish.  The cells were left to grow until 
holoclone, meroclone and paraclone colonies were formed. Colonies were scraped 
off using a fine needle under the microscope, such that two cover slips had only 
holoclone colonies and the other two cover slips only had paraclone colonies. The 
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expression of K13 or K15 promoter linked GFP constructs in holoclone and 
paraclone of oral SCC25 cells was then quantified by FACS.  
 
2.18.3 Analysis of K13 or K15 Promoter linked GFP Construct Expression using 
Colony Forming Assay  
Oral SCC25 cells stably transfected with K13 or K15 promoter-linked GFP 
constructs were trypsinized and sorted into four distinct GFP populations (negative 
expressing, low expressing, medium expressing and high expressing) using FACS. 
Once sorted, the cells were seeded at a clonal cell density of 600 cells/ml onto 6 well 
plates. Cells were fixed with 4% paraformaldehyde for 20 mins at 4oC, washed with 
PBS and then 1ml of 2% rhodamine blue was added to each of the 6 well plates and 
left on a shaker at a speed of 10 rpm overnight. Cells were then washed with distilled 
water and left to dry. The number of colonies formed was counted by taking pictures 
of the 6 well using a Nikon ECLIPSE TE2000-S biomedical microscope equipped 
with an epifluorescence attachment, a high speed filter wheel (Lambda 10-3) and 
photographed using an integrated digital camera. All images were obtained using 
Metamorph software, reproduction and editing was completed using Adobe 
Photoshop and Corel Graphics Suite 11. 
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3.1 Introduction  
A gene can be expressed either at a specific time point or in a specific tissue in 
response to environmental changes, developmental signals and differentiation 
processes (Song et al, 2005). The rate at which a gene is transcribed, and hence 
expressed, is largely dictated by transcription factors which bind and alter the affinity 
of the RNA polymerase for the promoter (Song et al, 2005). Transcription factors are 
proteins which bind to the upstream regions of a gene and then either increase or 
decrease the expression of that particular gene and regulate gene expression (Tompa 
et al, 2005). Understanding the mechanism by which a gene is regulated has been a 
great hurdle, and a vital step towards understanding the mechanisms of gene 
regulation, is to identify the binding sites for transcription factors (also known as 
transcriptional elements or regulatory elements) (Tompa et al, 2005). Moreover, what 
makes the identification of transcription factor binding sites so essential is that it 
enables a better understanding of the regulatory network which controls cellular 
processes such as cell proliferation and differentiation (Euskirchen et al, 2007). 
 
3.2 Computational Approach to Identifying Transcription Factor Binding Sites  
The computational prediction programme for transcription factor binding sites is 
based on pattern matching or pattern detection. The pattern matching detection 
pathway is based on knowledge of previously characterised sequences after input 
into a transcription factor search database and matching to defined sequences of 
interest. The pattern detection pathway relies on the programme to detect these 
patterns on a genome-wide scale to identify putative transcription factor binding sites 
which might be present in the entered DNA sequence (Elnitski et al, 2006). The 
prediction of a transcription factor binding site (known as a motif) was initially a 
problem since binding sites were traditionally characterised by experimental methods 
which are labour intensive and costly (Song et al, 2005). However, this problem was 
later resolved by computational biologists who developed methods for predicting the 
transcription factor binding sites in the promoter DNA sequence of a gene (Tompa, 
et al. 2005). Furthermore, in mammalian cells many transcription factors work 
synergeristically, which enables the cells to respond to different types of 
environmental and developmental stimuli (Zhu et al, 2005). The functional 
interaction of transcription factors working in concert requires that they must be in 
close proximity to each other (Zhu et al, 2005). Thus, when the user of the 
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computational database provides a specific region of the DNA sequence of interest, 
which is believed to be co-regulated by combinatorial transcription, the database 
identifies a very small motif sequence which is statistically over represented in the 
regulatory regions (Tompa et al, 2005). According to the literature, prediction 
databases cannot accurately identify all transcription factor binding sites (motifs), for 
the following reasons: 
• The motifs are very short DNA sequences (about 10bp long), which are in 
the centre of a much larger DNA sequence (usually about 1kb long) entered 
into the database by the user and hence in the midst of statistical noise 
• The DNA sequence of the binding sites for different transcription factors 
varies (Tompa et al, 2005).  
Another disadvantage of using the transcription factor search database is that the 
promoter DNA sequence being analysed is in a linear form (one-dimensional) but the 
transcription factor binding in-vivo is in a 3-dimensional form, thereby entering the 
promoter DNA sequence into the database is not expected to simulate fully the in-
vivo environment. Transcription factors can bind to the promoter sequence in either 
orientation, but the database only predicts the binding sites of transcription factors in 
a linear form.  
 
However, in this thesis, the difficulty of accurate identification of motifs was 
partially addressed by increasing the default setting on the database from 85% to 
90% or above (their motif binding sites predicted to be 90% or above that which 
corresponds to any given transcription factor should be identified); this was done in 
attempt to reduce the number of false positive prediction binding sites for the 
database used.  
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3.2.2 Technical Approach used to Identify Regulatory Elements  
Although the computational approach for finding potential binding sites for 
transcription factors  (Figure 3.2) is used after the  promoter has been truncated, there 
are other experimental methods which are used to validate the computational 
prediction databases. These methods include: 
• The formaldehyde based ChIP (chromatin immunopreciptation assay). 
• Placing the  promoter sequence into a reporter plasmid and co-expressing the 
transcription factor and the reporter construct and measuring the activity of 
the reporter gene in the presence and absence of the transcription factor to 
see whether it activates, represses or has no effect on the reporter construct. 
• Using RNAi (RNA interference) to knock down the mRNA expression of the 
transcription factor in question (Oberley et al, 2006). 
•  DNaseI hypersensitivity: this method is used to observe whether the 
expression of a particular gene is switched off because of DNA methylation 
and histone acetylation and thus detects altered chromatin structure (Elnitski 
et al, 2006). 
However, although these technical approaches are vital for identifying the 
interaction between DNA and its cognate binding protein, the disadvantage is 
that they do not address the interaction of both the DNA and the transcription 
factors, which bind to them at the endogenous loci. Furthermore, transcription 
factors normally work synergistically to bring about regulation of gene 
expression, and using a co-transfection of the DNA regulatory region in question 
and the transcription factor which is thought to regulate the region, a false 
negative result may be obtained from imbalances due over expression of a 
specific transcription factor  (Oberley et al, 2006). 
 
In summary, although both computational and technical validation (Figure 3.1) 
methods are equally important, bearing in mind that both approaches have their 
advantages and disadvantages, the inter-dependence of the two approaches when 
used together by far outweighs the use of only one approach (Elnitski et al, 
2006). 
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Figure 3.1: Diagrammatic illustration of the inter-dependence of both computational 
and experimental approaches for identifying the binding of transcription factors and 
its functional relevance (adapted from Elnitski et al, 2006). 
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Figure 3.2: Simplified diagram (adapted from Werner et al, 2003), illustrating the 
basic principle behind any of the widely used transcription factor database searches 
available on the internet, from the moment the user inputs the DNA sequence into the 
database, through to how the sequence is pattern matched  and pattern detected from 
prior knowledge of previous DNA sequences inputted into the database or genome 
wide based search (Elnitski et al, 2006). 
 
3.2.3 Computational Databases used to Identify Tissue-Specific Keratin and 
their Transcription Factors  
The control of gene expression occurs at numerous levels including: 
• regulation of the rate at which mRNA is made 
• the stability of the mRNA product 
• the rate at which mRNA is translated into protein  
• the stability of the protein product (Eckert et al, 1997).  
Although the regulation of keratin expression is on occasion reported to be regulated 
at both translational and post-translational stages (McBride  et al, 1999), most of the 
studies carried out from as early as Lersch et al, (1989), through to Jiang et al, 
(1990); Leask et al, (1991); Eckert et al, (1997); Wang et al, (2002); Popa et al, 
(2004) have shown that keratin gene expression is regulated at the post-
transcriptional level. Moreover, a given single transcription factor alone does not 
govern keratin gene expression, but rather several transcription factors act 
synergistically to bring about tissue specific expression. To account for the tissue-
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specific expression of keratin genes, two mechanisms have been suggested of which 
the most observable is 1) a positive regulatory element, which specifically activates  
keratin genes in epithelial tissue only, or 2) a negative regulatory element which 
either decreases the expression of keratin genes in non-epithelial tissue or an 
epithelial tissue which does not express the endogenous keratin gene (Jiang et al, 
1990). Furthermore, in order to find these positive or negative regulatory elements 
many studies have utilized both experimental technologies and computational 
approaches  to map the transcription factors binding sites in keratin gene promoters 
(Dale et al, 1990; Eckert et al, 1997; Casatorres et al, 1994; Tomic-Canic et al, 
1998). Comparing transcription factors which bind basal and suprabasal keratin gene 
promoters, would give a better understanding of how basal and suprabasal cell 
specific keratin gene promoter expression is controlled by transcription factors in 
different environments (Casatorres et al, 1994). 
 
In chapter 4, we showed that suppressor elements, which reside within the K13 full-
length promoter construct, appear to confer K13 mucosal tissue-specific expression. 
Using the TFsearch database, GATA-1, Oct-1 and HSF transcription factors were 
identified. Also, in chapter 5, expression of basal K15 and suprabasal K13 markers 
of oral mucosa, correlation with sub-populations present in oral cell lines 
(differentiation) was investigated. This chapter links with chapter 4 and 5, in that in 
order to understand basal and suprabasal keratin gene regulation, the key is to map 
transcription factor binding sites and detect an emerging pattern of transcription 
factors. Therefore, this chapter aims to use bioinformatics to map transcription 
factors which govern keratin specific differentiation and the sequential basal to 
suprabasal keratin specific expression.  
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3.3 Aims 
1) Use NCBI database to obtain approximately 2-3kb (Section 3.5.1) upstream 
sequence of 3 basal and 17 suprabasal keratin promoters.  
2) To compare the transcription factor binding sites in basal and suprabasal 
keratin promoters.  
 
3.4 Materials and Methods 
Chapter 2 section 2.13 contains a detailed protocol of how the promoter sequence of 
each of the K1-K20 was searched. Once the keratin promoter sequence was obtained, 
then TF search database was used to find potential transcription factor binding sites 
in keratin gene promoters and several criteria was used to select specific  
transcription factors. 
 
 
 
 
Figure 3.3: Diagram showing basal K15 and suprabasal K13 keratin genes 
expression and transcription factors though to be important for conferring their 
sequential basal to suprabasal specific expression.  NF-κB which has been shown to 
suppress the expression of K15 gene promoter (Radoja et al, 2004) and Oct-1 
transcription factor might be important (found in this study but not confirmed) for 
suppressing the expression of K13 promoter in all non-permissive cell lines. 
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3.5 Results 
3.5.1    5'-upstream region of Keratin Genes 
Genes are normally organized in a linear form in the chromosome and keratins genes 
are organized in type-specific clusters in the chromosome (Bowden, 2005). To assess 
the maximum 5'-upstream region of keratin genes, the intergene distance is required. 
An intergenic region is a stretch of DNA sequence located between clusters of genes 
(Figure 3.4), which contains a few or no genes (Reference: website 18). Although, 
the exact role of the intergenic regions is not known, they are thought to act to 
control genes close to them (Reference: website 18). The intergenic region sequences 
in humans, comprise a large percentage of the genome (Reference: website 18). The 
5'-upstream region of keratin genes lies in between the ATG site of the specific gene 
of interest and the poly A tail of the gene before it in the chromosome location. The 
maximum 5'-upstream region of K13 and K15 was determined to be 8kb for K13 and 
4.6kb for K15 using the NCBI website (Appendix: Figure 7.6). Although in this 
chapter the size of the 5'-upstream region analyzed for all 20 epithelial keratins is 2-
3kb, it should be noted that the 5'-upstream region of some keratin genes could be 
quite large. The importance of analyzing the maximum 5'-upstream region of keratin 
genes for correct regulation in-vivo is exemplified by human keratin 1 (HK1). By 
using a larger HK1 fragment, generated from transgenic mice, containing the coding 
region, 13Kb of upstream sequence and 3.4Kb of downstream sequence was shown 
to impart the correct regulation with regards to tissue and developmental specific 
expression of K1 gene and not the 12kb HKI fragment that was originally used 
(Blomhoff, 1994). It should be noted that the sizes chosen for analysis of 20 
epithelial keratin 5'-upstream regions in study is incomplete especially for larger 
keratins such as K1.  
 
 
 
 
 
Figure 3.4: Diagram illustrating the intergenic DNA region (red line), which is in 
between two sets of gene (blue line) clusters (adapted from website number 18 in the 
Reference section) 
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Table 3.1: The number of nucleotides in the 5'-end upstream promoter region of 
keratin genes analysed by TFsearch database. 
Name of Keratin The size of 5'-end -
Upstream region of the 
keratin promoter (bp) 
analysed 
Keratin Type  
Basal keratin gene promoters 
K5 2465 Type II 
K14 2061 Type I 
K15 3050 Type I 
Suprabasal keratin gene promoters 
K1 2557 Type II 
K76 (K2p oral mucosa) 2658 Type II 
K3 2456 Type II 
K4 2619 Type II 
K6a 2627 Type II 
K7 2265 Type II 
K8 2341 Type II 
K9 2449 Type I 
K10 2458 Type I 
K12 2457 Type I 
K13 3050 Type I 
K16 2254 Type I 
K17 2251 Type I 
K18 2108 Type I 
K19 2225 Type I 
K20 2518 Type I 
Table 3.1 above shows the length of each of the keratin promoter sequences selected 
for analysis. Of the 20 keratin promoters analyzed in this study, three were basal 
keratin promoters and 17 were suprabasal keratin promoters. -2000 to +100bp of 
basal and suprabasal keratin promoter sequence was obtained.  
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1 CAGCCGAAG GATTTTAGTG CTAGGACAGA GTCCCAGACA GCAGTGCCAC   entry score
51 AGTGATGGCG AGGGAGAGGA GTAGCAGGGG AGCGGTGAGG GGCACTTTCT entry score
<---- M00028 HSF 100.0
<---- M00029 HSF  96.0
-------->        M00154 STRE 92.5
- M00048 ADR1 92.3
--------->                                        M00075 GATA-1 91.4
------>        M00048 ADR1 90.8
101 GGAGGAGGGT ATAGGGCAAA AACTGGGAGG AGAAGAGGGA CAAGGTTCAA entry score
---->                 M00028 HSF  95.3
---->                 M00029 HSF  93.7
---->                                                  M00048 ADR1 92.3
151 TAGCGGAGTG CAATGGAGAG GACCGACACA GCCAGCCCGA TTCAGAGCCA entry score
----->                                             M00048 ADR1 92.3
201 CAGAGTAATG GGACCAGATG ATCTTCACAG ACTCCCTTTC TCCCATAGAT entry score
<----- M00028 HSF  100.0
<----- M00029 HSF  96.0
<-------------- M00033 p300 90.1
1             2                                        3        4          5          65   6  
 
 
 
 
 
 
3.5.2 Data Organisation and Analysis 
Table 3.2 shows an example of the transcription factors which bind the basal keratin 
5 promoter. The table was organized such that it contains the name of the relevant 
transcription factor, the Reference number allocated to the particular transcription 
factor, and the motif sequence within the promoter to which the transcription factor 
is predicted to bind. The similarity of the transcription endogenous binding motif to 
the binding motif present in each of the 20 keratin promoters and the position within 
each of the promoters was also noted. Many transcription factors were selected for 
each of the 20 keratin promoters but only 9 transcription factors are analysed and 
presented in this chapter. Tables 3.2 and 3.3 show examples of transcription factors 
which bind to the basal K5 and suprabasal K76 promoter of the oral mucosa. 
 
Figure 3.5: An example of results obtained when the keratin promoter sequence was 
entered into the TF search database. The dark black arrows with the corresponding 
numbers below them illustrate the following: the sequence number (1), the actual K1 
promoter sequence (2). The exact site with in the sequence where the transcription 
factor binds to (3), the entry number given to that transcription factor (4), the name of 
the transcription factor (5), and score expressed as percentage of the likely similarities 
between the site and the transcription factors which binds that part of the sequence (6). 
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Table 3.2: An example of information on the selected transcription factor binding 
sites within basal K5 promoter sequence  
-551
-1451
92.9
96.0
AAGCCATCCCC
TGGGATAGCT
M00076GATA-2
-20192.1ATGTGAA 
AATGGTGAGC
M00059YY1  Yin and 
Yang 1
-192.5GGGGCTTCCCM00054NF-KB
Position 
within K5
promoter 
sequence
Similarity 
To K5 
promoter 
sequence
Motif 
sequence
Reference in 
database
Transcription 
Factor
 
 
 
A threshold of 90% and above was selected for the similarity of the transcription 
factor endogenous binding motif to the binding motif present in each of the 20 
keratin promoters. 
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Table 3.3: An example of information on the selected transcription factor binding 
sites within suprabasal K76 promoter sequence  
-1851
-1901
92.9
92.9
AGATGATTC
TCAACT
M00147HSF2
-1701
-2051
-2051
92.3
94.2
91.3
TTCCCTGAA
TTCCAGGAAT
TTCCAGGAAT
M00223STATx
-1051
-1051
98.1
98.1
GGGGATCCCC
GGGGATCCCC
M00051
M00051
NF-kap
- 201
- 201
-951
-1001
-1651
-1951
-2051
90.9
98.6
90.6
90.6
90.2
90.2
94.3
CGC
GTGGATAGTG
CACGAT
GGGAA
TCCGGATCACC
CCCTATCCCT
GGTGA TGGTC
M00128
M00075
M00075
GATA-1
- 201
-1951
90.9
93.3
GTGGATAGTG
CCCTATCCCT
M00076GATA-2 
-51
-101
-1301
90.2
90.2
96.0
TTTAT
CTTGTTT
ACTTGTTTGCTC
M00131
M00131
HNF-3b
Position 
within K2p
promoter 
sequence
Similarity
to K2p 
promoter 
sequence
Motif 
sequence
Reference in 
database
Transcription 
factor
 
 
 
A threshold of 90% and above was selected for the similarity of the transcription 
factor endogenous binding motif to the binding motif present in each of the 20 
keratin promoters  
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Table 3.4: The keratins grouped according to their endogenous site of expression in 
normal and diseased states.  
K6, K16, and K17Suprabasal keratins expressed in 
pathological conditions 
K7, K17, K8, K18 and K19 and K20Suprabasal keratins expressed in the 
simple epithelia.
K2p, K4, and K13Suprabasal keratins expressed in the oral 
mucosa
K3  and K12 Suprabasal keratins expressed in the 
cornea 
K7, K6, K16,  K9 and K1Suprabasal keratins expressed in palm and 
sole epidermis 
K1 and K10Suprabasal keratins expressed in the skin
K5, K14, and K15Basal keratins expressed in basal layer of 
all stratified epithelia
Name of keratin (s)Site of Keratins expression in the body 
 
 
3.5.3 Transcription Factor Selection  
Prior to any analysis of the preselected 9 transcription factors and their putative 
binding sites in the 20 keratin promoters, keratin gene promoters were grouped 
according their site of expression in normal and abnormal (disease) states. Then the 
number of binding sites for each of the specific 9 transcription factors in all of the 20 
keratin promoters was counted. Table 3.5 shows the raw data for a number of 
binding sites for 9 preselected transcription factors within each of the 20 keratin 
promoters, whilst Table 3.6 shows the presence or absence of the each of the 9 
preselected transcription factors. 
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Table 3.5: Basal versus suprabasal keratin gene promoters: preselected  transcription 
factors (n=9), putative number of binding sites found in each of the 20 keratin 
promoters.  
122129212
Suprabasal 
keratins of the 
oral mucosa
211227022Basal keratins 
C-relSTATxNF-KBAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPTranscription 
factor
100026002
Suprabasal 
keratins of the 
skin
211227022Basal keratins 
C-relSTATxNF-KBAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPTranscription 
factor
111124001
Suprabasal 
keratins of the 
Cornea 
211227022Basal keratins 
C-relSTATxNF-KBAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPTranscription 
factor
01102334108
Suprabasal 
keratins of the 
Palm and sole
211227022Basal keratins 
C-relSTATxNF-KBAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPTranscription 
factor
011206122
Suprabasal 
keratins of the 
pathological 
conditions
211227022Basal keratins 
C-relSTATxNF-KBAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPTranscription 
factor
1016313144
simple 
epithelia
C-relSTATxNF-KBAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPTranscription 
factor
 
Key 
 
 
 
 
 
 
The number of each of the 9 selected transcription factor binding site within each of the 
20 keratin promoters. 
 
Body sites where a group of suprabasal keratin gene promoters are expressed. 
 
 
The name of the 9 transcription factors. 
 
The stratified basal group of keratin gene promoters.  
Results in Figure 3.5 to 3.10 are all based on the results from Table 3.5. 
  123
Table 3.6: A summary of the 20 keratin promoters grouped according to the site of  
expression and whether the promoters contain a binding site for the 9 transcription 
factors. 
XXX      XXXK20
XXXXXXK19
XXX
XXXXX
XXXXXX
XXXXXXXK7
K17
K8
K18
XXX
XXXX
XXXXXK6
K16
K9
XXXXXXXXXX
XXXXXXX
XXXXXK2p
K4
K13
XXXXXX
XXXXXK3
K12
XXXXX
XXXXXXK1
K10
NF-
KB
C-relSTATxAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPSuprabasal 
keratin 
gene 
partners
XXXXXXX
XXX
XXXXXXXXK5
K14
K15
NF-
KB
C-relSTATxAP-1Oct-1GATA-
1  2   3
USFSP1C/EBPBasal 
keratin 
gene 
partners
Transcription elementsName of 
Keratin
 
X= represents whether each of the 9 (C/EBP, Sp1, GATA 1, 2, 3, Oct-1, AP-1, 
STATx, C-rel, and NF-KB) transcription factor have a potential binding site in the 20 
keratin promoter sequence. Abbreviations for the transcription factors are as follows: 
C/EBP=caat box enhancing binding protein, Sp1=stimulating protein 1, GATA 1, 2, 
3, Oct-1, AP-1=activating protein 1, STATx=signal transducers and activator of 
transcription proteins, c-Rel, and NF-KB=nuclear factor kappa-light-chain-enhancer 
of activated B cell 
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Table 3.7: The function of C/EBP, Sp1, USF and GATA 1, 2, 3 transcription factors  
Factors Function of transcription factors Reference 
C/EBP Has role in differentiation in many tissues 
including the epidermis and also suppression 
of adipocyte differentiation 
(Smith, et al. 2004) 
(Tong, et al. 2005) 
 
Sp1 Positively regulates epidermal differentiation 
markers.  
(Presland and Dale 
2000) 
 
USF Regulates various target genes and has a key 
role in hereditary haemochromatosis and 
familial combined hyperlipidaemia. Also 
regulates the transcription of genes in lung, 
prostate, colorectal and breast tumours. 
(Ocejo-Garcia, et al. 
2005) 
 
GATA-  
1, 2, 3 
GATA-2 and 3 have a role in the suppression 
of adipocyte differentiation. 
(Tong, et al. 2005) 
 
Oct-1 Oct-1 is a transcription factor which 
regulates the expression of common house 
keeping genes like histone H2B and small 
nuclear RNA. In addition, it is also 
expressed in normal epidermis and it is a 
candidate for cell determining transcription 
factor in the skin.  
(Hsu and Chen-Kiang 
1993) 
(Andersen, et al. 1997) 
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Table 3.8:  The function of AP-1, STATx, c-Rel and NF-κB   transcription factors  
Factors Function of transcription factors Reference 
AP-1 AP-1 in the epidermis regulates cell growth, 
differentiation and cellular  transformation  
(Rao, et al. 2003) 
 
STATx STAT-1 has been shown to be activated by 
gamma interferon and, as result of this 
activation, STAT induces K17 expression. 
(Radoja, et al. 2004) 
c-Rel The intracellular Rel/NF-κB signalling 
pathway regulates skin development.  
(Gugasyan, et al. 
2004) 
 
NF-κB NF-κB, particularly the p65 isoform in the 
epidermis, regulates the transcriptional 
activation of keratin specific markers like 
K6a.  NF-κB also has an anti-proliferative 
role in the skin. 
 
 
(Rao, et al. 2003) 
(Radoja, et al. 2004) 
 
Tables 3.7 and 3.8 summarise the reported function of each of the 9 transcription 
factors in the literature, all reported functions of the transcription factors were not 
listed but merely some functions related to each transcription factor were 
summarized.  
 
3.5.4 Transcription Factor Binding Sites in Basal Keratin Promoters and Skin 
Suprabasal Keratins Promoters  
Figure 3.6 shows that basal and suprabasal keratin promoters contain the same 
number of binding sites for C/EBP. This family has been reported to have a role in 
the regulation of suprabasal keratinocytes, both C/EBPα and C/EBPβ are expressed 
in suprabasal keratinocytes of both mouse and human epidermis. Their expression is 
also up-regulated by calcium induced differentiation in primary keratinocytes which 
is accompanied by increased expression of K1 and K10, differentiation markers in 
the epidermis (Oh and Smart 1998). In addition, Sp-1, AP-1, STAT-1, NF-κB and 
the subunit of NF-κB c-Rel have more binding sites in basal (K5, K14 and K15) 
keratin promoters in comparison to suprabasal skin keratin (K1 and K10) promoters. 
It has been shown that Sp1 gene knock-down causes severe developmental defects, 
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which suggests that this transcription factor is important for maintaining 
differentiated phenotypes in many cells (Tomic-Canic et al, 1998). However, Tomic-
Canic et al, (1998) have reported that the basal keratins contain Sp1 binding sites in 
their promoters, but not the suprabasal keratin differentiation markers. The AP-1 
transcription factor is involved in regulation of many biological processes such cell 
proliferation, differentiation and cell transformation. The expression of AP-1 
proteins, such as c-FOS has been reported to be present in the basal layer of the 
epidermis, while other reports have shown that c-FOS is not expressed in the basal 
layer, which correlates with a lack of phenotype in c-FOS knock-down mice. 
However, these conflicting results might be due to different epitopes recognised by 
the the antibodies used  (Tomic-Canic et al, 1998).  Later studies have shown that 
different protein components of the AP-1 family are expressed in different layers, for 
example the junB, junD and c-FOS are found in the granular layer, while Fra-1 and 
Fra-2 are found in basal cells. The expression of C/EBP, AP-1, STAT and NF-B 
have also been shown to regulate the expression of both basal (K5 and K14) and 
suprabasal (K6a and K17) epidermal keratin genes (Radoja et al, 2004). 
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Figure 3.6: Comparison of C/EBP, Sp1, USF, GATA 1 2 3, Oct-1, AP-1, STATx, C-
rel and NF-κB transcription factor binding sites in basal (K5, K14 and K15) and skin 
suprabasal K1 and K10 promoters. 
 
  127
3.5.5 Transcription Factor binding sites in Basal Keratin Promoters and  
Pathological Suprabasal Keratins Promoters Suprabasal Keratins Promoters  
K6a, K16 and K17 expression is induced under conditions which are associated with 
hyper-proliferation and abnormal differentiation, such as viral infection, 
inflammation, psoriasis, after acute injury to various stratified epithelia and 
carcinoma (McGowan and Coulombe, 1998). The basal (K5, K14 and K15) and 
suprabasal keratin markers (K6a, K16, K17) have same number of binding sites for 
C/EBP, Sp1, AP-1, STATx and NF-κB (Figure 5.7).  However, these transcription 
factors, with the exception of Sp1, have been reported to regulate epidermal K5, K6a, 
K14 and K17, which indicates the importance of C/EBP, AP-1, STATx and NF-κB 
in the regulation of both basal and suprabasal keratin promoters (Tomic-Canic et al, 
1998).  
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Figure 3.7: Comparison of number of C/EBP, Sp1, USF, GATA 1 2 3, Oct-1, AP-1, 
STATx, C-rel and NF-κB transcription factor binding sites in basal K5, K14 and K15 
and pathological suprabasal K6a, K16 and K17 promoters.  
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3.5.6 Transcription Factor binding sites in Basal Keratin Promoters and Palm 
and Sole Suprabasal Keratin Promoters  
Amongst the epidermal skin, only glabrous skin of  the foreskin, sole and palm are 
unique in their structure (Compton, et al. 1998). They can be defined histologically 
as very thick, with a compact defined stratum corneum, a wide granulosum, long 
deep rete ridges and a stratum lucidum, where terminal differentiation occurs with 
formation of a cornified envelope (Compton, et al. 1998). Out of the selected K1, 
K6a, K9 and K16 promoters for palm and sole group, K9 is the only gene 
specifically expressed in palm and sole epidermis. Therefore although there are more 
C/EBP, USF, GATA -1,2,3, Oct-1 transcription factors binding sites of palm and sole  
suprabasal K1, K6a, K16, K1 K9 promoters in comparison to basal K5, K14 and K15 
promoters (Figure 3.8), this is not an indication that these factors confer suprabasal 
palm and sole keratin specific expression.  
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Figure 3.8: Comparison of C/EBP, Sp1, USF, GATA 1 2 3, Oct-1, AP-1, STATx, C-
rel and NF-κB transcription factor binding sites in palm and sole basal K5, K14 and 
K15 and suprabasal K6a, K16, K9 and K1 promoters.  
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3.5.7 Transcription Factor binding sites in Basal Keratin Promoters and Oral 
Mucosa Suprabasal Keratins Promoters  
There are more USF, GATA -1,2,3, STATx  and NF-κB transcription factors   
binding sites in the oral mucosa suprabasal K76, K4 and K13 promoters (Figure 3.9) 
in comparison to basal K5, K14 and K15 promoters.  
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Figure 3.9: Comparison of C/EBP, Sp1, USF, GATA 1 2 3, Oct-1, AP-1, STATx, C-
rel and NF-κB transcription factor binding sites in basal K5, K14 and K15 and oral 
mucosa suprabasal K76, K4 and K13 promoters.  
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3.5.8 Transcription Factor binding sites of Basal Keratin Promoters versus 
Cornea Suprabasal Keratins Promoters  
There are more C/EBP, SP-1, GATA -1,2,3, AP-1 and C-rel binding sites in basal 
(K5, K14 and K15) than corneal suprabasal K3 and K12 promoters. While, Oct-1, 
STATx  and NF-κB transcription factors have the same number of binding sites in 
both basal and cornea suprabasal K3 and K13 promoters (Figure 3.10). Both  Sp1 
and AP-2 family members have been shown to play an important role in regulation 
of basal keratin markers in general and specifically K14 (Waseem et al, 1998 and 
Ohkura et al, 2005).  
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Figure 3.10: Comparison of C/EBP, Sp1, USF, GATA 1 2 3, Oct-1, AP-1, STATx, 
C-rel and NF-κB transcription factor binding sites in cornea basal K5, K14, K15 and 
suprabasal K3 and K12 promoters.  
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3.5.9 Transcription Factor binding site of Basal Keratin Promoters versus 
Simple epithelia Suprabasal Keratin Promoters  
As simple epithelia do not express basal K5, K14, K15 keratin promoters, unlike 
stratified epithelia, thus these keratins were not included for the purpose of 
comparison to simple epithelia derived K7, K17, K8, K18, K19, K20 promoters. 
There are more C/EBP, Sp1, GATA-1,2,3, Oct-1 and AP-1 transcription factor 
binding sites then USF, STATx, C-rel and NF-κB in simple epithelia suprabasal K7, 
K17, K8,  K18, K19 and K20 promoters (Figure 3.11).  
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Figure 3.11: The number of C/EBP, Sp1, USF, GATA 1 2 3, Oct-1, AP-1, STATx, 
C-rel and NF-κB transcription factor binding sites in simple epithelia suprabasal K7,  
K17, K8,   K18, K19 and K20 promoters.  
 
3.5.10 Comparison of Transcription Factor binding sites of Basal and 
Suprabasal Keratin Promoters.  
A summary of analysis from the database of a transcription factor search in both 
basal and suprabasal keratin promoters (Table 3.9 and Figure 3.12) has shown that in 
basal keratin promoters there are Sp1 and C-rel transcription binding sites, while in 
suprabasal keratin promoters there are more CEBP, USF, GATA-1,2,3, Oct-1 and  
AP-1 transcription factor binding sites (Figure 5.13). 
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Table 3.9: The comparison of the number of transcription factor binding sites in 
basal keratin versus suprabasal layers of skin, pathological conditions, palm and sole, 
oral mucosa, simple epithelia and cornea. 
5110210511111NF-κB
51011111022222c-rel
5011210511111STATx
126221101022222AP-1
123032221022222Oct-1
72136349463577777GATA-1,2,3
5111200000000USF
74201001022222Sp1
194282121022222C/EBP
TotalCSEOMPSPCSTotalCOMPSPCSName of 
Transcription 
element  
Suprabasal keratin gene promotersBasal keratin gene promoters
 
S=skin, PC=pathological condition, PS=palm and sole, OM=oral mucosa, SE=simple 
epithelia C=cornea. 
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Figure 3.12: Comparison of C/EBP, Sp1, USF, GATA 1 2 3, Oct-1, AP-1, STATx, 
C-rel and NF-κB transcription factor binding sites in basal K5, K14 and K15 and 
suprabasal keratin promoters of skin, pathological conditions, palm and sole, oral 
mucosa, simple epithelia and cornea. 
  133
Suprabasal
Layer
C/EBP, USF, GATA 1 2 3, Oct-1 and AP-1 
K5 K14                       K15
Sp1 and c-Rel
Basal 
layer
K1 K2 K3 K4 K6 K7 K8 K9 K11 K12 K13 K16 K17 K18 K19 K20
 
 
 
 
Figure 3.13: Diagram showing a summary of common transcription factor binding 
sites in basal (Sp1 and C-rel) and those transcription factors which have more 
binding sites in suprabasal (C/EBP, GATA-1,2,3 and USF) keratin promoters.  
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K5
K14
K15
K1
K10
K3
K12
K2p
K4
K13
0bp
2456bp
2465bp
2458bp
2557bp
3050bp
2061bp
2457bp
3050bp
2658bp
2619bp
0bp
0bp
0bp
0bp
0bp
0bp
0bp
0bp
GATA-1
GATA-2
C/EBP
AP-1
GATA-3
GATA-2
GATA-1
GATA-3
GATA-2
GATA-1 GATA-2
GATA-1
GATA-2
GATA-2
Oct-1
Oct-1
AP-1
AP-1
AP-1 c-Rel SP-1
NF-κB
GATA-2
GATA-2 GATA-2
AP-1
AP-1
AP-1
GATA-2
GATA-1
GATA-2
GATA-1GATA-1 GATA-1
GATA-2
GATA-1
Sp1c-Rel
Oct-1 STAT  STAT
STAT  STAT
Transcription factors which bind to basal and suprabasal Keratin gene promoter
GATA-1
GATA-2
GATA-1
GATA-3
GATA-1 GATA-1c-Rel Oct-1
Oct-1
Oct-1C/EBP
C/EBP
GATA-2         NF- κB NF- κB GATA-3      STAT    STAT
NF- Κb STAT   STAT
GATA-1 GATA-1 GATA-1 GATA-1 GATA-1 GATA-1 GATA-2  GATA-1  
Oct-1 
GATA-1  GATA-1 GATA-3                    AP-1                 GATA-2              GATA-1  
GATA-2         NF- κB NF- κB GATA-3   GATA-2  GATA-2 GATA-2
USF                                                       Oct-1           c-Rel C/EBP  CEBP                    GATA-3                                    
USF GATA-1                                        GATA-1 GATA-1 C/EBP C/EBP GATA-1  GATA-1 GATA-1 GATA-1
USF                  GATA-3                                                               C/EBP               C/EBP GATA-3                                    
GATA-3                                GATA-2                                                               GATA-2
Oct-1  GATA-1                      GATA-1 GATA-1 Oct-1  GATA-1 C/EBP C/EBP
STAT     Oct-1    c-R el             Oct-1 Oct-1 Oct-1
Oct-1                           C/EBP C/EBP C/EBP NF- κB C/EBP
GATA-1                                GATA-1 GATA-1 GATA-1 GATA-1 GATA-1
NF-κB C/EBP                                   NF-κB AP-1  C/EBP   AP-1 C/EBP  NF-κB AP-1 AP-1
GATA-2     AP-1      AP-1 AP-1 Sp1  c-Rel c-Rel AP-1  Oct-1 Oct-1 Oct-1 Oct-1 STAT
GATA-3   Oct-1  Oct-1 Oct-1 GATA-2 GATA-2 GATA-2 GATA-2 AP-1             GATA-2 GATA-2 GATA-2 GATA-3
GATA-1                        GATA-1 GATA-1 GATA-1 GATA-1 AP-1    GATA-1 GATA-1 GATA-1 GATA-1
 
 
 
 
Figure 3.14: Computer analysis of transcription factors which bind to basal (K5, K14 
and K15) and suprabasal (K1, K10, K3, K12, K76, K4 and K13) keratin promoter 
sequences. 
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Transcription factors which bind to basal and suprabasal Keratin gene promoter
K6a
K16
K9
K7
K17
K8
K18
K19
K20
2518bp
2627bp0bp
0bp
0bp
0bp
0bp
0bp
0bp
0bp
0bp
2225bp
2108bp
2341bp
2251bp
2265bp
2449p
2254bp
GATA-1
C/EBP                    USF   C/EBP
GATA-1         GATA-2                STAT                    GATA-2            GATA-1           GATA-1 GATA-1 GATA-1
C/EBP           GATA-1
Oct-1          GATA-3                         C/EBP                                 GATA-2         C/EBP        GATA-2   AP-1         USF               
C/EBP         GATA-2                STAT                    GATA-2            GATA-1           GATA-1 USF      GATA-1
SP1         GATA-3                                                             GATA-3 Sp1   
GATA-2        GATA-2
GATA-2  GATA-1                 GATA-1 GATA-1 USF      GATA-1
GATA-2                GATA-2
GATA-1          GATA-1 GATA-3 GATA-1    GATA-3          GATA-1     GATA-1
GATA-1                           GATA-2    GATA-2 GATA-3
GATA-1          GATA-1 GATA-3 Sp1 AP-1    AP-1 Sp1              GATA-2 GATA-2 GATA-2 GATA-2
A P-1  AP-1                         GATA-1   GATA-1 GATA-3
C/EBP    C/EBP Sp1  Sp1 NF-κB GATA-2    AP-1   GATA-2   Sp1  Sp1 GATA-1                                       
AP-1      AP-1
GATA- 1                    GATA-1      GATA-2               GATA-1    GATA-1 GATA-1
Oct-1      
AP-1          GATA-1                                                               GATA-1 GATA-1 GATA-1 GATA-1
AP-1                   AP-1 C/EBP          c-Rel Oct-1              Sp1      Sp1 GATA-
AP-1   GATA-1 AP-1 GATA-1                                               GATA-1 GATA-1 GATA-2    GATA-1 GATA-1
AP-1 GATA-1 AP-1                          AP-1 GATA-1         GATA-2              GATA-2
C/EBP C/EBP Oct-1  AP-1                            Oct-1 
GATA-1         AP-1                      GATA-1  GATA-1 GATA-1 GATA-1
AP-1                                                          Oct-1 Oct-1
Figure 3.15: Computer analysis of transcription factors which bind to suprabasal (K6a, 
K16, K9, K7, K17, K8, K18, K19 and K20) keratin promoter sequences. 
  136
3.6 Discussion  
The aim of this chapter was to compare the transcription factors which bind basal 
and suprabasal keratin gene promoters, in an attempt to distinguish the pattern of 
transcription factors which regulates them. Analysis of the database search for   
transcription factors in both basal and suprabasal keratin promoters (Table 4.9 and 
Figure 3.12) has shown that in basal keratin promoters there are Sp1 and C-rel, while 
in suprabasal keratin promoters there are more CEBP, GATA-1,2,3 and USF 
transcription factor binding sites. It is interesting to note that Sp1 is a common 
transcription factor that is reported to regulate basal keratin expression and the 
transcription factor database has identified more Sp1 binding sites in basal keratin 
gene promoters. Furthermore, Sp1 transcription factor has a binding site in some of 
the suprabasal differentiation markers such as those keratins which are expressed in 
the oral mucosa (K76, K4 and K13), in those keratins (K6a, K16, K17) which are 
expressed under pathological conditions such as psoriasis and also in simple epithelia 
keratin markers (K7, K17, K8 and K18). Despite the fact that the Sp1 transcription 
factor appears to confer differentiation specific expression and therefore should have 
more binding sites in suprabasal keratin gene promoters rather than in basal keratin 
gene promoters (Tomic-Canic et al, 1998), this study did not support this notion. 
 
USF, GATA-1,2,3 and C/EBP transcription factors have more binding sites in  
suprabasal keratin promoters. C/EBP (Caat box enhanced binding protein) is a tissue 
specific transcription factor which is also expressed in the lung. The C/EBP 
transcription factor contains a binding site in almost all suprabasal keratin promoters 
of the skin, cornea, oral mucosa, pathological conditions and simple epithelial tissues 
apart from the suprabasal keratin gene promoters of palm and sole epidermis. C/EBP 
transcription factors normally interact with AP-1 and NF-κB and as result of this 
interaction C/EBP transcription is able to regulate the expression of wide variety of 
genes in many cell types. This would explain the presence of C/EBP transcription 
factor binding site along with AP-1 and NF-κB in most suprabasal keratin gene 
promoters (Tomic-Canic et al, 1998). The GATA family of proteins consists of a 
small, but enlarging, family of transcription factors with individual members 
represented in humans, mice, chicken, Drosophila melanogaster and fungi. GATA-1, 
the founding member of the family, was initially identified as an erythrocyte specific 
DNA-binding activity with presumptive target sites in the promoters or enhancers of 
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humans and chicken globin genes (Merika and Orkin, 1993). The GATA-1 
transcription factor is essential for cell maturation and differentiation of red blood 
cells and its function depends upon its ability to bind to both DNA and protein 
partners. Disruption of either of these functions causes severe hematopoietic 
dysfunction and results in blood disorders such as anaemia (Lowry and Mackay 
2006). Since the GATA-1 transcription factor is essential for cell maturation and 
differentiation of red blood cells, it could be possible that GATA-1 is involved in the 
maturation and differentiation of suprabasal keratinocytes and hence GATA-1 
transcription factor having more binding sites in suprabasal keratin promoters. 
 
It is well known that the regulation of keratin genes is not by a single transcription 
factor but rather several transcription factors which act together to bring about basal 
and suprabasal differentiation specific expression of keratin genes. However, it is 
unknown to date what initiates the up or down regulation of certain keratin genes. 
Although similar studies have been performed previously (Dale et al, 1990; Eckert et 
al, 1997; Tomic-Canic et al, 1998), in the present study we provide novel 
information derived from comparison of the transcription factors which regulate 
basal versus suprabasal keratin gene promoters. Therefore, our findings contribute to 
a better understanding of how basal and suprabasal cell specific keratin gene 
promoter expression are controlled by transcription factors in different environments  
(Casatorres et al, 1994).  
 
In conclusion, although the approach of using transcription factor database is not 
fully accurate, given that it is a prediction database, it does act as a guide to assist 
experimental methods to identify putative binding sites in uncharacterized biological 
sequences. In addition, the use of a transcription factor database eliminates the labour 
intensiveness and high cost of the experimental approach, and for this reason an in 
silico (which means preformed on computer), approach for searching putative 
transcription binding sites was used.  
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Expression 
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4.1 Introduction 
Developmental and tissue specific gene expression are usually conferred by enhancer 
or silencer DNA sequences (Strachan and Read, 2004). In addition, there are also 
other cis-acting sequences such as insulators and promoter; which are recognised by 
tissue specific transcription factors (Strachan and Read, 2004). Tissue specific 
silencer elements confer developmental site-specific expression of a gene by 
blocking the specific expression of the gene in all but the required tissue (Strachan 
and Read, 2004). 
 
Keratin gene expression shows tissue and developmental-specific differentiation 
patterns (Lu et al, 2000). This is exemplified by K19, which has a unique expression 
pattern with expression in simple epithelia, basal cells of non-keratinized stratified 
squamous epithelia and in epidermal cells of embryos, but not in adult epidermis (Lu 
et al, 2000). In an attempt to understand the temporal and spatial sequential specific 
expression of K19 in cultured epidermal keratinocytes, two stage human keratinocyte 
culture was used (Lu et al, 2000). In addition, immunoblot and 
immunohistochemistry were used to quantify K19 expression and the results have 
shown that K19 is not expressed in cultured epidermal keratinocytes grown in basal 
(proliferation) media with supplements but was later expressed after three days, 
when the culture medium was changed to the differentiation medium basal DMEM 
with 10% foetal calf serum (Lu et al, 2000). However, when the epidermal 
keratinocytes were cultured in inserted culture dishes, K19 was expressed in all 
keratinocyte layers fed by medium in both the inner and the outer chamber. Taken 
together these results indicate that there are differences in the down-regulated 
expression pattern of K19 in the two culture system used and these differences might 
be related to signal transduction mechanisms induced by calcium and other factors in 
the medium (Lu et al, 2000). 
 
It was reported that a 12kb DNA fragment of the human K8 locus containing 1.1kb 
of the 5'-flanking sequence, 7.7kb of the corresponding body of the gene and 3.2kb 
of the 3'-flanking sequence was required for the tissue specific and efficient 
expression of the human simple epithelial K8 gene in transgenic mice (Casanova et 
al, 1995). The expression pattern of the K8 transgene in simple epithelial cell types 
of the trachea, lung, liver and the kidney of the mice was identical to the expression 
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of the endogenous human K8 gene (Casanova et al, 1995). However, when the intron 
and exon sequence in the 7.7kb of the corresponding body of the K8 gene was 
replaced with Escherichia Coli lacZ gene, the resulting construct showed negligible 
expression in transgenic mice (Casanova et al, 1995). This result show the 
importance of intragenic sequences for conferring tissue specific expression of the 
K8 gene (Casanova et al, 1995). 
 
Immunoblotting and immunofluorecence of tissue section have been used to 
investigate differentiation-dependent expression of the keratins in human oral 
epithelia in comparison to epidermis (Clausen et al, 1986). The results have shown 
that keratin expression patterns in the hard palate and epidermis, which are both 
examples of keratinized stratified epithelia, are similar since both express K10 and 
K1 (Clausen et al, 1986). This differs from the expression pattern of non-keratinized 
stratified buccal epithelia which expresses K13 and K4 (Clausen et al, 1986). The 
aim of this work is to understand the mechanism that regulates such differentiation-
related specific expression with focus on K13 which is expressed in non-keratinized 
stratified buccal epithelia but not in keratinized stratified epidermal epithelia. Very 
little is known about the pathways that are important for the expression of K13 in 
oral mucosa. Thus, to provide insight into the pathways that govern K13 expression 
in general, as well as mucosal tissue specific expression, the 5′-upstream region of 
the KRT13 gene was linked to a GFP reporter gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  141
4.2 Aims  
1) To isolate the 5'-upstream sequences of the human K13 gene in order to 
determine whether then it could confer oral mucosal tissue specific expression. This 
was done by transiently transfecting the K13 full length (FL) promoter construct into 
epithelial and non-epithelial cell lines. 
2) To establish which regions of the K13 promoter are important for oral 
mucosal expression using deletion constructs. 
3) To identify the DNA-protein interactions important for the K13 gene 
promoter using a transcription factor database (bioinformatics).  
4) To investigate the influence of modulating individual transcription factor 
activities by pharmacological agents such as TPA and 4-αPMA, MEK 1/ 2 and  
PI3K/Akt inhibitor. 
5) To investigate whether chromatin alteration, by use of a histone deacetylase 
inhibitor on non-permissive HeLa cells, can induce K13 expression. 
 
4.3 Materials and Methods  
As outlined in Chapter 2 section 2.2, the 3.018kb K13 promoter was isolated from 
genomic DNA and amplified using PCR (Chapter 2 Figure 2.6 A-C). This K13 PCR 
product was cloned into a pCR2.1-TOPO vector and then sub-cloned into a pEGFP-
N3B expression vector (Chapter 2 Figure 2.6 D-G and Figure 4.1). The K13 FL 
promoter linked EGFP reporter gene expression in various epithelial and non-
epithelial cell lines was investigated. The strength of the K13 FL promoter linked 
GFP expression was determined by measuring GFP median fluorescence intensity 
(MFI) using FACS (Chapter 2 section 2.10.1 and Figure 2.1). The MFI of the K13 
FL promoter linked EGFP reporter gene was measured for each cell line to indicate 
whether K13 FL promoter was able to confer mucosal tissue-specific expression. The 
pathways that are important for the expression of K13 were also investigated using 
the K13 FL promoter construct. This was achieved by using various pharmacological 
inhibitors known to be important for the regulation of other keratin gene expression 
patterns (Chapter 2 section 2.11). The expression of K13 linked GFP reporter gene 
was assayed in the presence or absence of pharmacological agents using Western 
blot and FACS (Chapter 2 Figure 2.1).  
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(B)
Bst
Z17
I KpnI
(A)
(C)
K13 upstream DNA sequence
-3001 caattacaaactcaatgtccggcccctctccccttcccggaggaccagcgatggggtggg
-2941 ctgaaagtctttgtggtgaccagcctccctccgggagctcaccaagaatcacctcattag
-2881 aacagaagacgctcctttcactaggagattctaagggagtaaaagttctatgtcagaaac
-2821 tgggcttaaagactaaacattagaactaagatgctcctagcacccttattactcagggaa
-2761 ttacaagggttttaagaacattcagagatcatacatctgaattcacagcaaggttgctga
-2701 gatgtcatcagggtagagaaggccagaagccaggtctaaatcttgctttcttggtatcct
-2641 tggataagtgactttccctccctgaaccttggctgcctcatctataaaatggggctgact
-2581 taaaccctctcctgttgtgagacttggtgacagtgtgttaagcccagccttgcttgcagg
-2521 ggtactcataatgcagttttgctgctccttcccttgaaacgttcttgggaggagaccgca
-2461 gtcattgggtttctttttgttgttgttgttgtttttgccaaaaaacaaagcagaaagctt
-2401 aagacgaggtagcagtgcctcagccccagcgctctctccttcttccattaggaccagggt
-2341 ggaaataggaaaaaagatgggtccctggttggatctctgcctagcttcctcccagagggc
-2281 tctgggattcactgcgggttggaggaaggcagtcctgtgtcaaggcattacaagtccccg
-2221 ctaagcgggcagaggctgtgccctgaccccgcaaaggaaggaatgtcacgggccactccg
-2161 tgtttgtgttactggggctttggaggatctgcagcattgttactctaagaggcgttggcc
-2101 tgaacctgcttgtcagctctgggaggtttggggcattgttaccccaggcatggcaggttc
-2041 cattaatcaccttcttgtcagttttgatcctctaccgagagagcaagagctcctgctttg
-1981 ggctgaatcaccccttttcagagagagagagagagagagagagagctgagccatcagctt
-1921 gggcaggagggccgggcagggtcaggggttagcctgaatccctggcctcgcaaggctgtt
-1861 agaacactggcaacgtgccctggctctgtccctgctgatacccctgcgggaagcacaggc
-1801 ccgcttctctaccccagaaaacaaaggcccagaaagccctgactcagatttctcctttct
-1741 gatcttgctgaatcagtgaagggggttccaggagaacctcatgcctgtgccaccccaccc
-1681 agcccctggcctggtatcatccagacctttgtggctgctgtgggccagaaagctgctccc
-1621 aagatgccatccacagcaaccctggccccttggtgagtggggcctgggagtctgcattca
-1561 gggtcctccattgtcagccctggaatggaggaccttctatcctggcctcacagatgccat
-1501 ctgaggtccttttctcccagcctgaatggggaagctccctctggcagggttcttacatag
-1441 tccctgagtttctcagccacatctcaggatcctaagctgagaccctggccctgggtcctg
-1381 tgtcacatcctcttatgtggcctcttggctgggacagacctcatatgactggcgtactag
-1321 aaaggaccctgctcacattattacagggccgtcttcctggatgtgactgtgccctaaagc
-1261 agtcagcgtaatggagtgattcaacccgagggccagactgacccaggcatctcaacctca
-1201 acactattgatattttgggtctgataattctttgctgtggggacagtcctgcaccttata
-1141 ggatgtttagcagcatacctggtgtttagctatcagtagtgcccccaagttgtgacaacc
-1081 aaaatgttcctagacattgtcaaacgtcccctggagagcaaagcagcctctagctgagga
-1021 cctctgaacttgtctatggggacagaagttggaagagtggttacaccaggggtgtggagt
-961  caggtaattgactgggaaaaggtacaaggacctttatggaatgctgggaatgtcctgggt
-901  ggtgtttacacaggtcgtgcatacccatgcgtgacatcaagctggacacgtgatctatac
-841  attttactgtatgaaaaatgtacctaaaaaatgcaccttagcgtcagacagaaccagact
-781  tggatttcagtcctgattctgcccttaaggttcattttcctcatgtgtaaatgggggcaa
-721  tagtaggaccctcctcctgtggctgctgtgaaggttaaatgagatgatgagtgtaaagta
-661  acttcacccagttcctgcctatggtgagggctcggagaatattcgctatgataatggaca
-601  gggccacttcctctttccatgcctgagtttccacagctgtgtctgatggtccctaagatc
-541  ccttaaggtctctgtcactgtgactttttctgatggcctcggagctatttctttctcagt
-481  ctaaatactttcaaggcaggtgattctatcgaaccaagcaaagtttgtcatcagagttgc
-421  tggggcccctggagtagatgaagtgctaagaaggatccaggacatcccagtcagaagttt
-361  taggtatagaaaaaaggaaggtcgagggctacggtgaccttgcaaagcacagagccactc
-301  tgcacccaccaccctcgcatttgaagctcctggcaggcctccgcatctcaggtcccgttc
-241  taatactgggtggggctcagagcctgcacagtgaactccttaagtggaggtgaaacagaa
-181  ttcacttgtcaaaagggcagtctcaggcagaatgctgtcccctctgaatcattctttttg
-121  ttgaagattaaaaaaaaagccacccccaaaaggcacaacccaccctggagagatcagaga
-61   taactaagcttgtgggaaacagaagtgtagttggcaccaagtcagagggtggggaaggga
-1    ggagagaagataaccagcccctatggaggtgtataaaaggtgtccactctggggaagagc
+1    cacagtcctcggcccaggccaagcaagcttctatctgcacctgctctcaatcctgctctc
61    accatgagcctccgcctgcagagctcctctgccagctatggaggtggtttcgggggtggc
670bp  
289bp  
1017bp  
1953bp  
2540bp  
3018bp  
1512bp  
5′-end deletion series of K13 promoter
K13 FL fragment restriction site
 
 
 
 
 
 
 
 
 
Figure 4.1: Diagram showing important restriction enzyme sites and the K13 full 
length (3018bp) promoter DNA sequence. A: shows the different colour coding to 
represent the full length K13 promoter (turquoise, 3018bp) and deletion fragments 
R1-R6.  R1 fragment is represented by dashed red line (2540bp), R2 fragment is the 
dashed navy blue line (1953bp), R3 fragment is the dashed green line (1512bp), R4 
fragment is the dashed pink line (1017bp), R5 fragment is the dashed lime green 
(670bp) and R6 fragment is represented by the dashed brown line (289bp). B: shows 
the colour coded sequence of the full length K13 promoter and corresponding 
deletion fragments of the full length K13 promoter sequence.  The underlined six
nucleotide sequences correspond to the site where BstZ17I was introduced to the FL 
K13 promoter sequence or to make deletion fragments from the full length K13 
promoter construct. C: shows the full-length 3018bp K13 promoter DNA sequence 
and the fragment incorporated into pEGFP-N3B vector using a BstZ17I and KpnI 
(underlined 6 purple nucleotides) restriction enzymes.  
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4.4 Results 
4.4.1 Restriction Analysis of K13 and K15 Full Length (FL) Promoter Constructs in 
pEGFP-N3B Vector 
The K13 and K15 promoter reporter genes were constructed and verified in order to 
ascertain that they contained the correct K13 and K15 promoter sequences. The K13 
and K15 promoter sequences were both approximately 3.018kb long. The pEGFP-
N3B vector containing K13 or K15 promoters was subjected to endonuclease 
restriction digestion at certain sites contained either within the promoter or vector 
DNA sequence. Figure 4.2 shows endonuclease digestion of both K13 and K15 
assembled promoter constructs. The K13 or K15 promoter was digested with 
BstZ17I/KpnI or BstZ17I/EcoRI respectively to release the 3.018kb FL inserts 
(Figure 4.2 lane 3 and Figure 4.3) within a 4117bp vector. Then the pEGFP-N3B 
vector containing the K13 or K15 promoter was digested with BstZ17I and NotI 
(Figure 4.2) enzymes to release a 4416bp (3018bp insert plus 1398bp vector) 
fragment of K13 or K15 insert plus vector (Figure 4.2 lane 4). The pEGFP-N3B 
vector containing the K13 or K15 promoter (7135bp) was then double digested with 
FspI, which is present within the pEGFP-N3B vector (Figure 4.2). Once the pEGFP-
N3B constructs were digested with FspI enzyme, a fragment of 4416bp (BstZ17I and 
NotI sites in insert and vector) was released. In addition, a 1458bp (NotI and FspI 
sites in vector) fragment and a final vector fragment of 1261bp (vector=4117-FspI 
site of 2856=1261bp vector DNA) were released for K13 and K15 FL promoter 
DNA sequence. Moreover, once the K13 FL promoter in pEGFP-N3B vector (Figure 
4.2) and K13 promoter deletion constructs were confirmed to contain the correct size 
fragments (Figures 4.4 to 4.6), the assembled constructs were sequenced (Figure 4.8) 
and subsequently used for transfecting different cell lines.   
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Figure 4.2:  Restriction analysis of 7.135kb Keratin 13 (A) and 15 (B) promoter in 
pEGFP-N3B vector construct. Various enzyme digests of maxipreparation of K13 
(A) and K15 (B) promoter in pEGFP-N3B vector.  M=1Kb DNA ladder, 1=K13 or 
K15 uncut plasmid, 2= cut with BstZ17I to linearise, 3 = cut with BstZ17I and KpnI 
to release 3.018kb K13 promoter fragment and K15 cut with BstZ17I and EcoRI to 
release 3.018kb promoter fragment. 4= K13 promoter construct cut with BstZ17I 
and NotI  and K15 promoter construct cut with BstZ17I and NotI  5= and then both 
K13 and K15 promoter constructs double digested with FspI. Markers (M), 1 Kb 
DNA ladder was run on both edges of the gel. The 1.2% agarose gel was run for 
one hour and half at 80 volts and stained with Ethidium bromide. 
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Figure 4.3: Restriction map of pEGFP-N3B vector. A: shows replacement of AseI 
restriction site with BstZ17I site. B: shows the 3.018kb K13 or K15 promoter insert 
with appropriate restriction enzymes on either side of the insert in pEGFP-N3B 
vector. C: shows sequence and position of various restriction enzymes within the 
multiple cloning sites and the EcoRI (pink) and KpnI (turquoise) are highlighted. D: 
shows the NotI restriction enzyme site within the pEGFP-N3B vector map and E: 
shows the FspI restriction enzyme site within the pEGFP-N3B vector map. 
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4.4.2 Restriction Digestion Analysis of K13 Promoter Deletion Fragments  
A deletion clone is a copy of the parental DNA with a deletion mutation. Mutation 
can be defined as a change in the DNA sequence of a gene or chromosome of an 
organism, which results in a novel trait not found in the parental DNA. There are 
three main types of mutation which can be created in a DNA sequence and these 
include deletion, insertion and substitution. In this study the deletion mutation 
strategy was utilized to generate several truncated fragment deletion mutants of the 
K13 FL promoter. This was done in an attempt to determine which region of the K13 
promoter is important for conferring the tissue specific expression of the K13 
promoter. The 3.018kb K13 FL promoter in pEGFP-N3B was truncated using PCR 
based site directed mutagenesis (Chapter 2 section 2.14 and Figure 2.6 H-N). Several 
deletion fragments were constructed using the K13 FL promoter as a template 
(Chapter 2 Figure 2.6 H-N). The constructs (Chapter 2 Figure 2.6 H1-N1 and 4.4) 
generated are referred to as K13Pro-2540bp (R1), K13Pro-1953bp (R2), K13Pro-
1512bp (R3), K13Pro-1017bp (R4), K13Pro-670bp (R5) and K13Pro-289bp (R6). In 
Figure 4.6, the exact positions in which the BstZ17I site was introduced in the K13 
FL promoter DNA sequence to generate the six R1-R6 K13 promoter deletion 
fragments are marked in the sequence.  
 
Figure 4.4 shows restriction analysis of DNA from positive selected clones of K13 
R1 to R6 deletion fragments and the K13 FL promoter. This restriction analysis was 
carried out with BstZ17I and KpnI for the K13 FL promoter insert, while for the K13 
promoter deletion fragments R1 to R6 BstZ17I and KpnI sites in either end of the 
fragments were used. The result in Figure 4.4 show the 7135bp pEGFP-N3B K13 
promoter constructs releasing various sizes of K13 promoter fragments. These 
fragments released from the 7135bp pEGFP-N3B K13 promoter constructs include: 
479bp to yield the K13-2540bp plus 4117bp pEGFP-N3B construct, 1079bp to yield 
the K13-1953bp plus 4117bp pEGFP-N3B construct, 1499bp to yield the K13-
1512bp plus 4117bp pEGFP-N3B construct: in addition, 2039bp to yield the K13-
1017bp plus 4117bp pEGFP-N3B construct 2399bp to yield the K13-670bp and 
4117bp pEGFP-N3B construct and 2759bp to yield the K13-289bp plus 4117bp 
pEGFP-N3B construct.  
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Once the K13 FL promoter was deleted and confirmed via restriction analysis, the 
fragments generated were then ligated (Figure 4.5) back to 4117bp pEGFP-N3B 
vector, such that several deletion clone were created from parental K13 FL promoter. 
The deletion constructs generated from K13 FL promoter insert in pEGFP-N3B 
construct (7135bp) were as follows K13 R1 deletion promoter fragment 6657bp 
pEGFP-N3B construct, K13 R2 deletion promoter fragment 6070bp pEGFP-N3B 
construct. K13 R3 deletion promoter fragment 5629bp pEGFP-N3B construct, K13 
R4 deletion promoter fragment 5134bp pEGFP-N3B construct, K13 R5 deletion 
promoter fragment 4787bp pEGFP-N3B construct, K13 R6 deletion promoter 
fragment 4406bp pEGFP-N3B construct. Furthermore, Figure 4.5 appears to show 
very little difference between these different K13 promoter fragments, although 
approximately 400-500bp difference exists between the K13 FL promoter, R1, R2, 
R3, R4, R5 and R6 K13 deletion fragments. This might be because the constructs of 
interest lie in the upper spectrum of the DNA ladder and using a different percentage 
gel or allowing the gel to over-run might have resolved the various close K13 
deletion fragment sizes.  
 
To ensure that the K13 promoter fragments have been successfully ligated to 4117bp 
pEGFP-N3B vector and contained the expected size of the K13 promoter fragments, 
the constructs were digested with BstZ171 and KpnI (Figure 4.6). This led to the 
release of a 3018bp K13 FL promoter from the 7135bp pEGFP-N3B vector construct 
using BstZ17I and KpnI. The 2540bp, 1953bp, 1512bp, 1017bp, 670bp and 289bp 
K13 deletion R1 to R6 fragment are released from the 7135bp pEGFP-N3B vector 
construct using BstZ17I and KpnI on either side of the fragment.  
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Figure 4.4: Restriction analysis of DNA from positive clones of the K13 promoter 
deletion series using BstZ17I and KpnI enzyme. The pEGFP-N3B vector gives a 
band at 7135bp and inserts of various sizes are released. Lane 1, uncut 3.018kb FL 
K13 promoter DNA; lane 2, 479bp; lane 3, 1079bp; lane 4, 1499bp; lane 5, 2039bp; 
lane 6, 2399bp and lane 7, 2759bp. Markers (M), 1 Kb DNA ladder was run on both 
edges of the gel . The 1.2% agarose gel was run for one hour and half at 80 volts and 
stained with Ethidium bromide. 
Figure 4.5: Analysis of DNA from positive clones of the K13 promoter deletion 
series re-ligated back to the pEGFP-N3B vector. The pEGFP-N3B vector plus various 
insert sizes of K13 promoter fragment religated back to the pEGFP-N3B vector 
constructs is shown. Lane 1 shows a religated construct consisting of the 3018bp K13 
FL promoter insert plus the 4117bp pEGFP-N3B vector. Lane 2 shows construct 
consisting of the 2540bp K13 promoter deletion fragment R1 plus the 4117bp 
pEGFP-N3B vector. Lane 3 shows construct consisting of the 1953bp K13 promoter 
deletion fragment R2 plus the 4117bp pEGFP-N3B vector. Lane 4 shows construct 
consisting of the 1512bp K13 promoter deletion fragment R3 plus the 4117bp 
pEGFP-N3B vector. Lane 5 shows construct consisting of the 1017bp K13 promoter 
deletion fragment R4 plus the 4117bp pEGFP-N3B vector. Lane 6 shows construct 
consisting of the 670bp K13 promoter deletion fragment R5 plus the 4117bp pEGFP-
N3B vector. Lane 7 shows construct consisting of the 289bp K13 promoter deletion 
fragment R6 plus the 4117bp pEGFP-N3B vector. Markers (M), 1 Kb DNA ladder 
was run on both edges of the gel. The 1.2% agarose gel was run for one hour and half 
at 80 volts and stained with Ethidium bromide.  
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4.4.3 K13 FL Promoter DNA Sequence and Transcription Factor Database  
The K13 FL upstream and downstream sequence was obtained using the NCBI 
database (www.pubmed.org) as shown in Figure 4.7. Entrez Pubmed NCBI database. 
Transcription factor search (TFSearch) database was used to identify putative 
transcription factor (Table 4.1) binding sites in each of the colour coded upstream 
K13 promoter DNA sequences (Figure 4.7). This was done in an attempt to unravel 
novel transcription factor binding sites in the uncharacterised K13 promoter deletion 
DNA sequence. A summary of transcription factors identified to bind to the K13 
promoter deletion fragment DNA sequence is shown in Table 4.1. In addition in 
Figure 4.7 the K13 upstream coloured (turquoise to brown) sequence corresponds to 
K13 FL, R1, R2, R3, R4, R5 and R6 deletion fragments. Thus it should be noted that 
the same colours are used in the transcription identified and its corresponding 
Figure 4.6: Restriction analysis of DNA from positive clones of the K13 promoter 
deletion series using BstZ17I and KpnI enzyme. The pEGFP-N3B vector construct 
gives a band at 7.135kb and inserts of various sizes are released. Lane 1, the 3.018kb 
FL K13 promoter DNA released from 7135bp pEGFP-N3B vector construct using 
BstZ17I and KpnI on either side of the fragment. Lane 2, the 2540bp K13 deletion R1 
fragment is released from the 7135bp pEGFP-N3B vector construct using BstZ17I on 
either side of the fragment. Lane 3, the 1921bp K13 deletion R2 fragment is released 
from the 7117bp pEGFP-N3B vector construct. Lane 4, the 1512bp K13 deletion R3 
fragment is released from the 7135bp pEGFP-N3B vector construct using BstZ17I 
and KpnI on either side of the fragment. Lane 5, the 1017bp K13 deletion R4 
fragment is released from the 7135bp pEGFP-N3B vector construct using BstZ17I 
and KpnI on either side of the fragment. Lane 6, the 670bp K13 deletion R5 fragment 
is released from the 7135bp pEGFP-N3B vector construct using BstZ17I and KpnI on 
either side of the fragment. Markers (M), 1 Kb DNA ladder was run on both edges of 
the gel. The 1.2% agarose gel was run for one hour and half at 80 volts and stained 
with Ethidium bromide. 
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sequence (Figure 4.7 and Table 4.1) in which it was identified. This was done to 
show that each set of transcription factors was identified to bind each of the truncated 
K13 promoter fragments DNA sequence (Table 4.1 and Figure 4.2). Furthermore, 
each deletion fragment of the K13 FL promoter DNA sequence was analysed 
individually using the TFSearch database. When searching for transcription factor 
binding sites, 90% stringency at the sequence level was selected: this was done in an 
attempt to eliminate false positive transcription factor binding sites in the DNA 
sequence. Also in Figure 4.7, the three red nucleotides highlighted in the sequence 
correspond to the ATG and the yellow highlighted sequence corresponds to the start 
of the coding region (exon 1), while the light blue highlighted sequence corresponds 
to the K13 intron 1 sequence (Figure 4.7). 
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-3001 caattacaaactcaatgtccggcccctctccccttcccggaggaccagcgatggggtggg
-2941 ctgaaagtctttgtggtgaccagcctccctccgggagctcaccaagaatcacctcattag
-2881 aacagaagacgctcctttcactaggagattctaagggagtaaaagttctatgtcagaaac
-2821 tgggcttaaagactaaacattagaactaagatgctcctagcacccttattactcagggaa
-2761 ttacaagggttttaagaacattcagagatcatacatctgaattcacagcaaggttgctga
-2701 gatgtcatcagggtagagaaggccagaagccaggtctaaatcttgctttcttggtatcct
-2641 tggataagtgactttccctccctgaaccttggctgcctcatctataaaatggggctgact
-2581 taaaccctctcctgttgtgagacttggtgacagtgtgttaagcccagccttgcttgcagg
-2521 ggtactcataatgcagttttgctgctccttcccttgaaacgttcttgggaggagaccgca
-2461 gtcattgggtttctttttgttgttgttgttgtttttgccaaaaaacaaagcagaaagctt
-2401 aagacgaggtagcagtgcctcagccccagcgctctctccttcttccattaggaccagggt
-2341 ggaaataggaaaaaagatgggtccctggttggatctctgcctagcttcctcccagagggc
-2281 tctgggattcactgcgggttggaggaaggcagtcctgtgtcaaggcattacaagtccccg
-2221 ctaagcgggcagaggctgtgccctgaccccgcaaaggaaggaatgtcacgggccactccg
-2161 tgtttgtgttactggggctttggaggatctgcagcattgttactctaagaggcgttggcc
-2101 tgaacctgcttgtcagctctgggaggtttggggcattgttaccccaggcatggcaggttc
-2041 cattaatcaccttcttgtcagttttgatcctctaccgagagagcaagagctcctgctttg
-1981 ggctgaatcaccccttttcagagagagagagagagagagagagagctgagccatcagctt
-1921 gggcaggagggccgggcagggtcaggggttagcctgaatccctggcctcgcaaggctgtt
-1861 agaacactggcaacgtgccctggctctgtccctgctgatacccctgcgggaagcacaggc
-1801 ccgcttctctaccccagaaaacaaaggcccagaaagccctgactcagatttctcctttct
-1741 gatcttgctgaatcagtgaagggggttccaggagaacctcatgcctgtgccaccccaccc
-1681 agcccctggcctggtatcatccagacctttgtggctgctgtgggccagaaagctgctccc
-1621 aagatgccatccacagcaaccctggccccttggtgagtggggcctgggagtctgcattca
-1561 gggtcctccattgtcagccctggaatggaggaccttctatcctggcctcacagatgccat
-1501 ctgaggtccttttctcccagcctgaatggggaagctccctctggcagggttcttacatag
-1441 tccctgagtttctcagccacatctcaggatcctaagctgagaccctggccctgggtcctg
-1381 tgtcacatcctcttatgtggcctcttggctgggacagacctcatatgactggcgtactag
-1321 aaaggaccctgctcacattattacagggccgtcttcctggatgtgactgtgccctaaagc
-1261 agtcagcgtaatggagtgattcaacccgagggccagactgacccaggcatctcaacctca
-1201 acactattgatattttgggtctgataattctttgctgtggggacagtcctgcaccttata
-1141 ggatgtttagcagcatacctggtgtttagctatcagtagtgcccccaagttgtgacaacc
-1081 aaaatgttcctagacattgtcaaacgtcccctggagagcaaagcagcctctagctgagga
-1021 cctctgaacttgtctatggggacagaagttggaagagtggttacaccaggggtgtggagt
-961  caggtaattgactgggaaaaggtacaaggacctttatggaatgctgggaatgtcctgggt
-901  ggtgtttacacaggtcgtgcatacccatgcgtgacatcaagctggacacgtgatctatac
-841  attttactgtatgaaaaatgtacctaaaaaatgcaccttagcgtcagacagaaccagact
-781  tggatttcagtcctgattctgcccttaaggttcattttcctcatgtgtaaatgggggcaa
-721  tagtaggaccctcctcctgtggctgctgtgaaggttaaatgagatgatgagtgtaaagta
-661  acttcacccagttcctgcctatggtgagggctcggagaatattcgctatgataatggaca
-601  gggccacttcctctttccatgcctgagtttccacagctgtgtctgatggtccctaagatc
-541  ccttaaggtctctgtcactgtgactttttctgatggcctcggagctatttctttctcagt
-481  ctaaatactttcaaggcaggtgattctatcgaaccaagcaaagtttgtcatcagagttgc
-421  tggggcccctggagtagatgaagtgctaagaaggatccaggacatcccagtcagaagttt
-361  taggtatagaaaaaaggaaggtcgagggctacggtgaccttgcaaagcacagagccactc
-301  tgcacccaccaccctcgcatttgaagctcctggcaggcctccgcatctcaggtcccgttc
-241  taatactgggtggggctcagagcctgcacagtgaactccttaagtggaggtgaaacagaa
-181  ttcacttgtcaaaagggcagtctcaggcagaatgctgtcccctctgaatcattctttttg
-121  ttgaagattaaaaaaaaagccacccccaaaaggcacaacccaccctggagagatcagaga
-61   taactaagcttgtgggaaacagaagtgtagttggcaccaagtcagagggtggggaaggga
-1    ggagagaagataaccagcccctatggaggtgtataaaaggtgtccactctggggaagagc
+1    cacagtcctcggcccaggccaagcaagcttctatctgcacctgctctcaatcctgctctc
61    accatgagcctccgcctgcagagctcctctgccagctatggaggtggtttcgggggtggc
121   tcttgccagctgggaggaggccgtggtgtctctacctgttcaactcggtttgtgtccggg
181   ggatcagctgggggctatggaggcggcgtgagctgtggttttggtggaggggctggtagt
241   ggctttggaggtggctatggaggtggccttggaggtggctatggaggtggccttggaggt
301   ggctttggtgggggttttgctggtggctttgttgactttggtgcttgtgatggcggcctc
361   ctcactggcaatgagaagatcaccatgcagaacctcaacgaccgcctggcttcctacctg
421   gagaaggtgcgcgccctggaggaggccaacgctgacctggaggtgaagatccgtgactgg
481   cacctgaagcagagcccagctagccctgagcgggactacagcccctactacaagaccatt
541   gaagagctccgggacaaggtgagcccttggaagctgaggaggggtcctccatgaagggca
601   gagcctccaaggccaagaaacacagtgttgtgggggactaggtgtggacggaattcacaa
661   acttcttgcaggggaaaagcctactgtttgactaccaagagtctctacctctgatgggct
721   ttctcatgccacaactccccaaatgcattttctctcattattcatttttatgattgttat
781   tactcaggtcagtttttttactgctttccagacagttatgttattcatgactcgatctct
841   ataatcctaacctactgagttatctggaaacatgacaggtttaaaagccattaagaatgc
901   atgaaatcaacagagaaagagagacgtgttcattcattgccctgggaataattgtttact
961   ttgtaggggacccattcaaactggtattctcaactggcgatggccaagttgggggagaga
1021  gaggcagaggcttaggcagtgccgagcctgggtgccctttgttgagccctgtctgttgtg
1081  ctgtgataccagcctgttggagcagaaatctaccagcctgggctgagtctcagccatgtg
1141  gagcaggctttcactgctttggaatataaacgtttagacaagaaattcaaagggatggga
1201  atatttgttggatttcccctccactcagctgggaagtcagctctagcaaagtgattgtga
1261  gatatgtggcaccaagccgagtccctcctgactttcaggggatggatctcaagacagtgg
1321  cctagggagggtgctagtctgaggctgccaagacatgacgaaccaaagatgttctcagca
1381  ggtcgttcctcagaaatgcactccctgcatctcccccagggtgctcagacatggaatatt
1441  aaagtgttagaaacgattggaggggatgcagccccactcctcactttacagaagagcaat
1501  ggaggcccagagggaaatgccttgtcccagctcacaggacagtttagaggtagagcccca
1561  tgggaaccaggtcctgcccatgttttcccaggccacctcctcaagcacgtggacccccca
1621  gagcaagcttgtctaacctgtggccggtgggctgcatgtggcccaggacagctttgattg
1681  aggcctaacacaaatttgtaagctttcttaaaacattgagtttttttttattttttattt
1741  ttgccaatttctttttagcccatcagctatcgttagtgttagcgtatttgatgtgttgcc
1801  caagacaattcttcttccaatgtggcccagggaagccaacagactggacacccatgccct
1861  agaggttaccttcttctgcattttgtagatcctgaccgccaccattgaaaacaaccgggt
-3.018kb K13 Promoter region
+1 ATG
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Figure 4.7: (A) Diagrammatic representation of K13 gene (with 3kb promoter, 8 
exons and 7 introns). (B) illustrates the K13 upstream and downstream sequence from 
exon 1 position, the different coloured sequences correspond to various different 
length of the full length K13  promoter (-3018bp, turquoise), and the six (R1-R6) 
fragments generated from full length K13 promoter, R1 (-2540bp, red), R2 (-1953bp, 
navy blue), R3 (-1512bp, green), R4 (-1017bp, pink),  R5 (-670bp  lime green) and 
R6 (-289bp,). The purple underlined 6 nucleotides sequence correspond to the site 
where KpnI was designed. The original K13 promoter sequence (6 nucleotides, 
underlined in black) does not differ much from the BstZ17I site (GTATAC), so this 
sequence corresponds to the site where BstZ17I primer was designed, in attempt to 
retain or minimise change to the BstZ17I sequence. The red 3 nucleotides sequence 
corresponds to the ATG and the yellow (+683-541) highlighted sequence corresponds 
to the start of coding region (exon 1). The light blue (+541-1861) highlighted 
sequence corresponds to K13 intron 1. 
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Table 4.1: Transcription factor binding sites in K13 FL promoter and K13 deletion 
R1-R6 fragments 
AP-1
C/EBP
AP-1
STATx
TATA
TATA
GATA-1
Evi-1
GATA-2
GATA-1
Sp1  
GATA-1
GATA-2
GATA-3
GATA-1
GATA-1
GATA-1
GATA-1
HSF2
HSF1
HSF2
HSF1
Oct-1
GATA-3
C/EBP
GATA-1
AP-4
AP-1
GATA-2
GATA-1
USF
USF
USF
GATA-1
HSF2
GATA-2
USF
USF
USF
USF
USF
USF
SREBP-
c-Myc/
Max
Max
N-Myc
CRE-BP
CRE-BP
CREB
CREB
CRE-BP
GATA-1
GATA-1
GATA-1
CRE-BP
Oct-1
Oct-1
AP-1
GATA-1
HSF2
GATA-X
HNF-3b
GATA-1
HSF2
GATA-X
HNF-3b
GATA-2
GATA-1
Sp1
GATA-2
GATA-1
c-Ets
c-Ets
AP-1
AP-1
AP-1
AP-1
AP-1
NF-E2  
C/EBPa
AP-1  
Sp1
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4.4.4 Sequencing the K13 Full Length 3.018kb Promoter and Deletion 
Constructs (R1-R6) 
To ensure no error was introduced during PCR or incorporated by the bacteria during 
the bacterial transformation stage of cloning the K13 promoter deletion constructs 
was sequenced (Chapter 2 section 2.12). Figure 4.8 shows the DNA sequencing 
result obtained for the K13 FL and some of the deletion constructs of K13 promoter 
DNA sequence put together. The K13 FL and deletion constructs of K13 promoter 
DNA sequence was obtained using both forward and reverse primers for K13-R1 to 
K13-R6 constructs. However, the K13 FL, R2 and R4 deletion constructs were not 
amplifiable with the reverse primers. It should be noted that the letter N, in the DNA 
sequencing result means that the computer was unable to recognise that specific 
nucleotide and thus it allocates the letter N (pink) for not recognised. The entire 
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sequence in Figure 4.8 was then blasted against the human genome using the NCBI 
database (Chapter 2 section 2.12) and the search located sequence in chromosome 17 
where all type I keratin genes are found in or the K13 sequence. The taxonomy blast 
result (Figure 4.9) shows a 99% homology of the sequence obtained to that of K13 
DNA sequence in the human genome database.   
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TGGCCTNTTTCTTAAATGTTTCTTTNCCTTNCGGTTATCCCCTGGAATTCTGGTGGATAACCGTATTACCGCC
ATGCATTAGTTATTATAGTATACGGGAGGAGACCGCAGTACATTGTTCTTTNCCTGTCGTTATCCACNGNAAT
TCTGTGGATAACCGTATTACCGCATGCATTAGTTATTATAGTATACCTGAATCCCTGGCCTCGCAAGGCTGTT
AGAACACTGGCAACGTGCCCTGGCTCTGTCCCTGCTGATACCCCTGCGGGAAGCACAGGCCCGCTTCTCTACC
CCAGAAAGCAAAGGCCCAGAAAGCCCTGACTCAGATTTCTCCTTTCTACGCTCGCCGCTCAGCTTCGAACAGG
AATGGGCACCACCCCGGATGAACAGCTCCTCGCCCTTGCTCACCATGGTGGCGATGGATCCCGGGCCCGCGGT
ACCGCTCTTCCCCAGAGTGGACACCTTTTATACACCTCCATAGGGGCCGGTTATCTTCTCTCCTCCCTTCCCC
ACCCTCTGACTTGGTGCCAACTACACTTCTGTTTCCCACAAGCTTAGTTATCTCTGATCTCTCCTACATNGTT
CTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCATTAGTTATTATAGTATACACATA
GTCCCTGAGTTTCTCAGCCACAATCAGGATCCTAAGCTGAGACCCTGGCCCTGGGTCCTGTGTCGCATCCTCT
TATGTGGCCTCTTGGCTGGGACAGACCTCATATGACTGGCGTACTANAAAGGACCCTGCTCACCGCTCGCCG
CTCAAGCTTCGAACAGGATGGGCACCACCCCGGGTGAACAGCTCCTCGCCCTTGCTCACCATGGTGGCGATGG
ATCCCGGGCCCGCGGTACCGCTCTTCCCCAGAGTGGACACCTTTTATACACCTCCATAGGGGCCGGTTATCTT
CTCTCCTCCCTTCCCCACCCTCTGACTTGGTGCCAACTACACTTCTGTTTCCCACAAGCTTAGTTATCTCTGA
TCTCTCCAGGGTGGGTTGTCCATNGTTCTTTCCTGGCG TTATCCCCTGGATTCTGTGGATAACCGTATTAC
CGCCATG CATTAGTTATTATAGTATACTGGACAGGGCCACTTCCTCTTTCCATGCCTGAGTTTCCACAGCTG
TGTCTGATGGTCCCTAAGATCCCTTAAGGTCTCTGTCACTGTGACTTTTTCTGATGGCCTCGCCGTCAGCTCG
ANCAGGATGGNGCACCAC CCCNGATGAACAGCTCCTCG CCCTTGCTCACCATGGTGGCGATGGATCCCGGG
CCCGCGGTACCGCTCTTCCCCAGAGTGGACACCTTTTATACACCTCCATAGGGGCCGGTTATCTTCTCTCCTC
CNTTCCCCACCCTCTGACTTGGTGNCAACTACACTTCTGTTTGGCTTTTNTNCATGTTCTTTCCTGGCGTTAT
CCCCTGGATTCTGTGGATAACCGTATTACCGCCATGCATTAGTTATTATAGTATACCTCAGAGCCTGCACAGT
GAACTCCTTAAGNCGGAGGTGAAACAGAATTCACTTGTCAAAAGGGCAGTCTCAGGCAGAATGCTGTCCCCCC
TGAATCATTCTTTTTGTTAAGGATTAAANCAAAAGCCACCCCTAAAAGGCACAACCCACCCTGGAGAGACGCT
CGCCGTNCAGCTTCGAACAGGAATGNTGCACCACCCCGAANGAAACAGCTCCTCGCCCTTGCTCACCATGGAN
GGCGATGGATCCCGGGCCCGCGGTACCGCTCTTCCCCAGAGTGGACACCTTTTATACACCTCCATAGGGGCCG 
GTTATCTTCTCTCCTCCCTTCCCCACCCTCTGACTTGGTGCCAACTACACTTCTGTTTCCCACAAGCTTAGTT
ATCTCTGATCTCTCCAGGGTGGGT
KpnIBstZ17I
K13 FL 3018bp and K13-R1 to R6
(A)
(B)
(C)
 
 
 
 
 
 
 
Figure 4.8: DNA sequencing Result of K13 FL and deletion fragments in pEGFP-N3B 
vector: (A) Shows the K13 R1 to R6 constructs of K13 promoter DNA sequence result
using forward and reverse primers, the pink highlighted N means that the computer was 
unable to recognise that specific nucleotide and thus it allocates the letter N for not 
recognised . (B) Shows the insert enzyme sites (BstZ17I and KpnI) used to digest the 
K13 FL fragment and K13 R1 to R6 promoter constructs. (C) Shows 4.7kb pEGFP-
N3B vector and the site where the K13 FL and subsequent deletion series fragments 
was cloned into using BstZ17I and KpnI enzymes sites by removing CMV promoter.  
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Tax BLAST Report
Features flanking this part of subject sequence:
64 bp at 5' side: keratin 13
Score =  265 bits (143),  Expect = 2e-67
Identities = 145/146 (99%), Gaps = 0/146 (0%)
Strand=Plus/Plus
Query 895     GCTCTTCCCCAGAGTGGACACCTTTTATACACCTCCATAGGGGCCGGTTATCTTCTCTCC  
|||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||
Sbjct 3386162 GCTCTTCCCCAGAGTGGACACCTTTTATACACCTCCATAGGGGCTGGTTATCTTCTCTCC  
 
 
 
4.4.5 GFP Expression can be used to Quantify K13 Promoter Activity using 
FACS 
To assess whether using GFP as a reporter gene provides good quantification of 
CMV, K13 and K15 promoter levels, increasing concentrations of promoter plasmid 
DNA versus GFP expression were investigated using FACS. An initial optimization 
of the project was done before any subsequent experiments were carried out with the 
constructs. Figure 4.10 shows representative images of GFP expression using 3.2µg 
of CMV, K13 and K15 gene reporter constructs, as well as the internal control 
(DsRed) and promoterless pEGFP-N3B vector transfected into an oral SCC25 cell 
line. A DNA concentration of 2.5µg of CMV, K13 and K15 promoter driven GFP 
constructs, which falls in the linear part of the graph (Figure 4.11), was used for 
subsequent transient transfection experiments.  These initial experiments do not 
quantify the CMV, K13 and K15 promoters as such, but rather demonstrate a linear 
relationship between the promoters used and the EGFP signal. This EGFP signal was 
measured using a FACS (Beckton Dickinson) with separate channels for EGFP and 
DsRed (Figure 4.10) with different band pass filters for different coloured 
fluorescent proteins. In addition, the units of GFP expression used throughout the 
thesis will be arbitrary units; this is because the fluorescence data is measured on a 
logarithmic scale and GFP units are noted as arbitrary units in previous reports which 
use GFP reporter gene.  It should also be noted that the data presented in Figure 4.11 
are the raw data for EGFP median fluorescence intensity and the data obtained for 
the internal controls (pDesRed-N1) were not used. This was done in an attempt to 
observe the EGFP median fluorescence intensity only as the aim of this particular 
experiment was to observe whether there is a linear relationship between EGFP 
signal and increasing CMV, K13 and K15 promoter plasmid DNA concentrations 
Figure 4.9: Taxonomy Blast result of short piece of sequence at the 3`end of the 
K13-R6 promoter fragment, which happens to be the reverse complement of the K13 
promoter sequence.   
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(Figure 4.11). Hence the data values in Figure 4.11 are smaller than all other data 
presented in the thesis. The data in Figure 4.11 also shows that CMV produces the 
largest MFI signal in comparison to K13 and K15. The percentage of oral SCC25 
cells that have taken up CMV promoter linked EGFP is about 10-20% while in the 
K13 and K15 promoter-linked EGFP expressions in oral SCC25 cells this was 3-
10%. The EGFP expression of CMV, K13 and K15 constructs transfected cells was 
not counter stained with DAPI. The data in Figure 4.11 also shows that the CMV, 
K13 and K15 promoter levels can be quantified and this quantitation of promoter 
activity can be used to deduce that the GFP reporter gene assay can be used as 
quantitative marker of keratin promoter activity. 
 
(A) CMV                                    (B) K13                                         (C) K15                       
(D) Promoterless                                    (E) DsRed
 
 
 
 
 
 
 
 
Figure 4.10: Representative images of human oral SCC25 cell line transfected with 
pEGFP-N3B, PL pEGFP-N3B and pDsRed-N1 vectors. A: shows oral SCC25 cells 
transfected with CMV promoter in pEGFP-N3B vector DNA (3.2µg) used as positive 
control.  B: shows oral SCC25 cells transfected with K13 promoter in pEGFP-N3B 
vector DNA (3.2µg).  C: shows oral SCC25 cells transfected with K15 promoter in 
pEGFP-N3B vector DNA (3.2µg). D: shows oral SCC25 cells transfected with 
promoterless (PL) pEGFP-N3B vector DNA (3.2µg) used as negative control.  D: 
shows oral SCC25 cells transfected with CMV promoter in pDsRed-N1 vector DNA 
(3.2µg) used as internal control. The cell populations were photographed using a 
fluorescent microscope and the picture magnification is 100x. 
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4.4.6 Qualitative data of K13 promoter linked GFP expression shows epithelial 
specific expression  
The K13 FL promoter-linked GFP construct was transiently transfected into various 
epithelial and non-epithelial cell lines (Figure 4.12 to 4.15). Comparison of K13 
promoter driven GFP expression in oral SCC25, RTS3b, HeLa and HFF cell lines 
shows the K13 promoter signal is the strongest in HeLa, then in oral SCC25, 
followed by RTS3b cells, while the K13 promoter expression in HFF cells is 
negligible.  In Figure 4.14 the co-expression of K13 promoter linked GFP and the 
DsRed internal control plasmid expression is shown by merging the same field view 
of GFP and DsRed fluorescent proteins. This type of qualitative data as shown in 
Figure 4.12 to 4.15 is one of the advantages that the use of GFP has over other 
reporter genes.   
Figure 4.11: Shows the effect of varying concentration of promoter driven GFP 
plasmid expression in SCC25 cell line. GFP reporter gene can be used to quantify 
CMV and keratin promoter level since there was a linear relationship between GFP 
expression (arbitrary units) and increasing DNA concentration of CMV (navy blue), 
K13 (pink), and K15 (yellow) promoter constructs. Each point in graph represents the 
mean of four different experimental values for each construct.
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(A) CMV                                                           (B) K13                    
 
 
 
4.3.5 Quantitative data of K13 promoter linked GFP shows oral mucosal tissue 
 
 
(A) CMV                                                           (B) K13                    
 
 
 
 
 
 
 
Figure 4.12: Representative images of human oral SCC25 cell line transfected with 
CMV or K13 promoter in pEGFP-N3B vector. A: shows oral SCC25 cells 
transfected with CMV promoter in pEGFP-N3B vector DNA used as a positive 
control.  B: shows oral SCC25 cells transfected with K13 promoter in pEGFP-N3B 
vector DNA. The cell populations were photographed using a fluorescent 
microscope and the picture magnification is 100x. 
Figure 4.13: Representative images of human epidermal derived RTS3b cell line 
transfected with CMV or K13 promoter in pEGFP-N3B vector. A: shows RTS3b 
cells transfected with CMV promoter in pEGFP-N3B vector DNA used as a 
positive control.  B: shows RTS3b cells transfected with K13 promoter in pEGFP-
N3B vector DNA. The cell populations were photographed using a fluorescent 
microscope and the picture magnification is 100x. 
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(A) CMV                                                           (B) K13                    
 
 
 
 
 
 
(A) CMV                                                           (B) K13                     
 
 
 
 
 
 
4.4.7 FACS analysis of K13 Promoter linked GFP to examine Oral Mucosal 
Tissue Specific Expression  
To examine the mucosal tissue specific expression of the K13 promoter construct, 
the K13 promoter construct was transiently transfected into various epithelial and 
non-epithelial cell lines. Although expression of the K13 promoter was highest in the 
oral SCC25 cell line (Figure 4.16) in comparison to RTS3b, HeLa and HFF cell 
lines, the increased level of expression was not significant (P=0.354, 0.249, 0.189). 
The CMV promoter-driven GFP in pEGFP-N3B vector, which was used as a positive 
Figure 4.14: Representative image of HeLa cell line transfected with CMV or K13 
promoter in pEGFP-N3B vector. A: shows HeLa cells transfected with CMV 
promoter in pEGFP-N3B vector DNA used as a positive control.  B: shows HeLa 
cells transfected with K13 promoter in pEGFP-N3B vector DNA. The cell 
populations were photographed using a fluorescent microscope and the picture 
magnification is 100x. 
Figure 4.15: Representative images of human foreskin fibroblast derived HFF cell 
line transfected with CMV or K13 promoter in pEGFP-N3B vector. A: shows HFF 
cells transfected with CMV promoter in pEGFP-N3B vector DNA used as a 
positive control.  B: shows HFF cells transfected with K13 promoter in pEGFP-
N3B vector DNA. The cell populations were photographed using a fluorescent 
microscope and the picture magnification is 100x. 
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control transiently transfected into SCC25, RTS3b, HeLa and HFF cell lines (Figure 
4.17), shows relatively similar expression levels in all cell lines tested.  This result 
was as expected given that the CMV promoter was used as a positive control and 
thus should not show variation in its expression in different cell lines (Figure 4.17). 
The data presented in Figure 4.16 and 4.17 are in the same arbitrary units, the 
expression of K13 promoter in comparison to CMV promoter differs by a factor of 
1000. This might be due to the fact that CMV is a very active constitutive viral 
promoter, which causes GFP to be expressed strongly at all times. The data in Figure 
4.16 and 4.17 were not presented together because any variation of K13 expression 
in different cell lines could not be observed as easily if data were combined. In 
Figure 4.16 and 4.17 the standard deviation is high and this might be because of 
inconsistence in the transfection efficiency.  Moreover, Table 4.2 shows the MFI of 
K13 promoter linked GFP expressing cells which was quantified using FACS and 
Figure 4.16 result is based on Table 4.2 raw data. 
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Figure 4.16: The expression of K13 promoter and promoterless (PL) pEGFP-N3B 
vector in epithelial and non-epithelial cell lines. PL (blue) is the promoterless pEGFP-
N3B construct expression in SCC25, RTS3b, HeLa and HFF cell lines, the PL 
construct was used as a negative control for transfection. The figure also shows the 
K13 promoter driven GFP construct expression in SCC25, RTS3b, and HeLa and 
HFF cell lines. There was no significant difference between K13 FL promoter 
construct expression in oral SCC25 cells in comparison to RTS3b (P=0.354), and 
HeLa (P=0.249), and HFF (P=0.189) cell lines. The results are expressed as the 
mean ± the standard deviation (SD) of three experiments. 
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Table 4.2: The K13 promoter linked GFP expression in epithelial and non-epithelial 
cell lines 
0.8NoForeskin fibroblastHuman foreskin 
fibroblast derived 
HFF cells
5NoCervical
carcinoma
Simple epithelia 
derived  HeLa cells 
10YesEpidermoid
carcinoma 
skin derived RTS3b 
cells
31YesVentral tongue 
carcinoma
Oral mucosa 
SCC25 cells 
MFI of 
GFP over  DsRed
expressing cells 
Expression
of
K13
OriginCell types
 
MFI= median fluorescence intensity 
 
 
 
 
Figure 4.17: The expression of CMV promoter driven GFP expression in epithelial 
cell lines oral SCC25, RTS3b, HeLa and non-epithelial HFF cell line. The 
expression of CMV promoter expression in oral SCC25 in comparison to RTS3b, 
HeLa and HFF cell lines was not significant (P=0.242, 0.122, 0.085).  
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4.4.8 K13 protein shows mucosal epithelial tissue-specific expression using 
Western Blot 
To confirm the results of the K13 FL promoter construct (Figure 4.16) showing 
tissue specific expression at protein level, Western blotting was used. This technique 
is sensitive, quantitative and specific for detecting target proteins (Figure 4.18). The 
disadvantages of using Western blotting include results are subject to interpretation, 
although the intensity of the bands can be addressed by the use of densitometry 
(Reference: website 19). The A431 cell line was used as a positive control for K13 
protein expression, since this cell line has been shown to have very high expression 
of K13 protein (Waseem, et al. 1998). The expression of K13 protein is the second 
highest in the oral SCC25 cell line after A431 positive control cell line, and in the 
skin derived RTS3b cell line K13 protein expression is moderate (Figure 4.19). 
Although in the literature both K13 and K19 are not normally expressed in the 
epidermis skin, K13 protein was detected by Western blot in RTS3b cells (Figure 
4.18). Western blot quantification of K13 protein band density is shown to be 
greatest in the oral SCC25 cell line (green) in comparison to RTS3b (purple, 
P=0.340), HeLa (pink, P=0.003) and HFF (black, P=0.05) cell lines (Figure 4.19). In 
summary, the western blot data for K13 showed greater protein expression in oral 
SCC25 cells is consistent with the K13 promoter construct expression pattern, which 
indicates that K13 shows epithelial cell specific expression. 
 
K13
-actin
52kDa
A
43
1
SC
C
25
R
T
S3
b
H
eL
a
H
FF
42kDa β
A
43
1
SC
C
25
R
T
S3
b
H
eL
a
H
FF
A
43
1
SC
C
25
R
T
S3
b
H
eL
a
H
FF
A
43
1
SC
C
25
R
T
S3
b
H
eL
a
H
FF
 
 
 
 
 
Figure 4.18: Expression of K13 protein in various epithelial and human foreskin 
fibroblast derived cell lines. The K13 protein is strongly expressed in A431 cell line, 
then in SCC25 and RTS3b cells show negligible K13 protein expression, while both 
HeLa and HHF cell lines show no K13 protein expression. A431, SCC25, RTS3b, 
HeLa and HFF cells were grown until 80% confluent and lysed in Laemmli buffer 
before analysing by SDS-PAGE. Proteins were transferred onto nitrocellulose and 
probed for K13 expression using AE8 antibody as described in Chapter 2 section 
2.17.  
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4.4.9 FACS Data  
A representative plot of typical FACS data for both positive control pEGFPN-3B and 
promoterless (PL) pEGFPN-3B vector are shown in Figure 4.20 A and B. The lower 
left quadrant shows the percentage of non-transfected oral SCC25 cells, while in the 
upper left quadrant shows the percentage of SCC25 cells transfected with CMV 
linked GFP pEGFP-N3B vector (positive control) or PL. However, in the lower right 
quadrant the percentage of oral SCC25 cells transfected with CMV promoter linked 
DsRed (internal control) is shown. In the upper right quadrant the percentage of oral 
SCC25 cells which have taken up the co-transfected CMV promoter linked DsRed 
and CMV promoter linked GFP plasmids are shown. 
 
Figure 4.19: Quantification of band density derived from western blot data in Figure 
4.18 using densitometry to quantify K13 protein expression in epithelial and non-
epithelial cell lines. The expression of K13 protein in epithelial A431 (blue), SCC25 
(green), RTS3b (purple), HeLa (pink) cell lines and in non-epithelial HFF (black) 
cell line are shown. The results are expressed as the mean ± the standard deviation 
(SD) of five experiments. Each K13 band has been normalised to β-actin band 
density (loading control). The expression of K13 protein is increased in oral SCC25 
cell in comparison to RTS3b (purple, P=0.340), HeLa (pink, P=0.003) and HFF 
(black, P=0.05) cell lines. A431 cell was used as positive control for western blot 
technique given that this cell line shows abundant K13 protein expression. 
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4.4.10 FACS Analysis of K13 FL promoter and Truncated K13 Promoter R1 
and R2 Deletion Fragments 
Representative FACS data of FL (red), R1 (green) and R2 (blue) K13 promoter 
fragments transfected into oral SCC25 (Figure 4.22), RTS3b (Figure 4.23), HeLa 
(Figure 4.24) and HFF (Figure 4.25) cells are shown. The ability of each fragment 
(FL-R2) to drive GFP is measured by FACS. The FACS data are circled  (red, green 
and blue) for each of the 4 cell lines used,  to indicate that there is an emerging trend 
in the pattern of K13pro-3018bp (FL), K13pro-2540bp (R1), K13pro-1953bp (R2) 
expression in SCC25, RTS3b, HeLa and HFF cells. The pattern (Figure 4.21) of 
expression for the three constructs in oral SCC25 cells (Figure 4.22) shows a basal 
expression of K13 FL promoter then with K13-R1 fragment the expression increases; 
this is then followed by a rapid decrease in GFP expression with K13-R2 fragment 
compared to R2. In RTS3b cells (Figure 4.23 and 4.21) the K13 FL promoter shows 
the basal expression, then the K13 promoter expression increases with the R1 
fragment, which is followed by a decrease in GFP expression with the K13-R2 
fragment compared to fragment R2. Also the same pattern is observed for HeLa and 
HFF cells (Figure 4.25) in that the pattern of expression of FL K13 promoter shows 
Figure 4.20: An example of FACS plot data obtained with CMV driven pEGFP-N3B 
vector (positive control) and PL plasmid transfected in oral SCC25 cells. The upper left 
quadrant shows the percentage of GFP positive SCC25 cells for pEGFP-N3B (A) and 
PL (B). The upper right quadrant shows the percentage of pEGFP-N3B or PL and 
pDsRed1-N1 (PE-A or PI-A fluorescence) positive cells. The lower left quadrant shows 
percentage of non-fluorescening cells and lower right quadrant shows percentage of 
positive cells expressing pDsRed1-N1 plasmid (PE-A fluorescence) alone. This FACS
plot figure was included to clarify that all data obtained looks similar but the percentage 
of cells, which have taken GFP (the upper left quadrant) changes depending on the 
construct used.   
B A 
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the basal expression, then the K13 promoter expression increases with R1; this rapid 
increase is followed by a decrease with the K13-R2 fragment compared to fragment 
R2. This data taken together indicate the presence of important suppressor regulatory 
elements which reside between the K13-FL and K13-R1 deletion fragments. 
 
 
FL R1 R2
K13-3018bp                                    K13-2540bp                                             K13-1953bp
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Diagrammatic representation of K13 full length promoter (FL), R1 and 
R2 fragment expression trend observed from FACS data. The diagram shows the K13 
FL (red) promoter as a starting point for the full length promoter expression, the 
diagram then shows that with R1 (green) fragment the expression of K13 promoter 
increases, this indicates that a repressor element which resides in the K13 FL has 
been removed. The K13 expression level goes back down to K13-FL level with R2 
(blue) fragment. The dashed lines in the diagram are used as a divider between the 
expression of FL, R1 and R2 K13 promoter constructs. This figure was included to 
simplify the overall expression of K13-FL, R1 and R2 fragments as shown in figure 
4.22 to 4.25. 
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SCC25     (A)                                                  (B)                                                          (C)
 
 
 
 
 
 
 
 
 
 
 
RTS3b     (D)                                                  (E)                                                          (F)
 
 
 
 
 
 
 
 
 
Figure 4.22: Represents FACS plot data for full length (FL) K13 promoter and 
various lengths (R1 and R2) of K13 promoter in oral SCC25 cells. A= shows FACS 
plot data for the full length K13 promoter, the red circle highlights the percentage of 
GFP positive oral SCC25 cells transfected with FL K13 promoter linked GFP 
construct. B= shows plot data for R1 K13 promoter fragment, the green circle in the 
data highlights the percentage of GFP positive oral SCC25 cells transfected with R1 
K13 promoter linked GFP construct. C= shows FACS plot data for R2 K13 
promoter fragment, the blue circle in the FACS data highlights the percentage of 
GFP positive oral SCC25 cells transfected with R2 K13 promoter linked GFP 
construct. The pattern emerging with FL, R1 and R2 K13 promoter fragments in 
oral SCC25 cells seems to increase with R1 fragment followed by a decrease in 
K13 promoter expression as indicated by decrease in percentage of GFP positive 
SCC25 cells which have up taken the K13pro-R2 construct.  
 
Figure 4.23: Shows FACS plot data for full length (FL) K13 promoter and various
lengths (R1 and R2) of K13 promoter in RTS3b cells. D= shows plot data for the 
full length K13 promoter, the red circle in the data highlights the percentage of GFP 
positive RTS3b cells transfected with FL K13 promoter linked GFP construct. E= 
shows plot data for R1 K13 promoter fragment, the green circle in the data 
highlights the percentage of GFP positive RTS3b cells transfected with R1 K13 
promoter linked GFP construct. F= shows FACS data for R2 K13 promoter 
fragment, the blue circle in the FACS data highlights the percentage of GFP 
positive RTS3b cells transfected with R2 K13 promoter linked GFP construct. The 
pattern emerging with FL, R1 and R2 K13 promoter fragments in RTS3b cells 
seems to increase with R1 fragment followed by a decrease back down to the level 
of K13-FL promoter expression as indicated by decrease in percentage of GFP 
positive RTS3b cells which have up taken the K13pro-R2 fragment construct. 
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HeLa     (A)                                                   (B)                                                         (C)
 
 
 
 
 
 
 
 
 
 
 
HFF      (D)                                                   (E)                                                      (F)
 
 
 
  
 
 
 
 
 
Figure 4.24: Representing FACS plot data for full length (FL) K13 promoter and 
various lengths (R1 and R2) of K13 promoter in HeLa cells. A= shows FACS data 
for the full length K13 promoter, the red circle in the highlights the percentage of 
GFP positive HeLa cells transfected with FL K13 promoter linked GFP construct. 
B= shows plot data for R1 K13 promoter fragment, the green circle in the FACS 
data was used to highlight the percentage of GFP positive HeLa cells transfected 
with R1 K13 promoter linked GFP construct. C= shows FACS plot data for R2 K13 
promoter fragment, the blue circle in the data highlights the percentage of GFP 
positive HeLa cells transfected with R2 K13 promoter linked GFP construct. The 
pattern emerging with FL, R1 and R2 K13 promoter fragments in HeLa cells seems 
to increase with R1 fragment followed by a decrease, compared to R1, in K13 
promoter expression as indicated by decrease in percentage of GFP positive HeLa 
cells which have up taken the K13pro-R2 fragment construct.  
Figure 4.25: Shows FACS plot data for full length (FL) K13 promoter and various
lengths (R1 and R2) of K13 promoter in HFF cells. D= shows FACS data for the 
full length K13 promoter, the red circle in the FACS data highlights the percentage 
of GFP positive HFF cells transfected with FL K13 promoter linked GFP construct. 
E= shows FACS data for R1 K13 promoter fragment, the green circle in the plot 
data highlights the percentage of GFP positive HFF cells transfected with R1 K13 
promoter linked GFP construct. F= shows FACS plot data for R2 K13 promoter 
fragment, the blue circle in the data highlights the percentage of GFP positive HFF 
cells transfected with R2 K13 promoter linked GFP construct. The pattern emerging 
with FL, R1 and R2 K13 promoter fragments in HFF cells seems to increase with 
R1 fragment followed by a decrease, compared to R1, in K13 promoter expression 
as indicated by decrease in percentage of GFP positive HFF cells which have up 
taken the K13pro-R2 fragment construct.  
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4.4.11 The 3.018kb K13 FL Promoter and K13 Truncated Promoter R1 to R6 
Deletion Fragments Transfected into Epithelial and non-Epithelial Cell Lines 
The K13 FL promoter and the R1 to R6 K13 promoter fragments were transiently 
transfected into oral SCC25, RTS3b, HeLa and HFF cell lines (Figure 4.26). The 
results indicate that there is a trend in the pattern of the K13 FL (K13-3018bp) and 
K13 R1 (K13-2540bp) to R2 (K13-1953bp) expression in SCC25, RTS3b, HeLa and 
HFF cell lines. As shown in Figure 4.26, after almost 500bp is removed from the 
K13 FL promoter the expression of R1 fragment goes up significantly in SCC25 
(P=0.003), RTS3b (P=0.01), HeLa (P=0.002) and HFF (P=0.01) cells relative to FL 
K13 promoter. This is then followed by a significant decrease in the K13 promoter 
driven GFP expression with the R2 fragment compared to K13 FL in HeLa 
(P=0.0003) and HFF (P=0.02)  cell lines. The expression pattern of the FL K13 
promoter, R1 and R2 K13 promoter fragments is consistent in oral SCC25, RTS3b, 
HeLa and HFF cells. However the expression of the K13 promoter deletion fragment 
R3 (K13-1512bp), R4 (K13-1017bp), R5 (K13-670bp) and R6 (K13-289bp) differ 
depending on the cell line being tested. The expression of the K13 promoter 
fragment R3 increases in SCC25, RTS3b and HFF (Figure 4.26 A, B and C) relative 
to FL K13 promoter, while in HeLa cells (Figure 4.26 D) there is a slight decrease in 
R3 fragment expression relative to the FL K13 promoter.  The expression of K13 
promoter fragment R4 increases in SCC25 (P=0.05), RTS3b and HFF (P=0.004) 
(Figure 4.26 A, B and D) relative to FL K13 promoter, while in HeLa cells (Figure 
4.25 C) there is a significant (P=0.001) decrease in R4 fragment relative to the FL 
K13 promoter. In addition, the expression of K13-R5 promoter fragment increases in 
SCC25 and HFF (Figure 4.26 A and D) relative to FL K13 promoter. While in 
RTS3b cells (Figure 4.26 B) the expression remains the same and with HeLa cells 
(Figure 4.26 C) there is decrease in R5 fragment relative to the FL K13 promoter. 
Finally the expression of K13-R6 promoter fragment increases in SCC25, RTS3b 
and HFF (P=0.004) (Figure 4.26 A, B and D) relative to FL K13 promoter. While in 
HeLa cells (Figure 4.26 C) there is a significant (P=0.0003) decrease in R6 fragment 
relative to the FL K13 promoter.  
 
Figure 4.26 results are based on Table 4.3 and they represent the average of FACS 
for three different transient transfection experiments of promoterless (PL) pEGFP-
N3B, K13 FL promoter and K13 promoter deletion fragments R1 to R6 into SCC25, 
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RTS3b, HeLa and HFF cell lines. The FACS data were normalized to the pDsRed1-
N1 internal control for PL, FL K13 promoter and K13 deletion R1 to R6 fragments. 
In addition, Table 4.3 shows the fold induction of PL, K13 FL and R1 to R6 K13 
promoter fragment expression in SCC25 cells in comparison to HeLa cells. This 
comparison was done to highlight the fact that, although K13 is not normally 
expressed in HeLa cells, they show greater expression of PL, K13 FL and R1 to R6 
K13 promoter fragment expression in comparison to SCC25 cells, which 
endogenously express K13. Possible reasons for abnormal expression K13 in HeLa 
cells are discussed in section 4.5.  
 
In summary the results for K13 FL promoter, K13-R1 and K13-R2 deletion fragment 
expression indicates that there similar expression pattern of all three constructs in 
SCC25, RTS3b, HeLa and HFF cell lines, with an increase in K13-R1 fragment 
expression in comparison to FL K13 promoter. This is then followed by a decrease in 
K13 R2 fragment expression in comparison to FL K13 promoter in HeLa and HFF 
cell lines. While the expression pattern of K13 promoter deletion fragments K13-R3 
to K13-R6 promoter driven GFP expression pattern differs depending on the cell line 
being tested.  
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Table 4.3: Average FACS data obtained for truncated K13 promoter fragment 
constructs transiently transfected into epithelial and non-epithelial cell lines. 
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Figure 4.26: The GFP expression of promoterless (PL) pEGFP-N3B vector, FL K13 
promoter and K13 R1 to R6 deletion fragments in SCC25 (A), RTS3b (B), HeLa (C)
and HFF (D) cell lines. The K13 promoter-linked GFP expression is the highest in 
HeLa, SCC25, RTS3b and then in HFF cell line. HFF cell line was used as a negative 
control for transfection experiment since fibroblasts don’t express keratins hence the 
negligible K13 fragment expression in HFF cells. The number of asterisks in each 
figure represents the significance of PL and K13 R1 to R6 (K13-2540 to K13-289bp)
deletion fragments relative to the FL K13 promoter (K13-3018bp). The white circle 
in each figure highlights the GFP expression of the FL K13 promoter in pEGFP-N3B 
vector relative to R1 to R6 K13 promoter fragments.  
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4.4.12 Pathways involved in the Induction of K13 Expression  
 The exact mechanism of transcriptional regulation of many mammalian genes which 
are required for maintaining normal cellular proliferation and differentiation is 
unknown. However, abnormal tissue growths and developmental disorders have been 
reported to result directly from abnormal expression of a single transcription factor, 
which eventually leads to deregulation of numerous target genes (Weinmann et al, 
2002). Furthermore, it could also be that aberrant gene expression might be an 
indirect result of a transcription factor altering signal transduction pathways 
(Weinmann et al, 2002). Therefore, by utilizing pharmacological agents such as 
TPA, PD98059 (MEK 1/2 inhibitor), and LY294002 (PI3K inhibitor), Trichostatin A 
and sodium butyrate, pathways important for K13 expression were investigated. 
These pathways has been investigated in an attempt to obtain information on the 
important signalling events related to K13 expression. MEK 1/2 and PI3K are the 
two major kinase pathways activated by growth stimulatory signals such as 
epidermal growth factor (Yano et al, 2004). The MEK 1/2 pathway has also been 
reported to be important for expression of other differentiation markers like K10.  
 
 
4.4.13 Cytotoxicity of Pharmacological Inhibitors on Oral SCC25, RTS3b and 
HeLa cells using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
a tetrazole (MTT) assay. 
Prior to their use an MTT assay was performed to examine the effect of each 
pharmacological agent on cell toxicity (Figure 4.35). The LD50, is an index of drug 
toxicity and a measure of the lethal dose of any given substance required to kill 50% 
of the test experimental cell population. The MTT assay showed the following drug 
concentrations 100nM 4-α-PMA, 100nM TPA, 50μM PD98059 were not toxic to 
oral SCC25 cells (P=0.88, 0.40, 0.60) in comparison to control. In addition, the 
treatment of RTS3b and HeLa cells (P=0.06, P=0.81) with 3μM Trichostatin A drug 
concentration which showed no cell toxicity in comparison to control. However, the 
MTT assay did show significant (P=0.001) difference between the untreated 
(control) and treated oral SCC25 cells with 25μM LY294002 (test). Moreover, the 
LY294002 compound only killed 32% of oral SCC25 cells and 68% of the cells were 
viable (Figure 4.27). Thus, if the LD50 is used as an index of LY294002 compound 
toxicity, it can be inferred that the decrease in K13 promoter construct and protein 
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expression in oral SCC25 cells is probably not due to LY294002 induced cell 
toxicity, but rather a true reflection of the importance of this pathway for K13 
expression. 
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4.4.14 Induction of K13 Expression by TPA through the Activation of Protein 
Kinase C Pathway 
Protein kinase C (PKC) is essential for the expression of certain differentiation 
related genes and TPA activates the PKC pathway, therefore one of the aims of the 
study was to address whether markers for epithelial differentiation such as K13 can 
be induced by TPA. While TPA is an activator of PKC, 4-α-PMA was used as a 
negative control for the experiment, since 4-α-PMA is an inactive analogue of TPA.  
Thus if K13 expression is higher in the presence of TPA in comparison to 4-α-PMA, 
Figure 4.27: Cytotoxicity of various pharmacological agents on oral SCC25, RTS3b 
and HeLa cell viability. Depending of the cell type being tested, 5x103 to 12x103 were 
plated per well into 96 well plate, in the presence or absence of 4-α-PMA (green), TPA
(green), PD98059 (green), LY294002 (green), TSA (purple) and sodium butyrate
(pink) and incubated overnight in a 5% CO2 incubator at 37ºC for various times. 
Cytotoxicity was measured with the MTT assay (as in the method and materials section 
2.16.1). The net absorbance taken from the wells with cells from cultured media was 
taken as a 100% viability value (control). The percentage viability of the treated cells 
was calculated from the net absorbance of the sample divide by the net absorbance of 
the control x 100. Each data point represents the mean ± SD from three individual 
wells.  
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it indicates that K13 expression can be activated via the PKC pathway. However, if 
the activity of K13 is the same or lower in the presence of TPA in comparison to 4-α-
PMA, then K13 expression is not induced by TPA through the PKC pathway. The 
results show that both K13 FL promoter construct and protein expression were not 
significantly increased (P=0.414 and P=0.89) in presence of TPA in comparison to 
4-α-PMA (Figures 4.28 and 4.31). This indicates that the K13 expression is not 
induced through the PKC pathway.  In addition, there was no significant (P=0.978) 
difference between the K13 promoter deletion R2 fragment in the presence of TPA 
or 4-α-PMA, which again indicates that K13-1953bp R2 fragment expression is not 
induced through the protein kinase C pathway. Moreover Figure 4.29 shows that the 
effect of TPA or 4-α-PMA on the CMV promoter was not significant (P=0.316), 
given that there was no difference between CMV promoter expression in presence of 
TPA or 4-α-PMA. This indicates the CMV promoter expression is not induced 
through the protein kinase C pathway.  These results taken together show that K13 
FL, K13-1953bp R2 fragment and CMV promoter expression are not induced 
through the PKC pathway, since there was no significant difference between the 
expressions of these constructs in the presence of TPA compared to 4-α-PMA. 
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Figure 4.28: The effect of 100nM 4-α-PMA and TPA on EGFP expression 
transfected in oral SCC25 cells containing promoterless (PL), truncated K13 
promoter (K13-1953bp) or the K13 full length promoter (K13-FL) construct
expression. The promoter constructs alone form the cell control (blue), while the 
addition of DMSO forms the vehicle control (mauve). The effects of the addition of 
either 100nM 4-α-PMA or TPA are shown in yellow and turquoise respectively. K13 
FL promoter and K13-1953bp deletion fragment activity in response to 100nM 4-α-
PMA versus TPA showed no significant difference (P=0.414 and 0.978). The results 
are expressed as the mean ± SD from three experiments. 
Figure 4.29: The effect of 100nM 4-α-PMA and TPA on EGFP expression 
transfected in oral SCC25 cells containing CMV promoter (pEGFP-N3B). The CMV 
promoter alone form the cell control (blue), while the addition of DMSO forms the 
vehicle control (mauve). The effects of the addition of either 100nM 4-α-PMA or TPA 
are shown in yellow and turquoise respectively. CMV promoter activity in response 
100nM 4-α-PMA versus TPA showed no significant difference (P=0.316). The results 
are expressed as the mean ± SD from three experiments. 
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4.4.15 MEK 1/ 2 and PI3K/Akt pathways 
MEK 1/2 and PI3K/Akt,  are the two major kinase pathways which are activated by 
growth stimulatory signals such as epidermal growth factor (Yano et al, 2004) and 
the effect of inhibition of these pathways on K13 was investigated using specific 
Figure 4.30: Effect of TPA and 4-α-PMA on K13 protein expression in oral SCC25 
cells. K13 protein expression appears slightly decreased in the presence of TPA 
compared to control. Cells were exposed to 100nM TPA and 4-α-PMA for 6 hours
and then lysed in Laemmli buffer before SDS PAGE analysis. Protein was transferred 
onto nitrocellulose and probed for K13 using AE8 antibody as described in Chapter 2 
section 2.17. 
Figure 4.31: Quantification of band density derived from western blot data in figure 
4.30 using densitometry to show alterations in K13 protein expression after treatment 
of SCC25 cells with DMSO (control vehicle), 4-α-PMA (100nM) and TPA (100nM) 
for 6 hours. The results are expressed as the mean ± SD from three experiments.
Each K13 band has been normalised to β-actin band density (loading control). There 
is no significant difference between K13 protein expression in the presence of 4-α-
PMA and TPA. 
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inhibitors. These pathways were examined to show whether altered differentiation in 
the oral mucosa reflects specific changes in either pathways. 
 
4.4.16 Inhibition of MEK 1/ 2 Pathway on the Induction of K13 FL Promoter 
Construct and Protein Expression  
Inhibition of MEK 1/2 pathway with 50μM PD98059 significantly decreased 
(P=0.030, Figure 4.32) the K13 FL promoter construct expression and insignificantly 
increased (P=0.162 Figure 4.34) the expression of K13 protein in comparison to the 
control. In Figure 4.33, the CMV promoter expression in the presence of 50μM 
PD98059, MEK1/2 pathway, inhibitor has shown significant decrease in GFP 
expression in comparison to control (P=0.01 Figure 4.33). Furthermore, although the 
data presented in Figure 4.32 and 4.33 are in the same arbitrary units, the expression 
of K13 FL promoter in comparison to CMV promoter differs by 10 fold. This might 
be because CMV is a very active constitutive viral promoter, which causes GFP to be 
expressed strongly at all times, therefore, greater CMV expression (Figure 4.33) in 
comparison to K13 promoter expression (Figure 4.32) is observed. The result for 
CMV promoter (Figure 4.33) was not as expected given that CMV promoter was 
used as positive control and thus should not be affected by a pharmacological agent. 
This highlights some of the flaws associated with the use of GFP reporter genes. 
Also the decrease in CMV promoter seems to be non-specific given that DMSO, 
which normally causes induction of cell differentiation, appears to be causing this 
decrease, rather then the PD98059 MEK 1/2 inhibitor (Figure 4.33), while the 
decrease in K13-FL promoter seems to be specifically caused by PD98059 MEK 1/2 
inhibitor, given that K13-FL promoter in the presence of DMSO is not decreased. 
This shows that inhibition of MEK 1/2 by PD98059 is specific for K13-FL promoter, 
but not for the CMV promoter. Moreover, inhibition of the MEK 1/2 pathway with 
50μM PD98059 did not significantly (P=0.162) increase the K13 protein expression 
in comparison to control (Figure 4.35). This contradictory result for both K13-FL 
promoter and K13 protein expression in the presence of PD98059 could mean that 
different mechanisms might exist for the inhibition of K13-FL promoter activity, 
which has nothing to do with K13 protein. In summary, the inhibition of MEK 1/2 
pathway with PD98059 significantly decreased the K13 FL promoter construct and 
the expression of CMV promoter, while the inhibition of this pathway insignificantly 
increased the K13 protein expression in comparison to control. 
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Figure 4.32: The effect of MEK 1/ 2 pathway inhibitor PD98059 on EGFP 
expression in oral SCC25 cells containing promoterless (PL) or the K13 full length 
promoter (K13-FL) construct expression. The promoter constructs alone form the cell 
control (blue), while the addition of DMSO forms the vehicle control (mauve). The 
effects of the addition of PD98059 are shown in yellow. K13 FL promoter activity in 
response to 50μM PD98059 versus control caused a significant (P=0.03) decrease in 
K13-FL promoter. The results are expressed as the mean ± SD from three 
experiments. 
Figure 4.33: The effect of MEK 1/ 2 pathway inhibitor PD98059 on EGFP 
expression in oral SCC25 cells containing CMV promoter in pEGFP-N3B vector 
(positive control). The CMV promoter in pEGFP-N3B vector alone form the cell 
control (blue), while the addition of DMSO forms the vehicle control (mauve). The 
effects of the addition of PD98059 are shown in yellow. CMV promoter in response 
to 50μM PD98059 versus control caused a significant (P=0.01) decrease in CMV 
promoter. The results are expressed as the mean ± SD from three experiments. 
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Figure 4.34: Effect of MEK 1/ 2 inhibitor PD98059 on K13 protein expression in an 
oral mucosa SCC25 cell line. K13 protein expression appears slightly increased in the 
presence of PD98059 compared to control Cells were grown in 50μM PD98059 for 
48 hours and lysed in Laemmli buffer before analysing on SDS gels. The gels were 
transferred on nitrocellulose and probed for K13 expression using AE8 antibody as 
described in Chapter 2 section 2.17.  
Figure 4.35: Quantification of band density derived from western blot data in Figure 
4.34 using densitometry to show the alteration in K13 protein expression after 
treatment of SCC25 cells, in absence and presence of DMSO (control vehicle) and 
MEK 1/ 2 pathway inhibitor PD98059 (50μM), for 48 hours. The results are 
expressed as the mean ± SD from three experiments. Each K13 band has been 
normalised to β-actin band density (loading control). There is no significant 
(P=0.162) difference between K13 protein expression in the presence of PD98059 in 
comparison to control. 
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4.4.17 Effect of inhibition of PI3K/Akt Pathway and Expression of K13 FL 
Promoter Construct and K13 Protein  
Inhibition of the PI3K/Akt pathway with 25μM LY294002 significantly decreased 
(P=0.01, Figure 4.36) the K13 FL promoter construct and K13 protein (P=0.003, 
Figure 4.38) expression in comparison to the control. In Figure 4.37, the CMV 
promoter expression in the presence of 25μM LY294002, a PI3K/Akt pathway 
inhibitor, shows a decrease in GFP expression in comparison to control. 
Furthermore, although the data presented in Figure 4.36 and 4.37 are in the same 
arbitrary units, the expression of K13 FL promoter in comparison to CMV promoter 
differs by 20 fold. This might be because CMV is a very active constitutive viral 
promoter, which causes GFP to be expressed strongly at all times. The CMV 
promoter appears to be affected by LY294002 compound (Figure 4.37). Inhibition of 
the PI3K/Akt pathway with 25μM LY294002, significantly (P=0.003) decreased 
K13 protein in comparison to control (Figure 4.38 and 4.39). In summary, the 
inhibition of the PI3K/Akt pathway with LY294002 compound significantly 
decreased the K13 FL promoter construct, K13 protein expression and insignificantly 
decreased the expression of CMV promoter in comparison to control. This consistent 
decrease in K13 promoter construct and protein expression caused by the LY294002 
compound might reflect the importance of this pathway for K13 expression in the 
oral mucosa. 
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Figure 4.36: The effect of PI3K/Akt pathway inhibitor LY294002 on EGFP 
expression transfected in oral SCC25 cells containing promoterless (PL) or the K13
full length promoter (K13-FL) construct expression. The promoter constructs alone 
form the cell control (blue), while the addition of DMSO forms the vehicle control 
(mauve). The effects of the addition of LY294002 are shown in yellow. K13 FL 
promoter activity in response to 25μM LY294002 versus control caused a significant 
(P=0.01) decrease in K13-FL promoter. The results are expressed as the mean ± SD 
from three experiments. 
Figure 4.37: The effect of PI3K/Akt pathway inhibitor LY294002 on EGFP 
expression transfected in oral SCC25 cells containing CMV promoter in pEGFP-N3B 
vector (positive control). The CMV promoter in pEGFP-N3B vector alone form the 
cell control (blue), while the addition of DMSO forms the vehicle control (mauve). 
The effects of the addition of LY294002 are shown in yellow. CMV promoter in 
response to 25μM LY294002 versus control caused insignificant (P=0.09) decrease 
in CMV promoter. The results are expressed as the mean ± SD from three 
experiments.  
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4.4.18 Post-transcriptional Regulation of K13 Gene Expression   
Regulation of gene expression includes many processes that cells use to convert the 
information in genes into gene products (Strachan and Read, 2004). Gene regulation 
is essential for eukaryotes as this leads to increased adaptability of the organism by 
allowing the cell to express protein when needed (Strachan and Read, 2004). Histone 
post-translational covalent modification is associated with regulating gene expression 
(Oberley et al, 2006). Histone is the major protein component of chromatin that acts 
Figure 4.38: Effect of PI3K/Akt pathway inhibitor LY294002 on K13 protein 
expression in oral SCC25 cells.  K13 protein expression is absent in the presence of 
LY294002 compound compared to control. Cells were grown in 25μM LY294002 for 
48 hour and lysed in Laemmli buffer before analysing on SDS gels. The gels were 
transferred on nitrocellulose and probed for K13 expression using AE8 antibody as 
described in Chapter 2 section 2.17. 
Figure 4.39: Quantification of band density derived from western blot data in Figure 
4.38 using densitometry to show the alteration in K13 protein expression after 
treatment of SCC25 cells, in absence and presence of DMSO (control vehicle) and 
PI3K/Akt pathway inhibitor LY294002 (25μM), for 48 hours. The results are 
expressed as the mean ± SD from three experiments. Each K13 band has been 
normalised to β-actin band density (loading control). There was a significant 
(P=0.003) difference between K13 protein expression in the presence of LY294002
in comparison to control. 
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as beads around which DNA winds. Histone acetylation involves the addition of an 
acetyl group to histone protein by acetylase and de-acetylation involves the removal 
of an acetyl group by the deacetylase enzyme known as HDACS. Trichostatin A is a 
selective inhibitor of histone deacetylase and sodium butyrate, a normal dietary 
constituent found in butter, an inhibitor of proliferation, inducer of differentiation 
and non-selective inhibitor of histone deacetylase (Gillenwater et al, 2000). 
Trichostatin A and sodium butyrate either directly or indirectly prevent removal of 
acetyl groups from the core histone proteins by inhibiting histone deacetylase. 
Addition of an acetyl group to histones is associated with active transcription of a 
gene, while removal of an acetyl group is associated with the repression of 
transcription of certain genes (Markova et al, 2007). Addition of both Trichostatin A 
and sodium butyrate causes increased gene transcription by inhibiting HDAC and 
thus allowing increased binding of acetyl groups to histones either through direct or 
indirect pathways respectively.  
 
Eukaryotic chromatin is usually present in two distinct forms: heterochromatin, 
condensed and transcriptionally silent regions of the genome or euchromatin, the 
transcriptional permissive state and less condensed form (Markova et al, 2007). The 
cell environment in which genes are expressed can be either permissive or non-
permissive. In a non-permissive environment chromatin is usually present in the  
heterochromatin state and here the DNA region of interest within the chromatin is in 
a condensed and transcriptionally silent region. Thus the transcription factor is 
unable to access that region; this is due the action of the deacetylase enzyme 
removing acetyl group from histone and causing a subsequent repression of 
transcription of certain genes (Markova et al, 2007). In a permissive environment, 
chromatin is usually present in the euchromatin form, where the region 
corresponding to the selected gene in the DNA region of interest of the chromatin is 
in a transcriptional permissive state and less condensed form (Markova et al, 2007). 
Thus the transcription factor can access that region, due to the action of acetylase 
enzyme adding an acetyl group to the N-terminal of histone proteins, and 
transcription of certain genes can occur (Markova et al, 2007).  
 
The question that is been asked in this thesis is why do some subset of genes present 
in the cell get expressed and translated into protein, while others genes do not get 
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expressed.  Therefore, the aim of this section was to investigate whether chromatin 
structures in epidermal RTS3b cells are in a non-permissive environment and this 
causes lack of K13 protein expression. This was addressed by using Trichostatin A 
and sodium butyrate. Trichostatin A and sodium butyrate might increase the KRT13 
transcription, which might lead to increased K13 protein expression.   
 
4.4.19 K13 Protein Expression in Permissive and Non-permissive Epithelial Cell 
Lines  
 An initial experiment was performed to assess the relative abundance of K13 protein 
expression in A431 (positive control), HeLa (negative control), HaCaT (test), RTS3b 
(test) and NHEK (test) cells. HaCaT, RTS3b, and NHEK (Chapter 2 Table 2.5) are 
epidermal keratinocytes that express K13 protein (Figures 4.40 and 4.41). This was 
done in an attempt to see if the expression of K13 protein can be induced or 
increased by Trichostatin A or sodium butyrate in cell lines which show low or 
negligible K13 protein expression.  The result has shown that K13 expression was 
lowest in the RTS3b and HeLa cells, therefore subsequent experiments of the effect 
of Trichostatin A and sodium butyrate on K13 expression in RTS3b and HeLa cell 
lines was assessed. Although K13 protein is already expressed at basal line level in 
RST3b cells, the question that was addressed in this study was: can Trichostatin A 
and sodium butyrate increase K13 protein expression. The results have shown that 
Trichostatin A did not increase (P=0.283) K13 protein expression in comparison to 
control, while sodium butyrate significantly (P=0.0027) increased K13 protein 
expression compared to control (Figures 4.42 and 4.43). This suggests that in derived 
RTS3b cells, K13 protein expression might be diminished because of the chromatin 
structure in skin cells being in a condensed and transcriptionally silent region in the 
genome (heterochromatin), which can be overcome by non-specific histone 
deacetylase inhibitor sodium butyrate.  
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 Figure 4.40: K13 protein expression in various epithelial cell lines. The K13 protein 
is strongly expressed in A431 and HaCat cells , then in NHEK cells, while the K13 
expression is absent in both RTS3b and HeLa cell lines. The expression of K13 
protein expression was initially assessed in 80% confluent A431, HaCaT, RTS3b, 
HeLa and NHEK cells and lysed in Laemmli buffer before analysing on SDS PAGE 
gels. The gels were transferred onto nitrocellulose and probed for K13 expression 
using AE8 antibody as described in Chapter 2 section 2.17. This experiment was done 
once only. 
Figure 4.41: Quantification of band density derived from western blot data in 
Figure 4.40 using densitometry to quantify K13 protein expression in permissive 
and non-permissive epithelial cell lines. The expression of K13 protein in epithelial 
A431 (blue), HaCaT (green), RTS3b (purple), HeLa (pink) and NHEK (lilac) cells 
are shown. Each K13 band has been normalised to β-actin band density (loading 
control). A431 cell was used as positive control for western blot technique given 
that this cell line shows abundant K13 protein expression. Error bars are not present 
in this figure because n=1 experiment.  
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 Figure 4.42: Effect of Trichostatin A and sodium butyrate on K13 protein expression 
in skin derived RTS3b cell line. K13 protein expression appears to increased in the 
presence of TSA and Sodium butyrate compared to control. Cells were grown in the 
presence of 3μM Trichostatin A and 2mM sodium butyrate for 14 and 24 hours 
respectively and lysed in Laemmli buffer before analysing on SDS gels. The gels 
were transferred on nitrocellulose and probed for K13 expression using AE8 antibody 
as described in Chapter 2 section 2.17.  
Figure 4.43: Quantification of band density derived from western blot data in Figure 
4.42 using densitometry to quantify the effect of 3μM Trichostatin A and 2mM 
sodium butyrate on K13 protein expression in epidermal derived RTS3b cells. There 
was no difference in the K13 protein expression in presence of Trichostatin A in 
comparison to control (P=0.283), while there was a significant increase in K13 
protein expression (P=0.002) in presence of sodium butyrate in comparison to 
control in RTS3b cells (purple). Each K13 band has been normalised to β-actin band 
density (loading control). The results are expressed as the mean ± SD from three 
experiments. RTS3b cells were chosen because initially they showed the lowest K13 
protein expression (Figure 4.41). 
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4.4.20 The effect of Trichostatin A and Sodium butyrate on Post-transcriptional 
Regulation of K13 Expression in HeLa Cell Line.   
After assessing the abundance and relative expression of K13 protein in various cells 
(Figure 4.44 and 4.45), the results showed that K13 protein expression was negligible 
in HeLa cells, as previously reported (Waseem et al. 1998). For this reason HeLa 
cells served as a negative control for the Western blot. Trichostatin A and sodium 
butyrate should have increased the expression of K13 protein expression if K13 
expression was switched off by a heterochromatin state in a non-permissive 
environment such as HeLa cells. However, the result has shown that both 
Trichostatin A and Sodium butyrate did not increase (P=0.4 and 0.8) K13 protein 
expression in HeLa cells (Figure 4.44 and 4.45). The value shown in the control in 
Figure 4.45 does not correlate with K13 protein but rather reflects the sensitivity of 
the densitometry detection, which picks up even non-specific background faint bands 
(Figure 4.44). In summary, Trichostatin A and sodium butyrate did not increase K13 
protein expression in HeLa cells. 
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Figure 4.44: Effect of Trichostatin A and sodium butyrate on K13 protein expression 
in simple epithelial cervical carcinoma derived HeLa cells. Cells were grown in the 
presence of 3μM Trichostatin A and 2mM sodium butyrate for 14 and 24 hours 
respectively and lysed in Laemmli buffer before analysing on SDS gels. The gels 
were transferred on nitrocellulose and probed for K13 expression using AE8 antibody 
as described in Chapter 2 section 2.17. 
 
  186
0
2
4
6
8
10
12
Control  DMSO 3μM TSA Control 2mM SB
Treatment
B
an
d 
de
ns
ity
 (O
D
)
(P=0.800)(P=0.400)
B
an
d 
de
ns
ity
 (O
D
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.45: Quantification of band density derived from western blot data in Figure 
4.44 using densitometry to quantify the effect of 3μM Trichostatin A and 2mM 
sodium butyrate on K13 protein expression in simple epithelial cervical carcinoma 
derived HeLa cells. There was no significant difference in the K13 protein 
expression in presence of Trichostatin A and sodium butyrate in comparison to 
control (P=0.4 and P=0.8) in HeLa cells (pink). Each K13 band has been normalised 
to β-actin band density (loading control). The results are expressed as the mean ± SD 
from three experiments. HeLa cells were chosen because initially they showed the 
lowest K13 protein expression after RTS3b cells (Figure 4.41). 
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4.5 Discussion   
The K13 FL promoter and deletion constructs showed expression in both permissive 
(SCC25) and non-permissive (RTS3b, HeLa and HFF) cell lines. This may be due to 
the chromatin structure playing an important role in the differential control of gene 
expression in eukaryotes. This is exemplified when tissue-specific genes are 
transcribed following transfection into cells which do not express their endogenous 
chromosomal counterparts, and are also transcribed in-vitro as purified DNA when 
added to extracts from non-expressing cells  (Workman et al, 1990).  
 
The quantitative FACS data of K13 FL promoter expression were not significantly 
increased in oral SCC25 cells in comparison to non-permissive epithelial RTS3b, 
HeLa and non-epithelial HFF cell lines. At the protein level, K13 expression was 
greater in oral SCC25 cells in comparison to non-permissive epithelial RTS3b, HeLa 
and non-epithelial HFF cell lines. The K13 FL promoter and protein expression 
shows epithelial specificity, since its expression is negligible in HFF, which do not 
normally express keratins. This finding is also consistent with the literature (Blessing 
et al, 1989 and  Jiang et al, 1990) in which an enhancer in the upstream region of the 
bovine keratin 6 gene conferred  epithelial specific expression and a 300bp upstream 
sequence of  keratin 14 driven CAT reporter gene was shown to confer epithelial 
specificity.  
 
Although K13 protein is not normally expressed in the epidermis, K13 protein was 
expressed in cultured epidermal-derived RTS3b cells; this K13 expression has also 
been reported in earlier studies in which K13 protein is expressed in cultured 
epidermal cells (Kopan et al, 1987). Thus although K13 expression is  absent in the 
normal epidermis, its up-regulated in squamous cell carcinoma of the skin (Kopan et 
al, 1987). Furthermore, since the RTS3b cell line is transformed with HPV-16 and 
passaged many times, it could have acquired genetic instability and hence abnormal 
expression of keratins. This inherent flaw associated with the use of transformed 
cells is one of the disadvantages in using cell culture models and must be considered 
at the initial stage when choosing models. Also several factors have been reported to 
influence keratinocyte differentiation, namely the age of the epithelium donor from 
which the monolayer was derived, the serum, retinoic acid and calcium concentration 
in the growth medium (Gasparoni et al, 2004).  The serum in the media contains 
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retinoic acid, which has been shown to influence the expression of K13 expression in 
skin (Kopan et al, 1987). The medium used to culture or grow RTS3b cells was 
E4/F12 medium with RM+ supplement which contains a calcium concentration of 
1.5-1.8mM, as well as extra growth hormones, as opposed to other types of medium 
such as E4/F12 media alone without the RM+ supplement which contains 1.2-1.5mM 
calcium.  
 
The K13 truncated promoter fragments revealed that the K13 FL promoter 3018bp 
could drive GFP expression in all the epithelial cells but not in the HFF cells (non-
epithelial). Secondly a suppressor element that confers K13 promoter tissue specific 
expression in oral SCC25 cell lines resides in the K13 FL (between -3018bp to -
2540bp) promoter construct (Figure 4.46). The K13 FL promoter construct and 
deletion fragments (R1-R6) promoter appear to show increased expression in HeLa 
cell line in comparison with SCC25 cells that endogenously expresses K13. Many 
factors could shed light in these findings, such as: 1) the endogenous K13 gene might 
be permanently shut off in HeLa cells by DNA methylation at the time the Hela cell 
type embarks on simple epithelial as opposed to a stratified, differentiation pathway 
(Jiang et al, 1990). This however, is unlikely, as one report (Waseem et al, 1998) 
suggests that human K13 gene, unlike its mouse counterpart, is not regulated by 
DNA methylation. Alternatively, 2) the 3018bp 5'-upstream K13 promoter sequence 
may contain all the necessary regulatory motifs but lack specific structural 
constraints imposed by the local chromosomal structure (Wu et al, 1993), which 
normally switches off K13 expression in the epidermis and simple epithelial tissues. 
Also, 3) it could be that the 3018bp K13 upstream promoter region might contain all 
the necessary information for conferring epithelial specificity but not all the 
necessary information for oral tissue specific expression (Wu et al, 1993). Lastly, 
HeLa was derived from an adenocarcnoma of the cervix in 1952 and was the first 
human epithelial cancer cell line established for long-term culture manipulation and 
as result it has become genetically unstable. Karyotyping has revealed 20 abnormal 
chromosomes in HeLa cells including chromosome 17 where K13 is expressed 
(Macville et al, 1999), and this might cause increased K13 expression.  
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Furthermore, it is worth mentioning that although the diagram shown in Figure 4.46 
only shows regulatory elements which seem important for the expression of K13 FL 
promoter construct in oral SCC25 cells versus epidermal RTS3b cells, there could 
Figure 4.46: Diagram showing regions important for the regulation of K13 promoter 
expression in oral SCC25 and skin RTS3b cell lines. Diagram A shows a positive 
regulatory element (green) which binds fragment 2540bp when 1000bp has been 
removed from the full length K13-3018bp promoter fragment in permissive oral 
mucosa SCC25 cell line, which might be causing increased K13 promoter driven GFP 
expression in oral SCC25 cell line.  Diagram B shows a negative regulatory element 
(red) which binds fragment 2540bp when 500bp has been removed from the FL K13-
3018bp promoter fragment in epidermal derived RTS3b cell line, which might be 
causing decreased K13 promoter driven GFP expression in RTS3b cells. This 
indicates that the K13 promoter driven GFP expression in non-permissive epidermal 
RTS3b cells might be regulated by suppressor elements.  
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equally be other important regulatory elements which could have been tested if a 
larger K13 upstream sequence had been analysed.  
 
Protein kinase C is known to be essential for the expression of differentiation and 
proliferation related genes in keratinocytes (Yuspa et al, 1991) and tumour-
promoting TPA causes the release of  in-vitro Ca2+ activated phospholipid-dependent 
protein kinase C (Castagna  et al, 1982). This leads to activation of PKC by 
diacylgycerol and TPA activates PKC by mimicking the action of diacylgycerol, 
which is a natural ligand and activator of PKC (Castagna  et al, 1982). TPA increases 
morphological differentiation, a change that is accompanied by an increase in the 
expression of keratinocyte-specific differentiation markers (Efimova et al, 1998). 
Given that K13 is a suprabasal keratinocyte-specific differentiation marker, it was 
thought that TPA might increase the activity of K13 protein expression. However, 
the results have shown that K13 expression is not induced through the protein kinase 
C pathway, since TPA did not increase the expression of K13 promoter construct or 
K13 protein. In addition, TPA had no effect on the K13-1953bp deletion fragment. 
The K13-1953bp deletion fragment was included in the TPA experiment for the 
following reason; TPA had no effect on FL K13-3018bp promoter and it could be 
argued that the suppressor elements in the K13-3018bp FL promoter construct could 
be opposing TPA overall effects on K13 expression. This might be overcome by 
directly adding TPA to the K13-1953bp deletion fragment of the K13 FL promoter; 
also the K13-1953bp deletion promoter fragment contains a cluster of AP-1 binding 
sites (Table 4.1). Furthermore, protein kinase C has been reported to be implicated in 
the regulation of several transcription factors such as AP-1 and NF-Κb (Richard et al, 
1999). Given that AP-1 and NF-Κb have been reported to regulate the expression of 
K5, K6, K14 and K17 (Ma et al, 1997) and the K13-1953bp deletion fragment 
contains a cluster of AP-1 binding sites it would seem logical to investigate the effect 
of TPA on this fragment. 
 
The results obtained for the effect of MEK 1/2 and PI3K/Akt pathway inhibition on 
K13 expression are similar to the results obtained previously (Dackour et al, 2005). 
In the Dackour study, an oesophageal carcinoma derived cell line was used, while in 
this study an oral SCC25 cell line was used, so the anatomical location under which 
K13 is expressed and the functional manifestations as a result of K13 aberrant 
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expression in oesophageal and oral cancer may differ. Thus, the pathways through 
which K13 aberrant expression is induced might or might not be the same in both 
oesophageal and oral cancer, therefore to address the importance of these pathways, 
known inhibitors affecting K13 expression were used. 
 
The finding that the inhibition of the MEK 1/2 pathway not increasing K13 protein 
expression in oral SCC25 cells is parallel to others reports for epidermal specific K1 
differentiation marker in mouse skin (Dackour et al, 2005). Also, mechanical 
stretching of human epidermal keratinocyte cell layers for 24 hours was concomitant 
with suppression of K10 which was further reduced in expression by U0126 (MEK 
1/2 inhibitor). This indicates that keratinocyte mechanical stretching (which occurs at 
times during pregnancy and wound healing) suppresses keratinocyte differentiation, 
as evident by further reduction in K10 expression (Yano et al, 2004). These results 
imply that although the MEK 1/2 pathways regulate the expression of differentiation 
markers of human oral mucosa (K13) and skin (K1) in the same manner, it may 
affect the expression of K1 compared to its partner K10 differently (which could be 
explained by the fact that both studies utilized different species; mouse and human). 
LY249002 (PI3K/Akt pathway inhibitor) caused a significant decrease in the 
expression of the K13 promoter construct and protein expression in oral SCC25 cells, 
which implies the importance of the PI3K/Akt pathway in altered differentiation of 
oral mucosa. Furthermore, recent reports have shown that the inhibition of the 
PI3K/Akt pathway and transducing cells with the dominant negative form of PI3K 
increased the expression of K1/ K10 in normal human skin keratinocytes (Sayama et 
al, 2002). Thus, the same pathways which regulate the expression of suprabasal 
keratin genes might have different effects on the induction of keratin expression. 
 
Sodium butyrate caused an increase in K13 protein expression in skin derived RTS3b 
cells, which suggests that in non-permissive skin derived RTS3b cells, K13 protein 
expression might be decreased in comparison to permissive oral mucosa SCC25 
cells, because the chromatin structure in skin is in a heterochromatin state. These 
experiments were repeated on three separate occasions and on three different lysate 
samples. Sodium butyrate is a non-selective histone deacetylase inhibitor, thus it is 
arguable that it might be causing increased K13 gene transcription and subsequently 
protein expression through other unknown indirect pathways rather then influencing 
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the acetylation state of nuclear core histone gene expression. Nevertheless, the 
importance of sodium butyrate in increased K13 gene transcription, and hence K13 
protein expression, is a step towards understanding why K13 protein is not expressed 
in normal epidermis.  
 
In conclusion, this study has shown that the K13 promoter is expressed in an 
epithelial specific manner, and a suppressor element which confers this epithelial 
specific expression resides in the full length K13-3018bp promoter. K13 protein 
expression is induced by sodium butyrate which might or might not be through an 
alteration of chromatin structure in non-permissive skin derived RTS3b cells. The 
MEK 1/ 2 pathway seems not to be necessary for the expression of K13, but the 
PI3K pathway is important for expression of K13 in oral mucosa.  
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Chapter 5 
The Correlation of K15 
and K13 Expression 
with Oral Cell Line 
Maturation  
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5.1 Introduction 
Differentiation is process whereby cells undergo a change to become a specialized 
cell type within a tissue (Alberts et al, 1994). In the previous chapter, differentiation 
related K13 expression in both oral mucosa and skin was discussed. This chapter will 
focus on the maturation related K15 and K13 expression pattern in oral cell lines. In 
both maturation (Figure 5.2) and differentiation (Figure 5.1), keratin expression 
varies in different epithelia of the body and also within specific regions of the body 
such as the oral mucosa which shows regional variation (Clausen et al, 1986). K15 
and K13, represent basal and suprabasal markers of the oral mucosa and exemplify 
regional maturation in this tissue.  
 
Barrandon and Green (1985) showed that cultured keratinocytes isolated from 
epidermis form different types of colonies according to cell size. For example, cells 
of smaller size range (in a range of 11-20µm), produced small rapidly growing 
colonies in culture, while cells of diameter larger than 20µm did not divide and 
became committed to terminal differentiation. This indicates that cell size could be 
used to determine the clonal ability of human keratinocytes. When keratinocytes 
form colonies in culture, three different types can be distinguished. The small 
keratinocytes give rise to cells which have a high proliferative rate, termed 
holoclones, which are classified as the origin. Larger keratinocytes give rise to two 
other types of colonies: termed meroclones and paraclones. Meroclones contain a 
mixture of both growing and terminally differentiating cells, while paraclones give 
rise to cells with limited growth potential resulting in large and sparse colonies 
(Barrandon and Green, 1987). These three types of colonies are thought to be derived 
from stem cells, early and late amplifying cells (Mackenzie, 2006). 
 
When cells are plated in-vitro, an earlier degree of maturation is associated with a 
different morphology. The unidirectional growth of the three types of colony, with 
holoclones being the founding colony type, followed by the sequential formation of 
meroclones and paraclones, shows that a paraclone colony cannot become a 
holoclone. Also when keratinocytes are passaged and plated in-vitro there is a 
regeneration of clonal heterogeneity in keratinocytes (Mackenzie, 2005). Suggesting 
that the generation of stem and amplifying cells is an inherent characteristic of 
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keratinocytes whether they are plated in-vitro or whether the keratinocytes are 
present within the in-vivo natural epithelium (Mackenzie, 2005).   
 
In the previous chapter, the data presented suggested that subpopulations of oral 
SCC25 and skin derived RTS3b cells either express or not express K13; therefore, 
there is heterogeneity, and If this is the case there maybe be molecules expressed by 
colonies, that identify holoclones or paraclones. 
 
Maturation in the oral mucosa epithelia involves sequential synthesis of specific 
basal and suprabasal keratin genes. This chapter aims to address whether keratin 
expression can be correlated with morphological heterogeneity typically found in 
oral malignant epithelial cell lines, by the use of K15, a marker of basal and K13, a 
marker of suprabasal buccal epithelial maturation or differentiation. Depending on 
the whether the result shows a positive correlation between increased K15 expression 
in holoclones in comparison to paraclones and increased K13 expression in paraclone 
in comparison to holoclones. It is anticipated that potential novel transcription factors 
associated with the maturation specific K15 and K13 expression in holoclones and 
paraclone cell population might be identified.  
 
The K15 and K13 maturation specific expression will be studied by the use of stable 
transfection, FACS, colony forming assay and immunocytochemistry. There are 
several disadvantages of studying tumours ex-vivo and this includes the availability 
of tissue biopsies, constraint with conserving the tissue, heterogeneity that exists 
amongst tissues and the difficulty in isolating cellular components such as RNA from 
epithelial cells. For these reasons, the use of cell lines as an in-vitro model of the oral 
epithelium as opposed to using oral mucosa biopsies was adopted. 
  196
A                                  B                            C 
 
  
 
 
 
 
 
K13
K15
Paraclone
Meroclone
Holoclone
K1/K10
K4/K13
K6/K16
K5/K14
K15
K19
M
at
ur
at
io
n
M
at
ur
at
io
n
 
 
 
 
 
 
 
 
 
Figure 5.2: Schematic representation of maturation specific keratin expression in 
normal oral epithelium (on the left side of the diagram) as exemplified by K15, basal 
marker and K13, marker of buccal epithelial differentiation. While, on the right side 
of the diagram, the three distinct cell type populations known as holoclone, 
meroclone and paraclone are shown and in relation to where these different three 
subpopulation of cells are found relative to the in-vivo oral mucosa epithelia.  
Figure 5.1: Differentiation of specific keratin expression in (A) buccal cells, which 
expresses K13/K4 in the suprabasal layer, while in the basal layer K5, K14 and K19 
are expressed. In diagram (B) palate epithelia is shown, which expresses K1/K10 in 
suprabasal layer as well as K6/K16  and K5, K14 in the basal layer, while in diagram
(C) a epidermal epithelia is shown, which expresses K1/K10  in the suprabasal layer 
and K5, K14 in the basal layer (Dale et al, 1990). 
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5.2 Aims  
1) Stably transfect K13 and K15 promoter linked-GFP constructs into vulval 
epithelia carcinoma (A431) and oral mucosa (H357 and SCC25) derived cells lines, 
to see the level of K15 and K13 promoter linked-GFP expression.  
 
2) To use the intensity score semi-quantitative method to determine whether 
K15 and K13 promoter linked-GFP expression can be correlated with a 
heterogeneous population within oral mucosal SCC25 cells, using FACS. 
 
3) To use immunocytochemistry to investigate if endogenous K15 and K13 
protein expression can be correlated with oral mucosa SCC25 cell differentiation, 
using A431 cell as positive control. 
 
4) Use a colony forming assay to test if the pre-selected and FACS sorted oral 
mucosa SCC25 cells expressing K15 and K13 promoter linked-GFP positive cells 
can be correlated with the number of colonies formed. 
 
5.2.1 Hypothesis 
It is hypothesized that K15 and K13 expression is correlated with heterogeneous cell 
population present within the differentiating oral epithelial cell line. 
 
5.2.2 Materials and Methods 
 For a detailed protocol of how the stable transfection, immunocytochemistry, colony 
forming assay and FACS was carried refer to Chapter 2 sections 2.10.3, 2.18 to 
2.18.3. 
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5.3 Results 
5.3.1 RNA extracts of K15 and K13 in Holoclones and Paraclones using 
Affymetrix HG-U133A Arrays.  
Pilot experiments with RNA extracts of K15 and K13 from holoclones and 
paraclones using Affymetrix HG-U133A gene expression arrays in various head and 
neck tumour derived cell lines formed the preliminary data (Figure 5.3 and 5.4) 
which provided the hypothesis as to whether K13 and K15 promoter constructs 
expression can be correlated with oral mucosa cell line maturation. This data was 
kindly provided by Professor I. C. Mackenzie. Given that K15 is expressed in the 
basal layer and is a marker of proliferative potential and K13 is expressed in the 
suprabasal layer and is a marker of differentiation, it is thought that the expression of 
K15 should be high in holoclone and K13 high in paraclone colonies.  
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Figure 5.3: K15 RNA expression level in paraclones and holoclones of C1, CA1, 
CAL27, SCC71 and UK1 oral mucosal tumour derived cell lines. 
 
 
K15 RNA expression was high in holoclone colonies formed by three cell lines (C1, 
CA1, and UK1). K13 RNA expression was low in paraclones and high in holoclone 
colonies formed by three cell lines (C1, CA1, CAL27 and SCC71). Although the 
increased K15 RNA expression in holoclone colonies is consistent with the in-vivo 
environment of the oral epithelium, but the increase in K13 expression in holoclone 
colonies was inconsistent with the role of K13 as a marker of differentiation in the 
oral mucosa. However, this experiment was only done once on pooled holoclone or 
  199
paraclone colonies, so the data may not be a true biological reflection of K13 
expression, hence the reason why the work went further and few different methods 
was used to confirm this preliminary findings.  
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Figure 5.4: K13 RNA expression level in paraclone and holoclone of C1, CA1, 
CAL27, SCC71 and UK1 oral mucosal tumour derived cell lines. 
 
5.3.2 K15 and K13 Promoter driven GFP Expression in Oral (SCC25, H357) 
and (A431) Vulval Carcinoma Cell Lines. 
K15 and K13 promoter linked GFP reporter gene construct expression was initially 
assessed by stable transfection into oral (H357, SCC25) and vulval (A431) cell lines. 
A431 cells were used as a positive control, since these cells are known to express 
both K15 and K13 abundantly. However, the transfection efficiency of K15 and K13 
promoter construct in H357 and A431 was very low (Figure 5.5 and 5.6). For this 
reason, all subsequent K15 and K13 promoter linked GFP reporter gene construct 
expression experiments were carried out in the oral SCC25 cell line, as this cell line 
shows high K15 and K13 promoter expression (Figure 5.7). 
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Figure 5.5: EGFP expression in A431 vulval carcinoma cell line stably transfected
with CMV (A), K13 (B), and K15 (C) promoters in pEGFP-N3B vector. The cell 
population was photographed using a fluorescence microscope and the picture 
magnification is 100x. GFP expression was detected with blue light. Scale bar: 50µM, 
same for Figure 5.5 and 5.6). The EGFP expression of K13 (B) and K15 (B) promoter 
constructs are negligible in A431 cells.   
Figure 5.6: EGFP expression in H357 oral mucosa cell line stably transfected with 
CMV (A), K13 (B), and K15 (C) promoters in pEGFP-N3B vector. The cell 
population was photographed using a fluorescence microscope and the picture 
magnification is 100x. GFP expression was detected with blue light. The EGFP 
expression of K13 (B) and K15 (B) promoter constructs are negligible in H357 cells.  
Figure 5.7: EGFP expression in SCC25 oral mucosa cell line stably transfected with 
CMV (A), K13 (B), and K15 (C) promoters in pEGFP-N3B vector. The cell 
population was photographed using a fluorescence microscope and the picture 
magnification is 100x. GFP expression was detected with blue light. The EGFP 
expression of K13 (B) and K15 (B) promoter constructs are very high in SCC25 cells. 
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Figure 5.8: The expression of K15 and K13 promoter linked GFP construct 
expression in oral mucosa SCC25 cell line. This was done to determine the initial 
expression of both K15 and K13 promoter constructs in oral mucosa cell line 
(SCC25).  
Figure 5.9: Representative plots of typical FACS data obtained for K13 promoter 
linked GFP construct expression in oral mucosa SCC25 cells after selecting for 
several weeks. Image A shows a scatter of the total cell population gated to exclude 
cell debris,. Image B shows scatter plot based on image A, but divided into four (no 
expression, low, medium and high) distinct GFP expressing cell populations using 
FACS. Image C shows a histogram of the four distinct GFP expressing cell 
populations and image D shows the percentage of cells within each population 
expressing K13 promoter linked GFP construct and median fluorescence intensity of 
each of the four distinct GFP expressing cell populations. The colours used for the 
different four cell population are the same in image B and image D, black (P2) 
coloured cell population are those population which show no GFP expression, while 
the blue (P3) coloured cell population are those population which show low GFP 
expression. The green (P4) coloured cell population are those population which show 
medium GFP expression and the purple (P5) coloured cell population are those 
population which show high GFP expression. The red (P1) coloured cell population 
shown in image A, B, C and D are total gated cell population.  
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5.3.3 Stably Transfecting and Selecting the K15 and K13 Promoter Construct in 
Oral SCC25 Cell Lines. 
After initially establishing the effectiveness of GFP expression of the K15 or K13 
promoter constructs using FACS (Figure 5.8), the K15 and K13 promoter constructs 
were then stably transfected in oral SCC25 cells and selected for about a month. The 
oral SCC25 cells were then sorted according the four distinct population (Figure 
5.10).  In Figure 5.10, the FACS data of the EGFP expression of K15, K13 and CMV 
promoter in pEGFP-N3B vector are shown, in the negligible GFP expressing cell 
population, it can be seen that all three promoter constructs show the same level of 
GFP expression. This is also true for the low GFP expressing cell population, which 
shows low GFP expression (Figure 5.10). However, in the cell population, which 
shows medium and high GFP expression for K15, K13 and CMV promoter in 
pEGFP-N3B vector, the results are similar, in that the K15 promoter shows the 
lowest expression followed by CMV promoter and then the K13 promoter, which 
shows the greatest GFP expression. These results were unexpected, given the fact 
that CMV promoter was used as positive control and should ideally show the highest 
GFP expression. The aim of this part of the study was to use the CMV promoter as a 
positive control for stable transfection, it might not be of value, it should be noted 
that in chapter 4, the expression of CMV promoter compared to K13 promoter was 
10-30 fold higher. This might be explained by the fact that transient transfection was 
used in the experiments carried out in the previous chapter, while in this chapter 
stable transfection was used (Figure 5.10). It possible that the transient versus stable 
transfection of plasmid constructs can cause difference in the expression pattern of 
constitutive (K13) expressed gene versus the stronger viral (CMV) exogenous 
expressed gene. Furthermore, in Figure 5.11, phase contrast and GFP fluorescence 
oral SCC25 cells are shown, these pictures were taken after selecting and FACS 
sorting the oral SCC25 cells for about a month to confirm that the sorted K15 and 
K13 promoter construct stably transfected into SCC25 cells respectively contained 
negative and high GFP expressing cell population. Figure 5.11 shows picture of 
several paraclone and holoclone colonies formed by negative (Figure 5.11 E1 to H1) 
and high (Figure 5.11 A1 to D1) GFP expressing SCC25 sorted cells. The negative 
and high GFP expressing oral SCC25 cells contain K15 promoter linked GFP 
construct (Figure 5.11). Although in Figure 5.11 F1 and G1, which are the GFP 
negative SCC25 sorted cells that contain the K15 promoter linked GFP construct, 
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they do however show K15 GFP positive cells. One possible explanation for this 
dubious result could be when the FACS machine was used to sort cells, there could 
have been contamination of some high expressing GFP positive cells sorted into GFP 
negative oral SCC25 cells.  
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Figure 5.10: EGFP expression in oral SCC25 cells containing K15, K13 and CMV 
promoter in pEGFP-N3B vector.  After stably transfecting the K15, K13 or CMV 
promoter driven GFP in pEGFP-N3B vector expression in oral mucosa SCC25 cells 
after have been sorted into four distinct cell population, using CMV promoter as a 
positive control for the transfection efficiency.   
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5.3.4: The Correlation of K15 and K13 Promoter driven GFP High and 
Negative Expressing Oral SCC25 Cells with the Colony Forming efficiency of 
Oral SCC25 cell line 
The colony forming ability of both K15 and K13 promoter construct in negative and 
high GFP expressing oral SCC25 cells was assessed, and the results showed that 
there was is no significant difference between the expression of K15 and K13 
promoter construct in negative and high GFP expressing oral SCC25 cells. However, 
 A                                                  B                                       C                                           D
E F G H
A1                                               B1                                       C1                                           D1
E 1                                               F 1                                     G 1                                          H1
Figure 5.11: Brightfield and fluorescence pictures of holoclone and paraclone 
colonies formed by oral SCC25 cells stably transfected with K15 promoter in pEGFP-
N3B vector. The images show the distinct populations of plated cells after G418
(1mg/ml) selection for a month, and FACS sorted into GFP negative and GFP high 
expressing cell populations. Images A to D are brightfield view of holoclone colonies 
formed by high GFP expressing SCC25 cells, while images A1 to D1 are the 
corresponding fluorescence images of brightfield view images (A to D). Images E to 
H are brightfield view of paraclone colonies formed by negative GFP expressing 
SCC25 cells, while images E1 to H1 are the corresponding fluorescence images of 
brightfield view images (E to H). An inverted Fluorescence microscope was used to 
take above images and the image magnifications are 100x the original size, the scale 
bar for each image is 50µM. 
  205
the K15 negative and high expressing cells had more colonies compared to K13 
negative and high GFP  expressing SCC25 cells (Figure 5.13). This indicates that 
K15 might be used as a potential marker of cell proliferation (Porter, et al. 2000), but 
the fact that there was no significant difference between K15 and K13 negative and 
high GFP expressing SCC25 cells shows that K15 and K13 promoters expression 
cannot be correlated with oral SCC25 cell maturation. In addition, Figure 5.12, 
shows a representative image of the colony forming assay, and each well was 
analysed for the number of SCC25 cells colonies formed which were respectively 
transfected with the K15 and K13 promoter constructs. The black lines (Figure 5.12) 
were created using Adobe Photoshop Image Software to facilitate counting the 
number of SCC25 colonies formed. 
 
A               B              C
D               E              F   
 
 
Figure 5.12: A representative image of the colony forming assay used for negative 
GFP expressing oral SCC25 cells, containing the K15 and K13 promoter construct, 
plated at clonal density and fixed with Rodamine B. Each experiment was 
performed in triplicate. Images A to C show colonies formed by selected SCC25 
GFP negative cells containing K15 promoter construct,  plated at colony density 
and selected with G418 (1mg/ml) for 2 weeks. While, images D to F show colonies 
formed by selected SCC25 GFP negative cells containing K13 promoter construct, 
plated at colony density and selected with G418 (1mg/ml) for 2 weeks. The 
numbers of colonies formed by K15 and K13 promoter linked GFP expressing 
SCC25 cells were analysed using image software and black lines in each well were 
used to facilitate counting colonies formed. 
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5.3.5: K15 and K13 Promoter Expression in Holoclone and Paraclone Cell 
populations formed by Oral Mucosa SCC25 Cells using the Promoter Intensity 
Scoring Method. 
K15 and K13 promoter linked GFP reporter gene construct expression was initially 
assessed to detect whether promoter expression could be correlated with formation 
the of holoclone and paraclone colonies by oral SCC25 cells. The intensity of K15 
and K13 promoter expression in holoclones and paraclones was assessed by 
observing the GFP intensity in each type of colony formed and allocating a number 
ranging from zero for negligible expression to three for strong expression (Table 5.1 
and Figure 5.18).  Based on this scoring, the results showed that the K15 promoter 
expression was twice as high in holoclone colonies as paraclone, while the K13 
promoter expression was 4.5 times higher in paraclone colonies than holoclones 
(Figure 5.18). In addition, although these results seem interesting and blind scoring 
was used, it is however important to note that this type of GFP intensity 
measurement used is subjective and open to bias. However, FACS analysis was also 
utilized to confirm the data, given that this technique is quantitative and an accepted 
technique used for measuring GFP expression (Figure 5.20). In addition, holoclones 
in this experiment were defined morphologically as compact round colonies, while 
Figure 5.13: Number of colonies formed by negative and high expressing K15 and 
K13 promoter driven GFP expression in oral SCC25 cells. Results are expressed as 
the mean ± SD from three experiments and each experiment was done in triplicate.
There is no significant difference between negative and high GFP expressing SCC25 
cells containing K15 promoter construct (P=0.575) or between colonies expressing 
GFP negative or GFP high SCC25 cells containing K13 promoter construct 
(P=0.980). 
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paraclones were defined as colonies, which form loose irregular morphologies. 
However, it is arguable as to whether there is any difference in holoclone versus 
paraclone colony sizes and shape of images generated at 100x magnification in 
Figure 5.14 to 5.17. In retrospect, this might have been resolved by using a higher 
objective lens. In the images generated in Figure 5.14 to 5.17 the difference between 
low and background (no GFP expression) is undetectable at this magnification. This 
was why an initial FACS analysis was carried out to 1) sort the cells into four 
populations and 2) quantitate the GFP expression in the four populations (Figure 5.10 
and 5.20). The results in Figure 5.10 clearly show a difference, although not 
significant, in negative and low GFP expressing SCC25 cell population. In summary, 
although the data generated with the GFP intensity scoring approach (Figure 5.18) as 
it stands does not appear convincing enough, it is however, a novel approach to 
quantify K15 and K13 promoter linked GFP expression in holoclone and paraclone 
colonies. The GFP intensity scoring approach could also benefit from stringent 
selection criteria for defining and choosing negative, low, medium and high GFP 
expressing SCC25 cells forming holoclone and paraclone colonies and this can be 
implement in the future experiments. 
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Figure 5.14: Brightfield and fluorescence images of holoclone colonies formed 
by oral SCC25 cells stably transfected with K15 promoter in pEGFP-N3B vector. 
The holoclone colonies formed by SCC25 cells were correlated with the intensity 
of K15 promoter construct.  Image A and A1 show phase contrast (PC) and 
corresponding dark field (DF) view of holoclone colony showing negligible K15 
GFP expression. Image B and B1 show phase contrast (PC) and corresponding 
dark field (DF) view of h loclone colony showing low K15 GFP expression. 
Image C and C1 show phase contrast (PC) and corresponding dark field (DF) 
view of holoclone colony showing medium K15 GFP expression. Image D and 
D1 show phase contrast (PC) and dark field (DF) view of holoclone colony 
showing high K15 GFP expression. Pictures were photographed using a 
fluorescence microscope and the image magnifications are 100x the original size, 
the scale bar on each image is 50µM. 
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Figure 5.15: Brightfield and fluorescence images of paraclone colonies formed 
by oral SCC25 cells stably transfected with K15 promoter in pEGFP-N3B vector. 
The paraclone colonies formed by SCC25 cells were correlated with the intensity 
of K15 promoter construct.  Image A and A1 show phase contrast (PC) and 
corresponding dark field (DF) view of paraclone colony showing negligible K15 
GFP expression. Image B and B1 show phase contrast (PC) and corresponding 
dark field (DF) view of paraclone colony showing low K15 GFP expression. 
Image C and C1 show phase contrast (PC) and corresponding dark field (DF) 
view of paraclone colony showing medium K15 GFP expression. Image D and 
D1 show phase contrast (PC) and dark field (DF) view of paraclone colony 
showing high K15 GFP expression. Pictures were photographed using a 
fluorescence microscope and the image magnifications are 100x the original size, 
the scale bar on each image is 50µM. 
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Figure 5.16: Brightfield and fluorescence images of holoclone colonies formed 
by oral SCC25 cells stably transfected with K13 promoter in pEGFP-N3B vector. 
The holoclone colonies formed by SCC25 cells were correlated with the intensity 
of K13 promoter construct.  Image A and A1 show phase contrast (PC) and 
corresponding dark field (DF) view of holoclone colony showing negligible K13 
GFP expression. Image B and B1 show phase contrast (PC) and corresponding 
dark field (DF) view of holoclone colony showing low K13 GFP expression. 
Image C and C1 show phase contrast (PC) and corresponding dark field (DF) 
view of holoclone colony showing medium K13 GFP expression. Image D and 
D1 show phase contrast (PC) and dark field (DF) view of holoclone colony 
showing high K13 GFP expression. Pictures were photographed using a 
fluorescence microscope and the image magnifications are 100x the original size, 
the scale bar on each image is 50µM. 
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Figure 5.17: Brightfield and fluorescence images of paraclone colonies formed 
by oral SCC25 cells stably transfected with K13 promoter in pEGFP-N3B vector. 
The paraclone colonies formed by SCC25 cells were correlated with the intensity 
of K13 promoter construct.  Image A and A1 show phase contrast (PC) and 
corresponding dark field (DF) view of paraclone colony showing negligible K13 
GFP expression. Image B and B1 show phase contrast (PC) and corresponding 
dark field (DF) view of paraclone colony showing low K13 GFP expression. 
Image C and C1 show phase contrast (PC) and corresponding dark field (DF) 
view of paraclone colony showing medium K13 GFP expression. Image D and 
D1 show phase contrast (PC) and dark field (DF) view of paraclone colony 
showing high K13 GFP expression. Pictures were photographed using a 
fluorescence microscope and the image magnifications are 100x the original size, 
the scale bar on each image is 50µM. 
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Table 5.1: The name of different categories of K15 or K13 promoter linked GFP 
expression in SCC25 cell line and the score allocated to the different categories. 
Name of different categories Scoring number  
No expression of K15 or K13 promoter 
linked GFP expression in SCC25 cell 
line 
0 
Weak expression of K15 or K13 
promoter linked GFP expression in 
SCC25 cell line 
1 
Medium expression of K15 or K13 
promoter linked GFP expression in 
SCC25 cell line 
2 
Strong expression of K15 or K13 
promoter linked GFP expression in 
SCC25 cell line 
3 
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Figure 5.18: Pie chart showing the correlation of K15 and K13 promoter linked GFP 
plasmid intensity with the holoclone and paraclone formed by oral SCC25 cells plated 
at clonal density. The numbers in pie chart are measure of the intensity of GFP 
expression driven by K15 or K13 promoter in holoclone or paraclone colonies of 
SCC25 cells. The values in the pie chart are based on scoring number in table 5.1 
allocated to GFP intensity of K15 and K13 promoter. SCC25 cells were selected for 
several weeks with 0.5-1mg of G418 antibiotic. 
  213
5.3.6: K15 and K13 Promoter Driven GFP Expression in Holoclone and 
Paraclone Cell populations formed by Oral Mucosa SCC25 Cells using FACS. 
K15 or K13 promoter driven GFP expression in holoclone and paraclone colony 
formed by oral SCC25 cells (Figure 5.20) was determined using FACS in order to 
confirm the promoter intensity scoring results (Figure 5.18). However, there was 
inconsistency in the results obtained for both the promoter intensity scoring and 
FACS technique. The FACS results has shown that K15 or K13 promoter linked 
GFP expression in holoclone and paraclone colonies formed by SCC25 cells were 
very similar (Figure 5.20). This indicates that there is no correlation between K15 or 
K13 promoter driven GFP expression and SCC25 cell line maturation as marked by 
similar K15 or K13 promoter linked GFP expression in holoclone and paraclone 
colonies (Figure 5.20). One advantage of using FACS to quantify keratin gene 
expression as opposed to K15 and K13 promoter intensity scoring, is a quantitative 
and accurate approach, while scoring promoter intensity is more subjective. 
However, it could also be that stably transfected K15 or K13 promoter linked GFP 
gene reporters in holoclones and paraclones formed by SCC25 cells may not be a 
suitable approach to address the aims.  
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Figure 5.19: Phase contrast images of SCC25 cells stably transfected with K15 (A and 
A1) and K13 (B and B1) promoter constructs and plated at clonal density such that 
when holoclone and paraclone colonies formed on cover slips, they were subsequently 
scraped off such that each of the four cover-slips either contained holoclones (A or B) 
or paraclones (A1 or B1). The relative K15 or K13 promoter linked GFP expression in 
holoclone and paraclone colonies formed by SCC25 cells was measured using FACS. 
10x objective was used for taking the above pictures. Scale bar: 50µM. 
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Figure 5.20: FACS plot data for K15 or K13 promoter driven GFP construct 
expression in holoclone and paraclone colonies formed by oral SCC25 cells. There is 
no significant (P=0.595 and 0.885) difference between K15 or K13 promoter linked 
GFP expression in holoclone and paraclone colonies formed by oral SCC25 cell. The 
results are expressed as the mean ± SD from three experiments. 
  215
5.3.7: The Correlation of K15 and K13 Protein Expression with Differentiation 
in Oral Mucosa derived SCC25  and A431 Vulval Carcinoma Cell Lines 
K15 protein expression has been investigated using monoclonal primary antibodies 
(Lyle et al, 1998) in Western blot and Immunohistochemistry assay. Using clone 
C8/144B and LHK15 monoclonal antibodies to detect K15 protein expression in 
holoclones and paraclones formed by A431 (positive control) and SCC25 cells, it 
was shown that both antibodies did not stain for K15 protein. In addition, there was 
no difference between the control (primary antibody omitted) and C8/144B, LHK15 
stained K15 expression in A431 and SCC25 cells (Figure 5.21 and 5.22).  K15 
protein expression using clone C8/144B antibody has been investigated (Lyle et al, 
1998) using in western blot and immunocytochemistry.  Lyle et al, 1998 were unable 
to detect K15 protein by Western blot, but it was detected via 
Immunohistochemistry. Western blot results in denaturing of the protein such that 
the clone C8/144B antibody cannot detect the K15 protein in the denatured form, but 
can detect it when immunohistochemistry is used, as the protein is in its native form 
and the epitope for K15 antigen is exposed. Both  Waseem et al, 1999 and Porter et 
al, 2000, used the LHK15 antibody to try to detect K15 protein via Western blots or 
immunohistochemistry on frozen section, and have successfully detected a 54kDa 
band corresponding to K15 protein in western blots. No other study has been 
reported so far using clone C8/144B and LHK15 monoclonal antibodies to detect 
K15 protein expression by immunocytochemistry, which prevents comparison of this 
study with other studies.  
 
 K13 protein immunostaining in holoclone and paraclone colonies formed by oral 
SCC25 cells using IC7 primary monoclonal antibody has shown that K13 protein 
staining is much stronger in paraclone (Figure 5.23B) than in holoclone and primary 
omitted control colonies (Figure 5.23A, 5.22C). The A431 cell line is known to have 
abundant K13 protein expression (Waseem et al, 1998) and results of K13 protein 
immunostaining using IC7 has shown that in the founding holoclone colony 
differentiating into a paraclone colony, the staining is stronger in paraclone than in 
the holoclone (Figure 5.24A). While in Figure 5.24B K13 protein staining in 
paraclone colony formed by A431 cells show strong K13 protein expression in 
comparison to the primary omitted control colony (Figure 5.24C).  In summary, these 
data taken together show, the K15 staining with C8/144B and LHK15 and in 
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holoclone and paraclone colonies formed by SCC25 and A431 cells are negative. 
While on the contrary, K13 protein staining with IC7 has shown stronger staining of 
K13 in paraclone colonies in comparison to holoclone formed by SCC25 and A431 
cells using primary antibody omitted as a control. The results taken together indicate 
that using immunocytochemistry to stain for K15 protein expression cannot be 
correlated with distinct heterogeneous population formed by epithelial SCC25 and 
A431 cells, while the opposite is true for K13 protein expression in correlating with 
oral SCC25 cell line maturation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A                                                                  B                                                                      C
A                                                                  B                                                                      C
Figure 5.21: K15 protein expression in oral SCC25 cell line as detected with 
C8/144B and LKH15 antibodies: Image A shows K15 protein expression in 
holoclone colony formed by SCC25 cells as detected with C8/144B antibody using 
1:100 dilution. Image B shows K15 protein expression in holoclone colony formed 
by SCC25 cells as detected with LHK15 antibody at 1:100 dilution. Image C shows 
K15 protein expression in holoclone colony formed by SCC25 cells as detected 
with primary antibody omitted (control). Magnification is x200, scale bar=100µM. 
 
Figure 5.22: K15 protein expression in A431 cell line as detected with C8/144B 
and LKH15 antibodies: Image A shows K15 protein expression in holoclone colony 
formed by A431 cells as detected with C8/144B antibody using 1:100 dilution. 
Image B shows K15 protein expression in holoclone colony formed by A431 cells 
as detected with LHK15 antibody at 1:100 dilutions. Image C shows K15 protein 
expression in holoclone colony formed by A431 cells as detected with primary 
antibody omitted (control). Picture magnification is x200, scale bar=100µM. 
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Figure 5.23: K13 protein expression in oral SCC25 cell line as detected with IC7
antibody: Image A shows K13 protein expression in holoclone colony formed by 
SCC25 cells as detected with IC7 antibody using 1:100 dilution. Image B shows 
K13 protein expression in paraclone colony formed by SCC25 cells as detected 
with IC7 antibody at 1:100 dilution. Image C shows control with primary IC7 
antibody omitted in holoclone colony formed by SCC25 cells. Magnification is 
x200 and scale bar=100µM.
Figure 5.24: K13 protein expression in A431 cell line as detected with IC7
antibody: Image A shows K13 protein expression in holoclone colony formed by 
A431 cells as detected with IC7 antibody using 1:100 dilution. Image B shows K13 
protein expression in paraclone colony formed by A431 cells as detected with IC7 
antibody at 1:100 dilutions. Image C shows control with primary IC7 antibody 
omitted in holoclone colony formed by A431 cells. Picture magnification is x200, 
scale bar is=100µM. 
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5.4 Discussion  
This chapter examined the hypothesis that if heterogeneity exists within a particular 
type of cell, then there may be molecules expressed by the subpopulation of cells, 
which identify which stage of maturation the cells have attained which is identified 
by colony morphologies, corresponding to holoclone, meroclone and paraclone. 
These three types of colonies are thought to be derived from stem, early and late 
amplifying cells (Mackenzie, 2006). Maturation in the oral mucosal epithelia 
involves sequential synthesis of specific basal and suprabasal keratin genes. K15 and 
K13 were chosen as representative of basal and suprabasal markers because of their 
in-vivo sequential specific expression. 
 
The purpose of this study was to identify molecular differences between holoclone 
and paraclone cells within malignant oral cell lines, as this  might provide a new 
opportunity for in-vitro monitoring of the effectiveness of methods developed to 
target the malignant oral stem cell population (Mackenzie 2005). Both K15 and K13, 
which are respectively expressed by holoclone and paraclones were used in this 
study and the association of K15 and K13 promoter and protein expression with oral 
SCC25 cell line maturation was assessed. This was done using the following 
experimental techniques: colony-forming assay, GFP reporter gene expression 
quantification, FACS, scoring method, gene array and immunocytochemistry.  
 
From the Affymetrix data, K15 RNA expression (Figure 5.3) in holoclone versus 
paraclone in several oral cell lines has been shown to have several fold higher 
expression in holoclone colonies. However, K13 RNA expression (Figure 5.4) also 
shows a several fold increased expression in holoclone colonies compared to 
paraclone. This result is opposite to that expected, since K13 is a maturation marker 
in buccal oral mucosa (Bloor et al. 2000) and thus should be increased in expression 
in paraclone compared to holoclone. 
 
The results of colony forming assay, FACS, scoring method, gene array and 
immunocytochemistry taken together indicate that the K15 and K13 promoter 
construct and protein expression does not correlate with maturation of oral SCC25 
cells. As there was no significant difference between the K15 or K13 promoter 
linked GFP construct expression in holoclone and paraclone colonies formed by oral 
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SCC25 cells. There could be several reasons to explain why K15 and K13 expression 
could be not be correlated with oral SCC25 cell maturation. Firstly, it could be the 
fact that cancer cells lines are being used, which means cell maturation is altered 
which could  account for the lack of correlation between K15 and K13 expression 
and SCC25 cell line maturation. Also although using cell lines is much easier and 
less laborious way to assess whether the expression of K15 and K13 can be 
correlated with cell maturation, this approach may not be suitable. 
 
These experiments could have benefited from being done in primary normal oral 
keratinocytes (NOK). Although a limitation of this approach is that, the transfection 
efficiency is very low, especially in primary cells. This low transfection efficiency, 
could have been overcome by cloning the K15 and K13 promoter into retrovirus and 
transducing the oral cells with the K15 and K13 promoters. Transfection has the 
advantages that it is technically simple and fast to set up, safe and non-biologically 
hazardous compared to viral transduction. However, retroviral transduction is better 
than stable transfection, as some classes of virus can transduce both dividing and 
non-dividing cells. This approach was taken into consideration in the initial part of 
the project (Appendix: Figure 7.1, 7.2 and 7.3). However, cloning K15 and K13 
promoter PCR into pRRL/m Cherry and pRRL/GFP respectively was unsuccessful, 
since the 3kb insert (K15 or K13 promoter) and transfer vector (10kb) into which it 
had been cloned were large. Due to time limitation, this approach could no longer be 
pursued, and stable transfection of K15 and K13 promoter into oral cell lines was 
adopted.   
 
Quantitative-polymerase chain reaction (q-PCR) could have been used to quantify 
the K15 and K13 endogenous and exogenous (i.e. stably transfection of K15 and K13 
promoters) expression in holoclone and paraclone colonies formed by SCC25 cells to 
follow up the Affymetrix gene array data as shown in Figure 5.3. This could be done 
using laser capture microdissection (LCM), a method used for isolating DNA, RNA 
or protein from specific microscopic region from colonies formed by cell lines or 
tissue section (Reference: website 20). Tissue sections or cell lines are either grown 
on a palm duplex petridish (P.A.L.M Microlaser Technologies AG, Inc, Munich, 
Germany) or slides made from specific material such that it is clear enough to be 
penetrated by the light beam and then the petridish or slides are placed under a 
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microscope (Reference: website 20). Once the specific required region are found in 
the center of the field of view within slide or petridish, the operator pushes a button, 
which activates a near IR laser diode integral with the microscope optics (Reference: 
website 20). This pulsated laser beam activates a precise spot on the transfer film, 
fusing the film with the underlying cells of choice, then this cells are catapulted into 
a small transfer film, which then placed into a tiny eppendorf tube in case of when 
cell lines are been used (Reference: website 20). The LCM method has the advantage 
of not altering, damaging the morphology or chemistry of the sample collected 
without disturbing surrounding cells (Reference: website 20). However, although an 
initial experiments with LCM is shown in Figure 7.4 and 7.5 in the appendices 
section was carried out, however due to time constraints this technique could not be 
carried out.  
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Chapter 6 
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and  
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6.1 General Overview 
K15 and K13 are basal and suprabasal markers of differentiating oral epithelium and 
very little is known about the mechanism of transcriptional regulation which governs 
their sequential specific expression in the oral mucosa. Establishing the mechanism 
which confers tissue specific expression of K15 and K13 using a reporter gene assay 
and an in silico approach, were expected to give a better understanding about the 
mechanism of transcriptional regulation of the K15 and K13 genes. Therefore the 
aim of the study was to look at three important aspects of differentiation in oral 
mucosa. The first was to examine tissue specific expression of differentiation 
markers. The second aim involved using an in silico approach to find out whether 
there is a pattern of transcription factor binding sites in the basal keratin promoters 
and suprabasal keratin promoters. The third aim was to investigate whether the in-
vitro expression of differentiation marker expression can be correlated with 
differentiating epithelial cell lines, using a keratin promoter linked GFP reporter gene 
assay as an in-vitro model. 
 
6.2 Chapter 3 Discussion  
The molecular mechanisms that govern keratin tissue specific expression are still 
unknown and investigations which have looked into keratin gene regulation and how 
this is linked to keratin differentiation specific expression have led to the 
identification of numerous transcription factors (Wanner et al, 1997).  The discovery 
and analysis of these regulatory elements were facilitated by a database based bio-
informatics approach. These databases, which include TFsearch and TRANSFAC, 
normally contain information on transcription name, their origins, the exact binding 
site within the sequence, and the function of the transcription factor (Hehl and 
Wingender, 2001). The search for transcription factor binding sites in 
uncharacterised biological sequences utilizing databases of keratin promoters was 
first carried out in oral mucosa in studies done by Dale et al, 1990. This study found 
that there was Sp1 transcription factor binding sites in the promoter of basally 
expressed K14 gene. Furthermore, the TRANSFAC database was used to scan the 5-
flanking region of human K16 gene, with results showing that the identified 
regulatory elements in the K16 gene include AP1 and Sp1 (Wang and Chang, 2003). 
In addition, using the TRANSFAC transcription database to scan a 1.251kb sequence 
of the K15 promoter led to the identification of the following transcription factors: 
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AP-1, AP-2, C/EBP, GATA-1, GATA-3 and c-Myc (Radoja et al, 2004).  The 
transcription factors, PAX6, AP-1 and CREB, were identified as conferring mouse 
K12 promoter specific expression in corneal epithelium (Liu et al, 1999). In Chapter 
3, an in silico investigation using TFsearch for transcriptional binding sites in basal 
and suprabasal keratin promoters was adopted in an attempt to identify patterns 
emerging in transcription factor binding sites in keratin promoter DNA sequences. 
The results have revealed that basal keratin promoters contain more binding sites for 
Sp1 and C-rel than for CEBP, GATA-1, 2, 3 and USF transcription factor binding 
sites. This finding for basal keratin promoters is similar to other findings by Dale et 
al, 1990 and Liu et al, 2003. The mouse K15 promoter was used to target epithelial 
stem cell hair follicle bulge and analysis of promoter DNA sequences has revealed a 
number of regulatory elements including Sp1 (Liu et al, 2003).   
 
6.2.1 TFsearch and Suprabasal Keratin Promoters  
The results for suprabasal keratin promoters in this study has revealed that there are 
more C/EBP, GATA-1,2,3, USF, Oct-1 and AP-1 transcription factor binding sites in 
suprabasal keratin promoters than Sp1 and C-rel. Some of these transcription factors, 
such as AP-1, correlate with reports in the literature of suprabasal keratins promoters 
such as the K1 containing binding site for AP-1. Human epidermal differentiation 
specific calcium induced K1 expression is mediated by AP-1, which binds to a 5'-
upstream element to mediate the calcium response element  (Lu et al, 1994). AP-2 
transcription factor has been shown to act in concert with Notch to orchestrate 
terminal differentiation in skin epidermis (Wang, et al. 2008). The parallel pathways 
of AP-2 and Notch signalling converge to govern C/EBP genes and coordinate the 
transition from basal proliferation to suprabasal differentiation. C/EBP transcription 
factor has also been shown to work concomitantly with AP-2 factors to orchestrate a 
complex program of gene expression which is vital for the formation of epidermal 
barrier (Wang, et al. 2008). Moreover, mouse epidermal K10 promoter analysis has 
revealed that differentiation specific expression requires both C/EBP and AP-2   
transcription  factors (Maytin et al, 1999). Given that differentiation signals lead to 
loss of the AP-2 transcription factor and this in turn causes depression of C/EBPα 
isoform promoter, which is specifically expressed in the upper layers of the 
epidermis,  this then results in the activation of K10 expression as the keratinocytes 
migrate towards the surface (Maytin et al, 1999). However, C/EBP transcription 
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factors normally interact with AP-1 and NF-κB and when this interaction occurs 
C/EBP transcription is able to regulate the expression of wide variety of genes in 
many cell types (Tomic-Canic et al, 1998). This prequisite interaction of C/EBP with 
AP-1 and NF-κB transcription factors would explain the presence of C/EBP along 
with AP-1 and NF-κB in most of the analysed suprabasal keratin gene promoters. In 
summary, the results of chapter 3 show similar findings to other published literature 
and through the use of TFsearch database to scan basal versus suprabasal keratin 
promoter sequences have led to the identification of basal and suprabasal promoter 
specific transcription factors. 
 
6.3 Chapter 4 Discussion  
The aim of chapter 4 was to understand the mechanism of K13 transcriptional oral 
mucosal specific regulation, given that K13 is not normally expressed in the 
epidermis. The results have shown that there is increased K13 FL promoter 
expression in oral SCC25 cells in comparison to epidermal derived RTS3b, simple 
epithelial derived HeLa and human foreskin fibroblast HFF cell lines. However, 
when the K13 FL and deletion fragment (R1-R6) of the K13 FL promoter were 
transfected into SCC25, RTS3b, HeLa and HFF cell lines, the K13 FL and deletion 
fragment (R1-R6) expression was increased in HeLa (which does not expresses 
endogenous K13) cells in comparison to SCC25 cells (which does expresses the 
endogenous K13). These observations suggest that the K13 FL promoter and deletion 
fragments (R1-R6) show epithelial specific expression, given that the K13 promoter 
is expressed in all epithelial cell lines (SCC25, RTS3b and HeLa) and there is 
negligible K13 promoter expression in non-epithelial cells (HFF cell line). 
Furthermore, although the K13 deletion fragments (R1-R6) show epithelial 
expression, they do not however show oral mucosa tissue specific expression. Other 
studies by Jiang et al, 1990, have shown similar unusual expression for the 300bp 
K14 promoter which confers K14 epithelial  specific expression. The K14 promoter 
showed negligible expression in fibroblast cell lines, it was however highly 
expressed in MCF-7 and HeLa cells derived from simple epithelial cell lines that do 
not express the endogenous K14 gene in comparison to SCC-12 cells (Jiang et al, 
1990).  Other studies which report similar findings to this study also include Wu et 
al, 1993,  in which the 300bp upstream sequence of rabbit K13 promoter was able to 
confer keratinocyte specific expression but lacked corneal  specificity. Although the 
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exact reason as to why there is abnormal expression of keratin promoter linked 
reporter gene is unknown, it could be that the K13 promoter lacks specific structural 
constraints imposed by local chromosomal structure which normally shut off  K13 in 
all but the permissive environment (Wu et al, 1993). This also highlights the 
importance of using an in-vivo approach (i.e. transgenic mice), as this would 
eliminate some of the disadvantages encountered with using reporter gene assays and 
cell lines. 
 
6.3.1 K13 FL Promoter and Deletion Fragments (R1-R6)  
Important observations were noted concerning the trend of K13 promoter deletion 
fragment driven GFP expression in oral SCC25, RTS3b, HeLa, and HFF cells. From 
the pattern of K13 FL and deletion fragments (R1-R6) expression, there appears to 
be a suppressor element that confers K13 FL promoter oral SCC25 tissue specific 
expression in comparison to epidermal RTS3b cells. However, this study did not 
identify the specific transcription factors which confer K13 promoter specific oral 
expression. In line with these suppressor regulatory elements involved in the K13 
promoter, other studies have found that SP-1 activates, while AP-2 suppresses, K3 
gene in differentiating rabbit corneal epithelia (Chen et al, 1997). 
 
6.3.2 Important Pathways Involved in K13 Induction in Oral SCC25 Cells 
In this study, I have shown that the PI3K/Akt pathway appears to be important for 
K13 expression in oral mucosa. LY249002, a PI3K/Akt pathways inhibitor, caused a 
significant decrease in K13 promoter and protein expression in oral SCC25 cell lines, 
and this implies the importance of the PI3K/Akt pathway in altered differentiation of 
oral mucosa. This inhibitor killed 32% of SCC25 cells in comparison to the control 
(untreated) as measured by MTT assay. It could be argued that the reduction in K13 
expression as measured by Western blot might be due to cell death rather than a 
reflection of the importance of the PI3K/Akt pathway for K13 expression in the oral 
SCC25 cells. However, this 32% death in oral SCC25 cells can in part be explained 
by the fact that active expression of Akt, a downstream effector of PI3K in 
keratinocytes, is involved in both growth arrest and differentiation. This means that 
pharmacological inhibition of the PI3K/Akt pathway not only leads to inhibition of 
differentiation  but also causes cell death (Calautti et al, 2005). In addition, the 
normal activation of PI3K/Akt pathways in keratinocyte differentiation is dependent 
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on epidermal growth factor receptor, Src families of tyrosine kinase and E-cadherin-
mediated adhesion activity (Calautti et al, 2005). PI3K increasingly associates with 
cadherin-catenin protein complex with their tyrosine phosphorylated YXXM motif 
(Calautti et al, 2005). Therefore the PI3K/Akt pathway is thought to regulate either 
epidermal differentiation or cell death  as a reciprocal cross talk between tyrosine 
kinase and the cadherin-catenin protein complex (Calautti et al, 2005). A proposed 
mechanism of PI3K activation, subsequent signalling of downstream effectors, and 
their involvement in cell differentiation or cell death is shown in Figure 6.1. 
 
(A) (B)
 
 
 
 
 
 
 
 
Figure 6.1: Diagrammatic representation of the proposed role of PI3K/Akt activation 
of its downstream effector E-cadherin and tyrosine kinases in differentiation and cell 
death. Diagram A shows when the EGFR and Cadherin-catenin activation leads to 
their tyrosine phosphorylated at YXXM motif by Fyn/Src, this results in the 
activation of PI3K and phosphorylation of Akt by PI3K, which in turn leads to 
phosphorylation of FoxO, GSK-3 and MDM2. Activation of these proteins taken 
together with activation of caspase, cMyc and PKCs lead to signal integration sent to 
the nucleus which in turn causes cell differentiation. While diagram B shows when 
the EGFR and Cadherin-catenin activation leads to their tyrosine phosphorylated at 
YXXM motif. This in turn leads to direct phosphorylation of Akt by PI3K, which in 
turn leads to phosphorylation of FoxO, GSK-3 and MDM2. Activation of these 
proteins taken together with activation of caspase, cMyc and PKCs lead to a signal 
integration sent to the nucleus which in turn causes cell death (adapted from Calautti 
et al, 2005). 
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6.3.3 K13 Expression in Simple and Stratified Epidermal Non-Permissive 
Environment Induced Sodium Butyrate 
Sodium butyrate, a non specific histone deacetylase inhibitor, caused an increase in 
K13 protein expression in epidermal derived RTS3b cells. This suggests that in these 
cells K13 protein expression might be decreased in comparison with oral mucosa 
SCC25 cells, because the chromatin structure in skin is in the heterochromatin state. 
However, sodium butyrate is a non-selective histone deacetylase inhibitor, and its 
effects on K13 gene transcription might not be through histone core protein 
alteration. Findings similar to those for K13 protein have been reported for K23 
mRNA expression which was highly induced by both specific and non specific 
histone deacetylase inhibitors, Trichostatin A (TSA) and sodium butyrate (SB) 
during pancreatic (AsPC-I cancer line) cell differentiation (Zhang et al, 2001). The 
mechanism of TSA and SB induced K23 expression in AsPC-I cells is thought to be 
through histone hyperacetylation, given that using antisense RNA to block 
expression of p21 WAF/CIPI (cell cycle regulator) caused K23 induction. It was 
thought that p21 WAF/CIPI might serve as a vital mediator of SB induced K23 
expression (Zhang et al, 2001). 
 
6.4 Chapter 5 Discussion  
The aim of Chapter 5 was to investigate whether there is a correlation between K15 
or K13 expression and differentiation of distinct heterogeneous populations in oral 
SCC25 cells. There was negative staining for K15 protein expression in holoclones 
or paraclones formed by oral SCC25 cells using immunocytochemistry, this appeared 
to due to the un-availability of a specific K15 antibody for immunocytochemistry. 
However studies have found that immunohistochemical staining to identify 
molecules, which are differentially expressed by stem and differentiating cells, can 
be used to assess the position of stem cells (Mackenzie, 2006). These molecules, 
which include integrins α6 and β1, p63, CD44, K19 and K15, whose higher 
expression levels have been reported in human progenitor and stem cells and are now 
used as a standard assessment to identify the anatomical location of stem cell zones 
in a given tissue (Mackenzie, 2006). This study shows that K15 can be used as a 
putative marker of  stem cell zones and hence K15 expression should be increased in 
and correlated with its representative in-vitro holoclone colonies which contain stem 
cells in the in-vivo environment. K15 was used as a molecular marker to identify 
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stem cells in both normal oral mucosa and diseased (hyperkeratosis) buccal mucosa 
(Kose, et al. 2007). K15 staining has shown that its expressed in the basal layer in 
normal buccal and its expression is downregulated in oral lichen planus. This shows 
that stem cell phenotype as marked by K15, in pathology is altered in comparison to 
normal buccal mucosa (Kose, et al. 2007). Thus changes in responses to altered 
pathological signalling, as marked by decreased K15 expression, is important for the 
understanding of the role of adult stem cells in oral diseases which is characterised 
by abnormal keratinocyte proliferation and differentiation (Kose, et al. 2007). 
 
There was a positive staining for K13 protein expression in paraclones compared to 
holoclone colonies formed by SCC25 cells. This finding is similar to other studies, 
whereby using immunocytochemical staining of K6 differentiation marker has shown 
that K6 was strongly expressed in paraclones but absent in holoclones formed by 
CaLH2 and CaLH3 cell lines derived from head and neck squamous cell carcinoma 
(Harper et al, 2007). 
 
6.4.1 FACS Analysis and Colony Forming Assay of K15 or K13 Expressing 
SCC25 cells 
Colony forming assay and FACS analysis results of K15 or K13 promoter linked 
GFP reporter gene expression have shown that there was no significant difference 
between K15 and K13 promoter expression in holoclone and paraclone colonies 
formed by SCC25 cells. However, contrary  to this finding are the results of FACS 
analysis of cells previously stained for CD44, CD133 and CD29 cell surface 
markers, in the following cell lines; CA1, CaLH2, CaLH3 and H357 (Harper et al, 
2007). The results of the FACS analysis have shown that a small population of cells 
within the cell lines tested showed high CD133 expression (Harper et al, 2007). 
These high expressing populations are thought to be the stem cell population within 
the heterogeneous cell population present within cancer cell lines, while FACS 
analysis of cells co-stained for CD44 and CD29 has shown a high expressing 
population of both CD44 and CD29 present within in CA1, CaLH2, CaLH3 and 
H357 cell lines (Harper et al, 2007). 
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6.4.2 Use of Q-PCR for K15 or K13 Expression in Oral SCC25 cells 
An initial Q-PCR experiment, used to assess the expression of K15 and K13 in 
holoclone and paraclone colonies formed by oral SCC25 cells, was not completed 
due to time constraints. However other studies have utilized Q-PCR to assess the 
differences in gene expression between holoclones and paraclones formed by several 
oral cancer cell lines (Locke et al, 2005). Some of the molecules analysed include 
pirin, hurpin and Erb-B3 and their expression was upregulated in holoclone in 
comparison to paraclone colonies formed by C1, CA1, VB6, SCC71, CAL27 oral 
mucosa cell lines (Locke et al, 2005). It has also been reported that pirin, hurpin and 
Erb-B3 increased expression is associated with epithelial malignancy but their 
expression has not been related to stem cells as such and thus their expression in 
holoclones derived from malignant cells indicate that some markers are specifically 
expressed by stem cells in malignant tissue (Locke et al, 2005). Thus identifying 
molecules associated with stem cells in malignant tissue would hopefully lead to 
advances in therapy aimed at eliminating cancer stem cells (Locke et al, 2005) 
 
In summary, the expression of K15 and K13 did not correlate with heterogeneous 
populations present in oral SCC25 cells. However, if there was a positive correlation, 
this would have been the first study to utilize K15 or K13 promoters and associate 
their specific expression in holoclone or paraclone colonies to specific transcription 
factors governing their holoclone and paraclone colony restricted expression. This 
might have led to a better understanding of the transcription factors which not only 
governs the differentiation specific expression of keratins genes, but also show 
transcription factors involved in sequential basal to suprabasal keratin specific 
maturation related expression in the oral mucosa. 
 
6.5 Limitations of the study  
Some of the limitations encountered in this study with the use of the CMV promoter 
plasmid as positive control, showed a substantial difference in its  activity in 
different cell types, which has also been reported before (Qin and Gunning, 1997). 
This is a common problem with the use of viral promoter plasmid vectors. In an 
attempt to overcome this problem, Fugene 6 transfection reagent was used initially. 
However, the use of Fugene 6 transfection reagent for CMV promoter plasmid 
transfection into different cell lines did not result in similar transfection efficiency, 
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since there was a significant (P=0.01-0.0012) difference of CMV plasmid increased 
expression in SCC25 in comparison to other cell lines used in this study.  Although 
the CMV promoter has been widely used in a variety of human cell lines and 
supports a sustained expression of a variety of foreign genes, the CMV promoter has 
been reported to be incapable of directing the expression of a rotavirus antigen (VP7) 
used to transformed mouse fibroblast 3T3 and pig PF10 fibroblast cells (Qin and 
Gunning, 1997). It could be that in this present study viruses used to transform 
different cell types are driven or directed in their expression at different rates by 
CMV promoter plasmid. Therefore, in an attempt to resolve this problem, 
Lipofectamine another lipid based transfection reagent, was used, since this reagent 
gives very high transfection efficiency of positive controls (CMV) in fibroblast cell 
lines such as NIH3T3. However, out of all cell lines used in comparison to SCC25, 
only HeLa cell lines showed significant increase in  CMV expression (P=0.033 ) in 
comparison to oral SCC25 cell line. Moreover, this shows that the use of 
Lipofectamine partially resolved the problem; which indicates that some transfection 
reagents such as Lipofectamine are better in their relative transfection efficiency of 
plasmids across a spectrum of cell types than other transfection reagents like Fugene 
6. Another problem with CMV promoter plasmid is that some pharmacological 
agents, such as PD98059 and LY294002, an inhibitor MEK 1/2 and PI3K/Akt 
pathway, have also caused (Chapter 4; Figure 4.33 P=0.01 PD98059 and Figure 4.37 
P=0.09 for LY294002) a reduction of CMV promoter expression. This appears to 
cast a doubt on whether MEK 1/2 and PI3K/Akt pathways have functional 
significance in the K13 full length promoter expression since the pharmacological 
agents also effect the expression of CMV promoter plasmid in a similar manner 
(Chapter 4; Figure 4.33 and 4.37). However, in order to gain more confidence in the 
validity of the results and address the limitation of the CMV promoter plasmid, 
western blot was also used (Chapter 4; Figure 4.35 and Figure 4.39). The K13-FL 
promoter linked GFP expression was specifically decreased in the presence of 
PD98059 and LY294002 inhibitors but not in the presence of the DMSO, the vehicle 
control (Chapter 4; Figure 4.32 and Figure 4.36). This indicates that PD98059 and 
LY294002 effects are specific for the K13-FL promoter but not the CMV promoter 
(Chapter 4; Figure 4.33 and Figure 4.37). There was also inconsistency in replicating 
transient transfection experiments, as exemplified by K13 FL promoter expression in 
the oral SCC25 cell line (Chapter 4; Figure 4.21) as the standard error of the mean 
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was very large. This inconsistency of the K13 FL promoter linked GFP expression 
was addressed by the use of pDsRedN-1 plasmid as an internal control to take into 
account the biological variation, which occurs from day to day, and the relative 
transfection efficiency of K13 promoter linked GFP expression in each well.  
 
In summary, although the use of CMV promoter linked GFP reporter gene assay as a 
positive control has many advantages, the results however, highlight that no model is 
without flaws.  
 
6.6 Future Studies 
It is evident from the data obtained from this thesis in Chapter 4, that K13 contains 
suppressor elements, and so future studies could address the specific transcription 
factors involved in conferring the tissue specific expression of K13 in oral mucosa. 
This could be done by mutating specific transcription factor binding sites which were 
identified through the use of TFsearch  database which corresponds to 500bp in the 
full length K13 promoter fragment, by using PCR introduced mutation and 
comparing the  expression to wild type fragments using FACS.  
 
Once transcription factors thought to be important in suppressing the K13 promoter 
expression have been established, then dominant negative forms of these 
transcription factors can be co-transfected with the wild type K13 full length 
promoter fragment. The GFP activity of the construct in the presence and absence of 
dominant negative transcription can be measured using FACS.  
 
Also the 500bp suppressor elements conferring K13 tissue specific expression could 
be used to address whether this suppressor element is specific for K13 or could also 
be a suppressor for other keratins such as K15 promoter expression. This can be done 
through cloning the 500bp in front of the K15 promoter and comparing the activity 
of K15 original promoter and the altered one which contains 500bp fragment 
expression, using FACS.  
 
Sodium butyrate has been shown to increase K13 protein expression in epidermal 
derived RTS3b cell lines. To ensure whether sodium butyrate is increasing K13 
protein expression at posttranscriptional level, this experiment could be repeated 
  232
using northern blot or RT-PCR to see whether K13 mRNA is also increased in the 
presence of sodium butyrate. Other differentiation modulating pharmacological 
agents such as Bromodeoxyuridine which is known to increase K19 protein 
expression at posttranscriptional level (Meleady and Clynes, 2001) could also be 
used on K13, to detect if it is able to increase K13 protein expression. Both of these 
experiments could be done using primary cells rather then cell lines which show 
aberrant keratin expression.  
   
In Chapter 5 it was established that there was no correlation between K15 and K13 
promoter and protein expression with the limited differentiation that occurs in-vitro; 
these results have been performed in only one cell line (SCC25), and therefore the 
study could have benefited from using more oral cell lines. In addition, Western blots 
could have been used to detect K15 protein (LHK15 antibody) expression in both 
holoclone and paraclone colonies. Also Q-PCR could be used to quantify the K15 
and K13 exogenous (i.e. stable transfection of K15 and K13 promoters) expression in 
holoclone and paraclone colonies formed by SCC25 and other oral cells to follow up 
the affymetrix data. Moreover, the K15 and K13 stable transfection experiment 
lacked proper known positive stem cell (basal) and transient amplifying (suprabasal) 
markers which should have been included, such as CD44.  
 
All experiments should be done in primary oral cells, and poor transfection 
efficiency associated with primary cells would be overcome by cloning the K15 and 
K13 promoter into a lentivirus and transducing the orals cells with the K15 and K13 
promoter. With a viral transduction approach, a more consistent and reliable result is 
obtainable than with transfection. 
 
6.7 Conclusions 
In conclusion, the K13 promoter shows both epithelial and mucosal tissue specific 
expression and this tissue specificity might be conferred by suppressor elements 
within the K13 full length promoter. K13 expression is increased by Sodium butyrate 
in non-permissive skin-derived RTS3b cells. The MEK 1/2 pathway seems 
unnecessary for the expression of K13, but the PI3K/Akt pathway is important for 
expression of K13 in oral mucosa. K15 and K13 expression can not be correlated 
with oral SCC25 cell differentiation in-vitro. The restricted expression of basal and 
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suprabasal keratin promoters might be co-ordinated by the synergistic action of Sp1 
and c-rel in basal cells and GATA-1,2,3, C/EBP, Oct-1 and AP-1 transcription 
factors in suprabasal cells. 
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Appendices 
 
Table 7.1: Forward and reverse primer for K13 and K15 promoter sequences 
3'-tcccatatattcctccccctcgcactcCTTAAG-5'
EcoRI
K15
Reverse 
primer
5'-agtggggaGTATACggggagtgcctttacatcctg-3'
BstZ171
K15
Forward  
primer
3'-cacaggtgagaccccttctcgCCATGG-5'
KpnI
K13
Reverse  
primer
5'-tcccggagGTATACcgatggggtgggctgaaagtc -3'
BstZ171
K13
Forward  
primer 
 
 
 
 
Table 7.2: primers used to amplify the K15 and K13 gene for quantitative 
Polymerase chain reaction 
Nonone63.94503`-CTT 
GAG ATC 
CAT CCC 
CTG AA-5`
K15 PCR-R:
nonone64.01605`-CTC 
CAC TCA 
GCT GGG 
AAG TC-3`
K15 PCR-F:
Nonone63.94503`-CTT 
GAG ATC 
CAT CCC 
CTG AA-5`
K13 PCR-R:
nonone64.01605`-CTC 
CAC TCA 
GCT GGG 
AAG TC-3`
K13 PCR-F:
Primer 
dimer
Secondary 
structure 
Melting 
temperature 
OC
GC % 
content
SequenceName of 
primer
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Table 7.3:   The number of molecules in each mole of K13 promoter deletion 
fragments  
15212619637195
Average raw FACS 
data of pEGFP-N3B 
over pDsRed1-N1
1.071.161.251.371.471.601.731
The concentration 
of each K13 
promoter construct 
to take to give same 
of molecules as  
promoterless 
pEGFP-N3B
K13
R6-
289
K13 
R5-
670 
K13 
R4-
1017
K13
R3-
1501
K13
R2-
1953
K13R1 
-2540
K13Full 
length 
Promoter  
-3018
Promoterl
ess 
pEGFPN-
3B
4117FACS  result 
2.07
0E+
11
1.90
5E+
11
1.77
6E+
11
1.62
0E+
11
1.50
21E
+11
1.389E
+111.278E+112.215E+11
*Ratio of 
Promoterless 
pEGFPN-3B to all 
fragments 
6.02
E+1
7
6.02
E+1
7
6.02
E+1
7
6.02
E+1
7
6.02
E+1
7
6.02E+
176.02E+176.02E+17
Number of 
Molecules in (1μg)
6.02
E+2
3
6.02
E+2
3
6.02
E+2
3
6.02
E+2
3
6.02
E+2
3
6.02E+
236.02E+236.02E+23
Number of 
Molecules in (1g)
2.87
628
3.11
388
3.35
148
3.70
788
3.98
508
4.3810
84.697222.71722
Avogadro number 
6.022*1023 divide by
Molecular weight (g)
3348
840
3600
300
3828
000
4153
380
4445
760
483318
051341402656500
Avogadro number 
6.022*1023
2907
960
3159
420
3388
440
3715
140
4006
200
433422
047091002717220Molecular weight (g)
4406478751345629607065677135
4117
Insert plus vector 
(bp)
-289-670-
1017
-
1512
-
1953
-2540-30180Insert(bp)
R6R5R4R3R2R1K13 FL 
Pro
Promoterl
ess 
pEGFPN-
3B
SCC25 or Hela
 
*The concentration of DNA to take for each of the K13 promoter fragments, to give 
the same number of molecules as promoterless pEGFP-N3B  
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Table 7.4: The sequence of K13 promoter fragments 
SDM of 
2623bp
5` to 3`TTC ACT GTG CAG 
GCT CTG AGG 
TAT ACC CAG TAT 
TAG AAC GGG 
ACC T
10336-022
H2995H06
46K13-DR6
SDM of 
2039bp
5` to 3`AGA GGA AGT 
GGC CCT GTC 
CAG TAT ACT 
AGC GAA TAT 
TCT CCG AGC C
10336-022
H2995H04
46K13-DR5
SDM of 
1593bp
5` to 3`CCT TGT ACC TTT 
TCC CAG TCG TAT 
ACC TGA CTC CAC 
ACC CCT GGT G 
10336-022
H2995H02
46K13-DR4
SDM of 
1100bp
5` to 3`GAG AAA CTC 
AGG GAC TAT 
GTG TAT ACC CTG 
CCA GAG GGA 
GCT TC 
10336-022
H3022H06
44K13-DR3
SDM of 
755bp
5` to 3`TTG CGA GGC 
CAG GGA TTC 
AGG TAT ACC 
CCT GAC CCT GCC 
CGG CCC T
10336-022
H2995G10
46K13-DR2
SDM of first 
374bp
5` to 3`AAT GAC TGC 
GGT CTC CTC CCG 
TAT ACG TTT CAA 
GGG AAG GAG 
CAG C 
10336-022
H2995G08
46K13-DR1
PurposeOrientationSequence Cat No/ ID 
No of Primer 
Primer 
length
Primer name
 
 
Table 7.5:  pEGFP-N3B Vector sequence used for K13 full length and subsequent 
truncated promoter constructs DNA sequencing 
For 
sequencing 
(Reverse 
sequence 
of 4658 to 
4678 in 
pEGFP-
N3B 
vector)
3` to 5` GCT GGC CTT 
TTG CTC ACA 
TGT  T
10336-022
H2995G07
46pEGFPs
PurposeOrientationSequence Cat No/ ID 
No of Primer 
Primer 
length
Primer name
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Table 7.6: Standard solution and Media 
2.5g dissolved in 25ml dH2O, aliquoted into 5ml 
bijous and stored at -70oC or -20oC for long term 
storage.
Kanamycin (100mg/ml)
24mg of isopropyl-1-thio-β-D-galactopyranoside 
(IPTG), 10ml of sterile distilled water and store at -
20oC and to spread 100µl per LB-agar plate  
10mM IPTG (per 10ml )
400ml DMEM, 40 FCS, 4ml glutamine and 10µl 
insulin (50µg/ml) passed through 0.22 filter
E4 medium + insulin (only used for MCF 7 cell line)
Epidermal growth factor 100ng/ml, hydrocortisone 
0.18mg/ml, insulin 2.5mg/ml, transferrin 2.5mg/ml, 
BPE and PSA in which 1ml of each medium 
supplement was added to 400ml epilife medium . 
Epilife medium with calcium 
75% (v/v) Dulbecco’s Modified Eagle’s Medium 
(DMEM), 25% (v/v) Ham’s F12 medium. 
400ml of E4/F12 containing
100mg dissolved into 10ml of 0.01M sodium acetate 
at pH 5.3, this was then boiled to 100oC, in 50 ml 
falcon tubes in a glass beaker containing distilled 
water on top of busen burner for 15 minutes. This 
was then allowed to cool, then 1/10 of 10mM Tris
HCl at pH 7.4, was added , this mixture was then 
aliquoted into1.5ml eppendorf tubes  aliquots and 
stored at -20oC 
DNase free RNase-A
20mM EDTA, 30% sucrose, 0.1% bromophenol blue, 
0.1% xylene cyanol FF, 1M Tris HCL pH 8.0
DNA loading buffer
50mM Tris –HCL pH 8, 10mM EDTA, 100 μl/ml 
RNase A and store in 2-8% after addition of   RNase
A. 
Buffer P1 (Resuspension buffer)
2.5g dissolved in 25ml dH2O, aliquoted into 5ml 
bijous and stored at -70oC or -20oC for long term 
storage
Ampicillin (100mg/ml)
PreparationReagent  
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Table 7.7: Standard solution and Media 
10g of NZ amine (Casein hydrolysate)
5g of Yeast Extract, 5g of NaCL add distilled water to 
a final volume of 950ml and then adjusted pH to 7.5 
using NaOH and autoclave. Then added the following 
filter sterilized supplements prior to use 12.5mlof 1M 
MgCl2, 12.5mlof 1M Mg
SO4, 20ml of 20%(w/v) glucose (or 10ml of 2M 
glucose)
NZY- Broth (per litre)
246.08g in 1L dH2O, pH adjusted to 5.5 with glacial 
acetic acid
3M Na-acetate 
292.2g in 1L dH2O autoclaved5M NaCL
500mg dissolved in 5ml Tris HCLLysozyme (100mg/ml)
62mM Tris-HCl pH 6.8
2% w/v SDS
10% glycerol
0.05% -
mercaptoethanol
0.01% bromo-phenol blue
1 x Lysis buffer:   
LB media containing 100μl/ml ampicillinLB-Amp
As LB medium plus 1.5% Bacto agar (Oxoid)LB agar
10g Bacto-trytone (Oxoid), 5g Bacto-yeast (Oxoid), 
5g NaCL dissolved in 1L dH2O and autoclaved
LB medium 
PreparationReagent  
 
 
Table 7.8: Standard solution and Media 
Tris Base 3g, Glycine 14.4g, SDS 1g made to 1 litre 
was distilled water.
Running Buffer (1L): 
Hydrosorstine 0.4µg/ml, Cholera Toxin 10-10M, 
Transferrin 5µg/ml, Liothyronine 2 x 10-11M, Adenine 
1.8 x 10-4 M, Insulin 5µg/ml, Epidermal growth factor 
(EGF) 10 ng/ml.
4ml ‘Ready Mix’ concentrate was added to final 
concentration of :
400ml of E4/F12, 4ml of RM+, 40ml of Foetal Calf 
Serum (10% FCS v/v) and 4ml of glutamine(1% v/v).  
Ready Mix+ medium
dissolve 5g of powder skimmed milk in 100ml of 
PBS-T.
PBS-T+5% milk:
add 500l of Tween-20 detergent in 500ml of PBSPBS-T:
dissolve 1 PBS tablet per 100ml of distilled waterPBS:
Proteinase K 20mg/ml purchase as lyophilized powder  
and dissolved at concentration of 20mg/ml in sterile 
50mM Tris HCl at pH 8, 1.5 mM calcium acetate, 
stock was then divided into 1.5ml eppendorf tubes  
aliquots and stored at -20oC
Proteinase K enzyme
Two times Proteinase K  bufferProteinase K  buffer
Phenol, Phenol chloroform, Chloroform in the ratio of 
24:24:1.
PPC
137mM sodium chloride, 2.7mM KCl 10mM NaHPO4 
and 2mM KH2PO4  made up to 500ml with distilled 
water.
Phosphate Buffered Saline
PreparationReagent  
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Table 7.9: Standard solution and Media 
0.2g of 5-bromo-4-chloro-3-inodlyl- β-D-
galactopyranoside (X-Gal), 10ml of dimethylformide
(DMF) and store at -20oC and to spread 100µl per LB-
agar plate  
2% X-Gal (per 10 ml)
NaCL 8g, KCL 0.2g, Na2HPO4 1.2g, KH2PO4 0.2g, 
Versene (EDTA) 0.2g, phenol red 1.5ml these 
ingredients were all dissolved and made up to 1L in 
distilled water. pH adjusted with NaOH to 7.2, and 
the solution was aliquoted into 16ml universals and 
autoclaved for 20 minutes prior to storage at 4oC. 
Versene
0.01grams of Thiazolyl Blue Tetrazolium
Bromide into 20ml of appropriate media for the cells 
being used then container was wrapped with foil and 
left at 4oC till use.
Thiazolyl Blue Tetrazolium Bromide (Sigma) and also 
known as MTT
25mM Tris, 0.2M glycine, 20% methanol make to 
800ml with distilled water then adjusted pH 8.5, 
added enough distilled water to make 1 litre.
Transfer Buffer (1L)::  
NaCL 2.5g, Na2HPO4 8g, KH2PO4 0.2g, versene
(EDTA) 1g, Trypsin 2.5g, phenol red 1.5ml. These 
ingredients were made up to 1L of distilled water. pH 
adjusted with NaOH to 7.2. Aliquots were supplied 
filter sterilized and 15 ml bottled in universals and 
stored at -20oC until use. 
Trypsin (0.25% in Versene)
10mM Tris –HCL, 1mM EDTA, autoclavedTris HCL
445mM (54g/L) Tris, 445mM (27.5g/L) boric acid, 
10mM (3.7g/L) EDTA
10x TBE
20mM Tris HCL pH 8.0, 50mM EDTA, 8% sucrose 
made upto 100ml dH2O. 
STE
SOC medium was supplied as 10ml bottle which 
contained: 2% weight/volume Tryptone, 0.5% 
weight/volume yeast extract, 10mM NaCL, 2.5mM 
KCL,  10mM  MgCL2, 10mM  MgSO4 and 20mM 
glucose (Invitrogen) .
SOC medium 
PreparationReagent  
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Table 7.10: Materials used in the study and company of purchase 
Lipofectamine (Invitrogen).
Fugene 6 (Roche 6).
Sodium Butyrate (Calbiochem).
Trichostatin A (Calbiochem).
MEK 1/2 pathway  PD98059 inhibitor (Calbiochem).
PI3K and AkT pathway LY294002 inhibitor (Calbiochem).
4 alpha PMA and TPA (Promega).
DMEM  and Typsin (Biowest and Gibco).
Hams F12 and E4 media (cancer research UK).
Miniprep and maxiprepartion of DNA kits (Qiagen Ltd, Crawley, UK).
XLI0-Gold ultra competents cells  and  XLI0-Blue ultra competent cells (Stratagene).
One shot E.coli competent cells (Invitrogen).  
Topo TA vector cloning kit (Invitogen) and pEGFP-N3 vector (BD Biosciences).
Ampicillian and kanamycin (Sigma, UK).
2X quick ligation buffer and  T4 DNA Ligase (Invitrogen).
Restriction endonucleases and their buffers (New England biolabs UK).
Forward and reverse primers site directed mutagenesis of K13 promoter(Stratagene).
Forward and reverse primers for K13 and K15 promoter amplification (invitrogen).
DNA ladder (Promega).
Human genomic DNA (Promega).
BIO-X-ACT Long DNA polymerase, 10X OptiBuffer (Bioline, UK).
dATP, dTTP, dCTP, dGTP (100mM) (Promega).
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Figure 7.1: Ethidium-bromide stained agarose gel showing results of K13 and K15 
promoter PCR product amplified from K13 and K15 promoter pEGFP-N3B 
construct.  Lane 1: 10Kb DNA ladder, Lane 2 and 3: K13 promoter PCR product 
(3Kb) in absence and presence of enhancer, Lane 4 and 5:  K15 promoter PCR 
product (3Kb) in absence and presence of enhancer. The DNA was analysed on 1.5% 
agarose containing ethidium bromide.
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Figure 7.2: Ethidium-bromide stained agarose gel showing results of K13 and K15 
promoter PCR product and pRRL/m Cherry  and pRRL/GFP vectors digested with 
XbaI and ClaI prior to ligation. Lane 1: 10Kb DNA ladder, Lane 2: K13 promoter 
PCR product (3Kb) digested with Xba I and ClaI to linearize the K13 promoter, Lane 
3: pRRL/m Cherry vector digested with Xba I and ClaI to remove CMV promoter 
(562bp), Lane 4:  K15 promoter PCR product (3Kb) digested with Xba I and ClaI to 
linearize the K15 promoter, Lane 5: pRRL/GFP vector digested with Xba I and ClaI 
to remove CMV promoter (592bp). The DNA was analysed on 1.5% agarose 
containing ethidium bromide.  
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Figure 7.3: Ethidium-bromide stained agarose gel showing results of K13 and K15 
promoter PCR product ligated  to  pRRL/m Cherry  and pRRL/GFP vectors digested 
with XbaI and ClaI. Lane 1: 10Kb DNA ladder, Lane 2: K13 promoter PCR product 
(3Kb)  and pRRL/m Cherry digested with Xba I and ClaI to linearize the K13 
promoter, Lane 3: K15 promoter PCR product (3Kb) and pRRL/GFP vectors.The 
DNA was analysed on 1.5% agarose containing ethidium bromide.  
A                                                                                           B 
A 1                                                                                      B1 
Figure 7.4: K15 promoter construct expression in holoclone (A) and paraclone (B ) 
colony of oral SCC25 cells prior to catapulting (A and B) and after catapulting (A1 
and B1) using laser capture software, with a catapulting energy of 50 watts required 
to lift the cut section of duplex petridish.  
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chromosome: 17; Location: 17q12-q21.2See KRT13 in MapViewer
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Figure 7.6: Diagram showing the maximum upstream promoter size and the 3'-end 
downstream size of K13 and K15 gene relative to their gene positions in the 
chromosome 17: Using the ncbi database the maximum upstream promoter size of 
K13 and K15 was estimated to be around 8Kb for K13 and 4.6Kb for K15 (picture 
obtained through extrapolating the ncbi website number 14 in the reference 
section). 
A                                                                                          B 
A1                                                                                            B1 
Figure 7.5: K13 promoter construct expression in holoclone (A) and paraclone (B ) 
colony of oral SCC25 cells prior to catapulting (A and B) and after catapulting (A1 
and B1) using laser capture software, with a catapulting energy of 50 required to lift 
the cut section of duplex petridish.  
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-3001 ggacacttttctgtctcagcctggagacctgggataggagggagaggggagtggggaagt
-2941 tgaggggagtgcctttacatcctgctggtcatcgtggccacttcagtctgttgagcattt
-2881 cctgtgagtcatcttgctccaactgagagtcaggctgagctggagttatttccattttcc
-2821 tgattggtagactaaggctcagagagaggaggcggcattacccaaagccgcacagctggt
-2761 aaatgggaaaagaggggtttaaaggtaagtctctgggctccaggacacaccccctctccc
-2701 tggcatttccctggggaacaggagaggtgtgggagggttctaaggttgttggagacttca
-2641 ttctccttgtgccctcaaatgctcactatggccctgaggggagtctgtgttaatggccta
-2581 agtttaaatcaggaaccaggctcagagaggctgagtctctttccactgggctgcactgcc
-2521 tcattctaaggagaaaaggccagctccacagatggccccatctggctgcagtgggcaaag
-2461 gtcagaaactggcacagcatcctgggcaggctgcctggggcagggcccgg ggctacagc
-2401 tgggctggggccagacagagctttatcttcgcaaggccatcccacctggtgctaatgagg
-2341 aggctccgggccccacccagatctggagctcacagtagcggtttggactgaaaccaggga
-2281 tttgtgcgtggggcagtgaggggggcagctgccgcccctggcctgggcctgagagtatag
-2221 agaaagccacctcgaggggctgctggaggagagtcaggtgcagaaggggatctggctggg
-2161 gtccagcccttcctcaccctggggtgaaaggcgagtaattgttcttgagttaattgctgg
-2041 ggccacaatgtctgcagaggcttttaatgagctctggatgatctgagtttgattattttt
-1981 ctttcggaggaaaagacaataccctcccacccatgagacaataccacactgtctgtgccc
-1921 agcattggaggccaggctcactgcgaagatggatgagaaggaacccacccccagccttgc
-1861 tggctggcagttccccttgccagcccagctcagatgcaggaatttggggtctgcaggaag
-1801 gactctttccctgtgccctgtttggttgagggtgtgaggacctgtttgagtcctggcttt
-1741 gccccttaccagtggtgccacctggcacaagttgcttcacctctccaagtttcaatttca
-1681 ttctttctgaatcttgggtgggggtcaccctctgttgtgaggatgagaggaggtgatgga
-1621 tgcaaaagtgctttgtaaatcacaaagtgcagggtagaagtaaaggattatgctattata
-1561 gcaaaataagaacctaagaacaacctgcgttgccccataggagctggctatggaaggtcg
-1501 atgccgttgagcctaagaacatgctcaggctcacagggcatgttctgatgcccaacgaca
-1441 aagcccctcctggtgagggcactcaggcgcaggtgccggtcatgcaccctggcccctgca
-1381 tgtctggcacctgggtggggatccaggagggggcaggatgggggctcttgggccacaggg
-1321 cttccctggaagtgagagttgagagcgccccttgccacagggaaacagagacttaaaaag
-1261 gtaaatgtccacagtcttaccatggtaattggtagggtcaggatttgaacccaggcctca
-1201 cagtcttaccatgataattgataaagccaggattcaaacccgggcctgagggactccaga
-1141 gccctgtccacttcaccatgctgcaacctgggctaggaatcctcctcctgagtttctgta
-1081 agccctggggccaggtccagagggctgagccacacctccaagtggcactgcccacaggta
-1021 tcaggtgtccctggaaaggtgtccctgagctggtggcagagaaaagggctctcctgagtg
-961  ttcaactccccgtctgtgtgaagcaatgccttggtcttcaagatctccggtgtcttccag
-901  cctgcctgccagtctcccttctcttcccttccacagcattcaggcacatagagccttctg
-841  cagcggcccgtccccagccagcacttgacaggacagatgggggctaatctggccctgcta
-781  agcagcgacatgcctctcctggagaaggcaggggcttcctggaacttgccccagccttat
-721  cagcggaggtttgccccaacacatcccagaaacgagcaaaggttcagcgccgtgcagttg
-661  gcaggtgtcgggatcatcagtcatccccttgtcagtcccaagcctgctgggcttttgtga
-601  gggtgccaggaacacaggctggaggatggcaggaggggagtagaggtgggaggaggggag
-541  tccatctgcagcaccaggtaaggggatggatgctggctcctctggtcacctcagctggaa
-481  cactactcaaggtccctggctcctgtcctccacctgcccccaggggccctgcattcccat
-421  ccccagggcctccactctccctgagccctgcagtctctcactcactcactcactcactca
-361  ttcactcactcactcactcacagggttttgagttggataacacagcataatgatcggcca
-301  gtggactcccaaactaagaacacggagctgtcctcttggggagaggctcagggctcgggg
-241  aagtgaagtccagctgagggcacagttggcctgagctgctctcagtacaggcagaggcct
-181  tggtagctgtgctgtgatgagagttcgctccctgctgctctcttctggcatggagagatg
-121  aacctgtaatccaagtgttaaaaccgtgccctggggaaaaacactattaattctgaatca
-121  tctcttttgttgcattaaaaaaaaatagaagagaaaaacttcacatgacccactcaaggt
-61   gtgcaggcagctgtgtttgtcaggaaggcagaaggagttggctttgctttaggggaggag
-1    acgaggtcccacaacaccctctgaagggtatataaggagccccagcgtgcagcctggcct
+1   ggtacctcctgccagcatctcttgggtttgctgagaactcacgggctccagctacctggc
+61  catgaccaccacatttctgcaaacttcttcctccacctttgggggtggctcaacccgagg
+121 gggttccctcctggctgggggaggtggctttggtggggggagtctctctgggggaggtgg
+181 aagccgaagtatctcagcttcttctgctaggtttgtctcttcagggtcaggaggaggata
+241 tgggggtggcatgagggtctgtggctttggtggaggggctggtagtgttttcggtggagg
+301 ctttggagggggcgttggtgggggttttggtggtggctttggtggtggcgatggtggtct
+361 cctctctggcaatgagaaaattaccatgcagaacctcaatgaccgcctggcctcctacct
+421 ggacaaggtacgtgccctggaggaggccaatgctgacctggaggtgaagatccatgactg
+481 gtaccagaagcagaccccaaccagcccagaatgcgactacagccaatacttcaagaccat
+541 tgaagagctccgggacaaggtgagtcctcggatgtcaaagagaggggagcaggtggctgg
+601 taccctgtacacagctctaatgtcagtgttactgctgactcaaggaaatcctttcctgcc
+661 caggcaatgactgtctggtatgtaatctcagcaaatttggaatgcacctgctgtccaggt
+721 gcagaggccagtgcacatcttctcaacttggtggtgctgggggagggagagaggggtctt
+781 gggaatctggttaggaccaacaggggcacaggtgggggcaattataaagagccagaggca
+841 gtagctcacacctgtaatcccagtgctttggggggccaaggtgataggattgctcgtgtc
+901 caggatttagaggctgcagtgagctatgactgtgccactgcactccggcctaggtgacag
+961 agtggaacctgtatctaattaaataaaaataattaaaaaaaaagagcaactcgccctccc
+1021 tacctcatgcaccctgcaggcttctgcataaagtattcctttacctcttttgcaagaatg
+1081 ggattggagtgtggcctcatgagttccagatgctagaacctcttgtcttttcctataaag
+1141 aggtcttttgtgccaaaagtactgttgggtcttaggagacctgggaactcattacacatt
+1201 ctgccacccactcactcaccattttactccctaagactgggttcctcattcgtaaaatgc
+1261 cttcttaactgccctccaggttgctactggctggaatgttctgtagatccatggctgtgt
+1321 ccaaggtgtgcaggaggcagtgaccatgagttgtccacagtggggctggtggagtgtctc
+1381 tgagagagctattgtcagagctggctgcaccccactgccccactctcctgggcaaccaat
+1441 tcccacaggcaatactgcctccttggtctttcgtgccctggagataaggaaggcagctcc
+1501 tcaggtgtctcaaggaggctggatgggacaaaacaagaaatggacactgaaagtgaggct
+1561 ggactttgcccaccccagaagccgtacagatttttgttggtggtgtcagaggggtgattg
+1621 tcagtgaggggtgattttcaatgaggggctggccttgggtgcagagcagagagcagcagg
+1681 ggagagagaggagtcctctagacaccgactctgtctcctgcagatcatggccaccaccat  
 
 
 
 
Figure 7.7: The K15 upstream and downstream nucleotide sequence. The black 
coloured nucleotide sequence corresponds to the full length -3.018kb K15 promoter. 
The underlined black nucleotide at the top and bottom respectively correspond to the 
region where the forward and reverse primers was designed to amplify the 3.018kb 
K15 promoter. The original K15 promoter sequence (6 nucleotides, underlined in 
black) does not differ much from the BstZ17I site (GTATAC), so this sequence 
corresponds to the site where BstZ17I primer was designed, in attempt to retain or 
minimise change to the BstZ17I sequence. The underlined navey blue 6 nucleotides 
sequence correspond to the site where EcoRI was designed. The red 3 nucleotides 
sequence corresponds to the ATG and the yellow (+61-541) highlighted sequence 
corresponds to the start of coding region (exon 1). The light blue (+541-1681) 
highlighted sequence corresponds to K15 intron 1. 
